<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome - Franco, JVA - 2019 | Cochrane Library</title> <meta content="Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome - Franco, JVA - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012552.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome - Franco, JVA - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012552.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012552.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome" name="citation_title"/> <meta content="Juan VA Franco" name="citation_author"/> <meta content="Instituto Universitario Hospital Italiano" name="citation_author_institution"/> <meta content="juan.franco@hospitalitaliano.org.ar" name="citation_author_email"/> <meta content="Tarek Turk" name="citation_author"/> <meta content="Damascus University" name="citation_author_institution"/> <meta content="Jae Hung Jung" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Yu‐Tian Xiao" name="citation_author"/> <meta content="Changhai Hospital, Second Military Medical University" name="citation_author_institution"/> <meta content="Stanislav Iakhno" name="citation_author"/> <meta content="University of Tromso" name="citation_author_institution"/> <meta content="Federico Ignacio Tirapegui" name="citation_author"/> <meta content="Hospital Italiano de Buenos Aires" name="citation_author_institution"/> <meta content="Virginia Garrote" name="citation_author"/> <meta content="Instituto Universitario Hospital Italiano" name="citation_author_institution"/> <meta content="Valeria Vietto" name="citation_author"/> <meta content="Hospital Italiano de Buenos Aires" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD012552.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/10/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012552.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012552.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012552.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012552.pub2&amp;doi=10.1002/14651858.CD012552.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="na56WA6j";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012552\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012552\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fa","fr","ms","hr","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012552.pub2",title:"Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome",firstPublishedDate:"Oct 6, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012552.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012552.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012552.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012552.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012552.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012552.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012552.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012552.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012552.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012552.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11285 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012552.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-sec-0253"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-sec-0080"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-sec-0243"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/appendices#CD012552-sec-0258"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/table_n/CD012552StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/table_n/CD012552StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information#CD012552-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Juan VA Franco</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information#CD012552-cr-0003">Tarek Turk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information#CD012552-cr-0004">Jae Hung Jung</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information#CD012552-cr-0005">Yu‐Tian Xiao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information#CD012552-cr-0006">Stanislav Iakhno</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information#CD012552-cr-0007">Federico Ignacio Tirapegui</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information#CD012552-cr-0008">Virginia Garrote</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information#CD012552-cr-0009">Valeria Vietto</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information/en#CD012552-sec-0267">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 October 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012552.pub2">https://doi.org/10.1002/14651858.CD012552.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012552-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012552-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012552-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012552-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012552-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012552-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012552-abs-0001" lang="en"> <section id="CD012552-sec-0001"> <h3 class="title" id="CD012552-sec-0001">Background</h3> <p>Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common disorder in which the two main clinical features are pelvic pain and lower urinary tract symptoms. There are currently many approaches for its management, using both pharmacological and non‐pharmacological interventions. The National Institute of Health ‐ Chronic Prostatitis Symptom Index (NIH‐CPSI) score is a validated measure commonly used to measure CP/CPPS symptoms. We considered a 25% decrease of NIH‐CPSI baseline score or a six‐point reduction as MCID. </p> </section> <section id="CD012552-sec-0002"> <h3 class="title" id="CD012552-sec-0002">Objectives</h3> <p>To assess the effects of pharmacological therapies for chronic prostatitis/chronic pelvic pain syndrome. </p> </section> <section id="CD012552-sec-0003"> <h3 class="title" id="CD012552-sec-0003">Search methods</h3> <p>We performed a comprehensive search using CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, trial registries, grey literature and conference proceedings, with no restrictions on the language of publication or publication status. The date of the latest search of all databases was July 2019. </p> </section> <section id="CD012552-sec-0004"> <h3 class="title" id="CD012552-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials. Inclusion criteria were men with a diagnosis of CP/CPPS. We included all available pharmacological interventions compared to placebo or in head‐to‐head comparisons. </p> </section> <section id="CD012552-sec-0005"> <h3 class="title" id="CD012552-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed study eligibility, extracted data, and assessed the risks of bias of included studies. We assessed the quality of the evidence (QoE) using the GRADE approach. </p> </section> <section id="CD012552-sec-0006"> <h3 class="title" id="CD012552-sec-0006">Main results</h3> <p>We included 99 unique studies in 9119 men with CP/CPPS, with assessments of 16 types of pharmacological interventions. Unless stated otherwise, our comparisons were based on short‐term follow‐up (less than 12 months). Most studies did not specify their funding sources; 21 studies reported funding from pharmaceutical companies. </p> <p><b>1. Alpha blockers:</b> (24 studies, 2061 participants). We are uncertain about the effects of these drugs on prostatitis symptoms when compared to placebo at short‐term follow‐up (mean difference (MD) in total NIH‐CPSI score −5.01, 95% confidence interval (CI) −7.41 to −2.61; 18 studies, 1524 participants, very low QoE) and at long‐term follow‐up (MD −5.60, 95% CI −10.89 to −0.32; 4 studies, 235 participants, very low QoE). Alpha blockers may be associated with an increased incidence of adverse events, such as dizziness and postural hypotension (risk ratio (RR) 1.60, 95% CI 1.09 to 2.34; 19 studies, 1588 participants; low QoE). Alpha blockers probably result in little to no difference in sexual dysfunction, quality of life and anxiety and depression (moderate to low QoE). </p> <p><b>2. 5‐alpha reductase inhibitors (5‐ARI):</b> (2 studies, 177 participants). Finasteride probably reduces prostatitis symptoms compared to placebo (NIH‐CPSI score MD −4.60, 95% CI −5.43 to −3.77; 1 study, 64 participants; moderate QoE) and may not be associated with an increased incidence of adverse events (low QoE). There was no information on sexual dysfunction, quality of life or anxiety and depression. </p> <p><b>3. Antibiotics:</b> (6 studies, 693 participants). Antibiotics (quinolones) may reduce prostatitis symptoms compared to placebo (NIH‐CPSI score MD −2.43, 95% CI −4.72 to −0.15; 5 studies, 372 participants; low QoE) and are probably not associated with an increased incidence in adverse events (moderate QoE). Antibiotics probably result in little to no difference in sexual dysfunction and quality of life (moderate QoE). There was no information on anxiety or depression. </p> <p><b>4. Anti‐inflammatories</b>: (7 studies, 585 participants). Anti‐inflammatories may reduce prostatitis symptoms compared to placebo (NIH‐CPSI scores MD −2.50, 95% CI −3.74 to −1.26; 7 studies, 585 participants; low QoE) and may not be associated with an increased incidence in adverse events (low QoE). There was no information on sexual dysfunction, quality of life or anxiety and depression. </p> <p><b>5. Phytotherapy</b>: (7 studies, 551 participants). Phytotherapy may reduce prostatitis symptoms compared to placebo (NIH‐CPSI scores MD −5.02, 95% CI −6.81 to −3.23; 5 studies, 320 participants; low QoE) and may not be associated with an increased incidence in adverse events (low QoE). Phytotherapy may not improve sexual dysfunction (low QoE). There was no information on quality of life or anxiety and depression. </p> <p><b>6. Botulinum toxin A (BTA)</b>: Intraprostatic BTA injection (1 study, 60 participants) may cause a large reduction in prostatitis symptom (NIH‐CPSI scores MD −25.80, 95% CI −30.15 to −21.45), whereas pelvic floor muscle BTA injection (1 study, 29 participants) may not reduce prostatitis symptoms (low QoE). Both comparisons used a placebo injection. These interventions may not be associated with an increased incidence in adverse events (low QoE). There was no information on sexual dysfunction, quality of life or anxiety and depression. </p> <p><b>7. Allopurinol:</b> (2 studies, 110 participants). Allopurinol may result in little to no difference in prostatitis symptoms and adverse events when compared to placebo (low QoE). There was no information on sexual dysfunction, quality of life or anxiety and depression. </p> <p><b>8. Traditional Chinese medicine (TCM)</b>: (7 studies, 835 participants); TCM may reduce prostatitis symptoms (NIH‐CPSI score, MD ‐3.13, 95% CI ‐4.99 to ‐1.28; low QoE) and may not be associated with an increased incidence in adverse events (low QoE). TCM probably does not improve sexual dysfunction (moderate QoE) and may not improve symptoms of anxiety and depression (low QoE). There was no information on quality of life. </p> <p>The most frequent reasons for downgrading the QoE were study limitations, inconsistency and imprecision. We found few trials with active comparators. </p> </section> <section id="CD012552-sec-0007"> <h3 class="title" id="CD012552-sec-0007">Authors' conclusions</h3> <p>We found low‐ to very low‐quality evidence that alpha blockers, antibiotics, 5‐ARI, anti‐inflammatories, phytotherapy, intraprostatic BTA injection, and traditional Chinese medicine may cause a reduction in prostatitis symptoms without an increased incidence of adverse events in the short term, except for alpha blockers which may be associated with an increase in mild adverse events. We found few trials with active comparators and little evidence of the effects of these drugs on sexual dysfunction, quality of life or anxiety and depression. Future clinical trials should include a full report of their methods, including adequate masking, consistent assessment of all patient‐important outcomes, including potential treatment‐related adverse events, and appropriate sample sizes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012552-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012552-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012552-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012552-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012552-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012552-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012552-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012552-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012552-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012552-abs-0005" lang="en"> <h3>Intervention for treating chronic prostatitis and chronic pelvic pain in men</h3> <p><b>Review question</b> </p> <p>What are the effects of medical therapies in men with longstanding pain and discomfort around their prostate and pelvis, so‐called chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)? </p> <p><b>Background</b> </p> <p>CP/CPPS is a common disorder in which men feel pelvic pain or have bothersome symptoms (or both of these) when urinating. Its cause is unknown and there are many different treatments for this condition. </p> <p><b>Study characteristics</b> </p> <p>The evidence was current to July 2019. We found 96 studies that were conducted between 1983 and 2016 in 8646 men with CP/CPPS, with assessment of 16 types of pharmacological interventions. These therapies were given to men in an outpatient setting. Most studies did not specify their funding sources; 21 studies reported funding from pharmaceutical companies. </p> <p><b>Key results</b> </p> <p><i>Alpha blockers:</i> we are uncertain about the effects of alpha blockers on prostatitis symptoms. Alpha blockers may increase side‐effects, for example dizziness and low blood pressure. Alpha blockers probably result in little to no difference in sexual problems, quality of life or anxiety and depression. </p> <p><i>5‐alpha reductase inhibitors (5‐ARI):</i> 5‐ARI probably reduce prostatitis symptoms and may not be associated with more side effects than seen in men taking a placebo. There was no information on sexual problems, quality of life or anxiety and depression. </p> <p><i>Antibiotics:</i> antibiotics may reduce prostatitis symptoms and are probably not associated with side effects. Antibiotics probably result in little to no difference in sexual problems and quality of life. There was no information on anxiety and depression. </p> <p><i>Anti‐inflammatories:</i> anti‐inflammatories may reduce prostatitis symptoms and may not be associated with side effects. There was no information on sexual problems, quality of life or anxiety and depression. </p> <p><i>Phytotherapy:</i> phytotherapy may reduce prostatitis symptoms and may not be associated with side effects. Phytotherapy may not improve sexual problems. There was no information on quality of life and anxiety and depression. </p> <p><i>Botulinum toxin A (BTA):</i> the injection of this toxin into the prostate may cause a large reduction in prostatitis symptoms, but if it is applied to muscles of the pelvis, BTA may not cause this effect. These injections may not be associated with side effects. There was no information on sexual problems, quality of life or anxiety and depression. </p> <p><i>Allopurinol:</i> allopurinol may result in little to no difference in prostatitis symptoms and may not be associated with side effects. There was no information on sexual problems, quality of life or anxiety and depression. </p> <p><i>Traditional Chinese Medicine (TCM):</i> TCM may reduce prostatitis symptoms and may not be associated with side effects. TCM probably does not improve sexual problems and it may not improve symptoms of anxiety and depression. There was no information on quality of life. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence was low to very low in most cases, meaning that there is much uncertainty surrounding the results. The most frequent problems detected in the included studies were an inadequate design, a small sample size and a short follow‐up time (usually 12 weeks). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012552-sec-0253" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012552-sec-0253">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012552-sec-0343">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012552-sec-0253"></div> <h3 class="title" id="CD012552-sec-0254">Implications for practice</h3> <section id="CD012552-sec-0254"> <p>We found low‐ to very low‐quality evidence that alpha blockers may reduce prostatitis symptoms based on a reduction of NIH‐CPSI scores greater than two (but less than eight) with an increased incidence of minor adverse events such as dizziness and hypotension. Other interventions such as antibiotics, anti‐inflammatories, intraprostatic botulinum A injection, traditional Chinese medicine, mepartricin and phosphodiesterase inhibitors may cause a reduction in prostatitis symptoms without an increased incidence of adverse events. Moderate‐quality evidence indicates that phytotherapy and 5‐alpha reductase inhibitors probably cause a small decrease in prostatitis symptoms and may not be associated with a greater incidence of adverse events. </p> <p>Moderate‐ to high‐quality evidence indicates that the following interventions may be ineffective for the reduction of prostatitis symptoms: anticholinergics, OM‐89, pentosan, pregabalin. Low‐quality evidence indicates that allopurinol, antidepressants and tanezumab may be ineffective for the reduction of prostatitis symptoms. </p> <p>Frequently we found few trials with active comparators and little evidence of the effects of these drugs on sexual dysfunction, quality of life or anxiety and depression. </p> <p>Based on our uncertainty about the true effects of the wide variety of available interventions, the selection of the right pharmacological agent can be tailored based on different factors such as: the need to alleviate a predominant type of symptom, each agent's safety profile, the patient's values and preferences, and other contextual factors. </p> </section> <h3 class="title" id="CD012552-sec-0255">Implications for research</h3> <section id="CD012552-sec-0255"> <p>Given the low‐quality evidence for most comparisons and outcomes included in this review, there is a need for additional research on the effects of some of the included interventions.These include: </p> <p> <ul id="CD012552-list-0038"> <li> <p>future clinical trials should include a full report of their methods for greater transparency about potential sources of bias. Additionally, acknowledging the subjective nature of the participant‐reported outcomes that are critical for decision‐making, masking of these interventions is warranted, and providing information about the methods used to minimise attrition bias; </p> </li> <li> <p>future studies should include a greater variety of outcomes, including sexual dysfunction, quality of life, and depression and anxiety, since this would represent the actual impact of these interventions on participants with CP/CPPS. Long‐term follow‐up is also needed, recognising the chronicity of this condition. It is also essential for studies to report the incidence of adverse events, to assess the net benefit of the interventions; </p> </li> <li> <p>ideally, studies should include more than 74 participants to reduce the imprecision of the findings when considering prostatitis symptoms using the National Institute of Health ‐ Chronic Prostatitis Symptom Index (NIH‐CPSI) score. Larger sample sizes are required when assessing the number of responders to treatment or other outcomes; </p> </li> <li> <p>considering the high comorbidity of participants with CP/CPPS, it is important for studies to include participants with comorbid conditions to assess subgroup effects. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012552-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012552-sec-0029"></div> <div class="table" id="CD012552-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Alpha blockers compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Alpha blockers compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre and multicentre studies in Bosnia and Herzegovina, Canada, China, USA, Finland, Germany, Malaysia, Russia, South Korea and Turkey<br/> <b>Intervention:</b> alpha blockers (terazosin, doxazosin, phenoxybenzamine, tamsulosin, alfuzosin, silodosin)<br/> <b>Comparison:</b> placebo or no intervention </p> <p>Some comparisons included alpha blockers as add‐on therapy to medical therapy (e.g. antibiotics) versus medical therapy alone. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with alpha‐blockers</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: range 6 weeks to 6 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1524<br/> (18 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ranged from 12.1 to 24.14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.01 lower<br/> (7.41 lower to 2.61 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>253</p> <p>(4 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The mean prostatitis symptoms ranged from 18.7 to 22.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 5.6 lower<br/> (10.89 lower to 0.82 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostatitis symptoms: 'responders'<br/> Number of participants with a 25% or 6‐point decrease in NIH‐CPSI scores<br/> Follow‐up: range 6 weeks to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>721<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.23<br/> (0.94 to 1.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 more per 1000<br/> (29 fewer to 291 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> <p>Any adverse event<br/> Follow‐up: range 6 weeks to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1588<br/> (19 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.60<br/> (1.09 to 2.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 more per 1000<br/> (8 more to 126 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction<br/> Assessed with: International Index of Erectile Function Scale. Benefit is indicated by higher scores<br/> Scale from: 5 to 25<br/> Follow‐up: range 6 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>452<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual dysfunction ranged from 16.1 to 18.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.26 higher<br/> (1.13 lower to 1.65 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> Assessed with: Short Form‐12 Health Status Questionnaire. Benefit is indicated by higher scores. The effect is reported for mental domain.<br/> Scale from: 0 to 100<br/> Follow‐up: range 6 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>421<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life ranged from 41 to 46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.15 higher<br/> (2.63 lower to 2.92 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression<br/> Assessed with: Hospital Anxiety and Depression Scale. Benefit is indicated by lower scores<br/> Scale from: 0 to 21<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety and depression was 12.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.1 lower<br/> (2.54 lower to 0.34 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval;<b>MD:</b> Mean difference; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to study limitations: unclear or high risk of bias in most domains in most studies.<br/> <sup>b</sup>Downgraded one level due to inconsistency: substantial or considerable heterogeneity.<br/> <sup>c</sup>Downgraded one level due to imprecision: confidence interval crosses the assumed threshold for the minimal clinically important difference. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012552-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">5‐alpha reductase inhibitors compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>5‐alpha reductase inhibitors compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre studies in Finland and USA<br/> <b>Intervention:</b> finasteride<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with 5 alpha reductase inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: 6 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms was 21.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.6 lower<br/> (5.43 lower to 3.77 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostatitis symptoms: 'responders'<br/> Number of participants with a 25% decrease in NIH‐CPSI scores<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>64<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.13<br/> (0.82 to 5.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 more per 1000<br/> (27 fewer to 686 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>105<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/> (0.33 to 2.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 fewer per 1000<br/> (109 fewer to 212 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to high risk of bias: unclear or high risk of bias in most domains in the main study of this comparison.<br/> <sup>b</sup>Downgraded one level due to imprecision: confidence interval includes appreciable benefits and harms. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012552-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antibiotic therapy compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Antibiotic therapy compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre and multicentre studies in USA, Canada, South Korea, Bosnia and Herzegovina and China<br/> <b>Intervention:</b> antibiotic therapy (ciprofloxacin or levofloxacin)<br/> <b>Comparison:</b> placebo </p> <p>Some comparisons included antibiotics as add‐on therapy to medical therapy (e.g. alpha blockers) versus medical therapy alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with antibiotic therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: range 6 weeks to 3 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>372<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ranged from 8.6 to 18.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.43 lower<br/> (4.72 lower to 0.15 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostatitis symptoms: 'responders'<br/> Number of participants with a 25% or 6‐point decrease in NIH‐CPSI scores<br/> Follo‐up: range 6 weeks to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>178<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/> (0.73 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 more per 1000<br/> (77 fewer to 211 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: range 3 weeks to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>336<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/> (0.66 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 more per 1000<br/> (72 fewer to 117 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction<br/> Assessed with: International Index of Erectile Function Scale. Benefit is indicated by higher scores<br/> Scale from: 5 to 25<br/> Follow‐up: 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual dysfunction was 16.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.4 higher<br/> (1.59 lower to 2.39 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> Assessed with: SF‐12 Health Status Questionnaire. Benefit is indicated by higher scores. The effect is reported for mental domain<br/> Scale from: 0 to 100<br/> Follow up: 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was 44.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.9 lower<br/> (7.94 lower to 0.14 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to inconsistency: statistical heterogeneity 75%.<br/> <sup>b</sup>Downgraded one level due to high risk of bias: unclear or high risk of bias in most domains in the main study of this comparison.<br/> <sup>c</sup>Downgraded one level due to imprecision: confidence interval crosses the threshold for the minimal clinically important difference.<br/> <sup>d</sup>We did not downgrade for risk of bias since the main study contributing to this estimate has low risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012552-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Anti‐inflammatories compared to control for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Anti‐inflammatories compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre and multicentre studies in UK, South Korea, Turkey, China<br/> <b>Intervention:</b> anti‐inflammatories (non‐steroidal anti‐inflammatories, corticosteroids, antileukotrienes, tiocolchicoside)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with anti‐inflammatories</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: range 6 weeks to 6 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>585<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ranged from 8.6 to 19.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.5 lower<br/> (3.74 lower to 1.26 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostatitis symptoms: 'responders'<br/> Number of participants with a 25% or 6‐point decrease in NIH‐CPSI scores<br/> Follow‐up: range 8 weeks to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>82<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.44<br/> (0.68 to 3.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 more per 1000<br/> (29 fewer to 185 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: range 4 weeks to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>540<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.27<br/> (0.81 to 2.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 more per 1000<br/> (19 fewer to 98 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to high risk of bias: unclear or high risk of bias in most domains in most studies.<br/> <sup>b</sup>Downgraded one level due to inconsistency: high statistical heterogeneity (&gt; 80%).<br/> <sup>c</sup>Downgraded one level due to imprecision: confidence interval crosses the threshold for the minimal clinically important difference. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012552-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Phytotherapy compared to placebo or other agents for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Phytotherapy compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre and multicentre studies in Russia, USA, Italy, South Korea, Germany and China<br/> <b>Intervention:</b> phytotherapeutics agents (pollen extract, calendula‐curcuma, Prolit Super Septo®, flavonoids and cranberries)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or other agents</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with phytotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: range 1 month to 3 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ranged from 10.3 to 14.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.02 lower<br/> (6.81 lower to 3.23 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostatitis symptoms: 'responders'<br/> Number of participants with a 25% or 6‐point decrease in NIH‐CPSI scores<br/> Follow‐up: range 1 month to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>224<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.78<br/> (1.25 to 2.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>384 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299 more per 1000<br/> (96 more to 584 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: range 1 month to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>540<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.54 to 2.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 more per 1000<br/> (19 fewer to 56 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction<br/> Assessed with: International Index of Erectile Function Scale Benefit is indicated by higher scores<br/> Scale from: 5 to 25<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual dysfunction was 18.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.5 higher<br/> (2.67 higher to 4.33 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to high risk of bias: unclear or high risk of bias in most domains in most studies.<br/> <sup>b</sup>Downgraded one level due to imprecision: confidence interval crosses the threshold for the minimal clinically important difference.<br/> <sup>c</sup>Downgraded one level due to imprecision: few events, resulting in a confidence interval that includes appreciable benefits and harms. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012552-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Botulinum toxin A compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Botulinum toxin A compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient,outpatient, single‐centre studies in Iran and USA<br/> <b>Intervention:</b> botulinum toxin A injection (intraprostatic or pelvic floor muscles)<br/> <b>Comparison:</b> sham procedure (saline injection) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with botulinum toxin A</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms</p> <p><b>Subgroup</b>: Intraprostatic injection, participants age &gt; 50 years old, basal NIH‐CPSI score &gt; 30 </p> <p>Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: 6 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ‐ Intraprostatic injection was 36.37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 25.8 lower<br/> (30.15 lower to 21.45 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms</p> <p><b>Subgroup</b>: Pelvic floor muscles injection, participants age &lt; 50 years old, basal NIH‐CPSI score &lt; 30<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ‐ Pelvic floor muscles injection was 27.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.6 lower<br/> (5.59 lower to 0.39 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Assessed with: e.g.: haematuria<br/> Follow‐up: range 1 month to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>89<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.00<br/> (0.25 to 99.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 more per 1000<br/> (16 fewer to 2.151 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to unclear risk of bias (random sequence generation).<br/> <sup>b</sup>Downgraded one level due to imprecision: small sample size resulting in wide confidence interval.<br/> <sup>c</sup>Downgraded one level due to high risks of performance and detection bias,<br/> <sup>d</sup>Downgraded one level due to high risk of bias: unclear or high risks of bias in some domains.<br/> <sup>e</sup>Downgraded one level due to imprecision: few events. The number of adverse events was zero in the control group, but one case was imputed in this group in order to obtain the relative estimates. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012552-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Allopurinol compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Allopurinol compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre studies in Sweden and Iran<br/> <b>Intervention:</b> allopurinol<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with allopurinol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: 3 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms was 17.21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.21 lower<br/> (4.48 lower to 4.06 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p>Follow‐up: 3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No adverse events were observed in the included studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to imprecision: confidence interval includes appreciable benefits and harms.˜<br/> <sup>b</sup>Downgraded one level due to high risk of bias: unclear or high risks of bias in the main study of this comparison.<br/> <sup>c</sup>Downgraded one level due to imprecision: few events (zero events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012552-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Traditional Chinese Medicine compared to placebo or usual care for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Traditional Chinese Medicine compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre studies in China<br/> <b>Intervention:</b> Traditional Chinese Medicine (herbs decoctions, capsules and suppositories)<br/> <b>Comparison:</b> placebo </p> <p>Some comparisons included antibiotics, alpha blockers and other Western medications as co‐interventions </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or usual care</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with Traditional Chinese medicine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: range 2 weeks to 2 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>835<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ranged from 11.17 to 15.02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.13 lower<br/> (4.99 lower to 1.28 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: range 4 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>584<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.34<br/> (0.22 to 8.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 more per 1000<br/> (23 fewer to 203 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction<br/> Assessed with: International Index of Erectile Function Scale. Benefit is indicated by higher scores<br/> Scale from: 5 to 25<br/> Follow‐up: 2 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual dysfunction was 14.93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.27 higher<br/> (1.17 lower to 1.71 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression: anxiety<br/> Assessed with: Hamilton Anxiety Rating Scale (HAM‐A)<br/> Scale from: 0 to 56<br/> Follow‐up: 2 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety and depression: anxiety was 23.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.5 lower<br/> (11.7 lower to 7.3 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression: depression<br/> Assessed with: Hamilton Depression Rating Scale (HAM‐D)<br/> Scale from: 0 to 54<br/> Follow‐up: 2 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety and depression: depression was 24.07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 7.84 lower<br/> (10.71 lower to 4.97 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to inconsistency: high statistical heterogeneity (&gt; 80%). Some of this inconsistency might be explained by the differences between the interventions under this comparison.<br/> <sup>b</sup>Downgraded one level due to high risk of bias: unclear or high risks of bias in most domains in most studies.<br/> <sup>c</sup>Downgraded one level due to imprecision: few events, resulting in a confidence interval that includes appreciable benefits and harms.<br/> <sup>d</sup>Downgraded one level due to imprecision: small sample size resulting in wide confidence interval that crosses the threshold for the minimal clinically important difference. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012552-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012552-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012552-sec-0283">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012552-sec-0030"></div> <section id="CD012552-sec-0031"> <h3 class="title" id="CD012552-sec-0031">Description of the condition</h3> <p>Prostatitis is a common disorder affecting 1.8% of men in the USA (<a href="./references#CD012552-bbs2-0253" title="SuskindAM , BerrySH , EwingBA , ElliottMN , SuttorpMJ , ClemensJQ . The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. Journal of Urology2013;189(1):141‐5. [PUBMED: 23164386] ">Suskind 2013</a>), while 10% to 14% of men in Europe and the USA suffer from prostatitis‐like symptoms (<a href="./references#CD012552-bbs2-0171" title="BajpayeeP , KumarK , SharmaS , MauryaN , KumarP , SinghR , et al. Prostatitis: prevalence, health impact and quality improvement strategies. Acta Poloniae Pharmaceutica2012;69(4):571‐9. [PUBMED: 22876597] ">Bajpayee 2012</a>). This health problem motivates one per cent of primary care visits and eight per cent of urology consultations in the USA (<a href="./references#CD012552-bbs2-0182" title="CollinsMM , StaffordRS , O'LearyMP , BarryMJ . How common is prostatitis? A national survey of physician visits. Journal of Urology1998;159(4):1224‐8. [PUBMED: 9507840] ">Collins 1998</a>). Only 5 to 10 per cent of prostatitis cases have a bacterial origin (<a href="./references#CD012552-bbs2-0173" title="BartolettiR , CaiT , MondainiN , DinelliN , PinziN , PavoneC , et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case‐control observational study. Journal of Urology2007;178(6):2411‐5; discussion 2415. [PUBMED: 17937946] ">Bartoletti 2007</a>; <a href="./references#CD012552-bbs2-0185" title="De LaRosetteJJ , HubregtseMR , MeulemanEJ , Stolk‐EngelaarMV , DebruyneFM . Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology1993;41(4):301‐7. [PUBMED: 8470312] ">De La Rosette 1993</a>). This disorder can affect men of all ages and ethnic origins, but it is more common in younger men with a mean age at onset of 42 years old (<a href="./references#CD012552-bbs2-0245" title="SchaefferAJ , LandisJR , KnaussJS , PropertKJ , AlexanderRB , LitwinMS , et al. Demographic and clinical characteristics of men with chronic prostatitis: the National Institutes of Health chronic prostatitis cohort study. Journal of Urology2002;168(2):593‐8. [PUBMED: 12131316] ">Schaeffer 2002</a>). The two main clinical features of prostatitis are pelvic pain and lower urinary tract symptoms, although there is a wide range of clinical presentations (<a href="./references#CD012552-bbs2-0230" title="NickelJC , NybergLM , HennenfentM . Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology1999;54(2):229‐33. [PUBMED: 10443716] ">Nickel 1999</a>). </p> <p>The National Institutes of Health (NIH) classification identifies four types of prostatitis (<a href="./references#CD012552-bbs2-0230" title="NickelJC , NybergLM , HennenfentM . Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology1999;54(2):229‐33. [PUBMED: 10443716] ">Nickel 1999</a>): types I and II, being acute and chronic bacterial prostatitis respectively; type III, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS); and type IV, asymptomatic prostatitis. It remains unclear whether type III can be linked in all cases to prostatic involvement (<a href="./references#CD012552-bbs2-0256" title="TrueLD , BergerRE , RothmanI , RossSO , KriegerJN . Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study. Journal of Urology1999;162(6):2014‐8. [PUBMED: 10569559] ">True 1999</a>), hence the alternate denomination (Chronic Pelvic Pain Syndrome). CP/CPPS is sub‐classified as type IIIa (inflammatory), and type IIIb (non‐inflammatory), depending on the presence of inflammatory cells in prostatic secretions. </p> <p>CP/CPPS is defined when pelvic pain is present for at least three of the preceding six months and no other identifiable causes have been detected (<a href="./references#CD012552-bbs2-0230" title="NickelJC , NybergLM , HennenfentM . Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology1999;54(2):229‐33. [PUBMED: 10443716] ">Nickel 1999</a>). Other symptoms include obstructive or irritative voiding difficulties, ejaculatory pain, and haematospermia. Men affected by CP/CPPS have a significantly decreased quality of life, and the level of pelvic pain is strongly associated with sexual dysfunction (<a href="./references#CD012552-bbs2-0255" title="TrinchieriA , MagriV , CarianiL , BonamoreR , RestelliA , GarlaschiMC , et al. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome. Archivio Italiano di Urologia, Andrologia2007;79(2):67‐70. [PUBMED: 17695411] ">Trinchieri 2007</a>; <a href="./references#CD012552-bbs2-0259" title="WalzJ , PerrotteP , HuttererG , SuardiN , JeldresC , BenardF , et al. Impact of chronic prostatitis‐like symptoms on the quality of life in a large group of men. BJU International2007;100(6):1307‐11. [PUBMED: 17941922] ">Walz 2007</a>). CP/CPPS is associated with other functional somatic syndromes such as irritable bowel syndrome, interstitial cystitis, chronic fatigue syndrome and fibromyalgia (<a href="./references#CD012552-bbs2-0243" title="RodriguezMA , AfariN , BuchwaldDS . Evidence for overlap between urological and nonurological unexplained clinical conditions. Journal of Urology2009;182(5):2123‐31. [PUBMED: 19758633] ">Rodriguez 2009</a>; <a href="./references#CD012552-bbs2-0253" title="SuskindAM , BerrySH , EwingBA , ElliottMN , SuttorpMJ , ClemensJQ . The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. Journal of Urology2013;189(1):141‐5. [PUBMED: 23164386] ">Suskind 2013</a>). Diagnosis is usually based on the man's history, physical examination, urinalysis and the two‐ or four‐glass test (<a href="./references#CD012552-bbs2-0231" title="NickelJC . Prostatitis and related conditions, orchitis and epididymitis. Campbell‐Walsh: Urology. 10th Edition. Elsevier, 2012:337‐41. ">Nickel 2012</a>). Further investigations are performed when considering differential diagnosis. </p> <p>There are different theories about the aetiology and pathophysiology of CP/CPPS, as follows. </p> <p> <ul id="CD012552-list-0001"> <li> <p>Infection: bacterial DNA is detected in a significant proportion of men with CP/CPPS (<a href="./references#CD012552-bbs2-0206" title="HouDS , LongWM , ShenJ , ZhaoLP , PangXY , XuC . Characterisation of the bacterial community in expressed prostatic secretions from patients with chronic prostatitis/chronic pelvic pain syndrome and infertile men: a preliminary investigation. Asian Journal of Andrology2012;14(4):566‐73. [PUBMED: 22635162] ">Hou 2012</a>). A previous history of sexually‐transmitted infection is more frequent in men with CP/CPPS (<a href="./references#CD012552-bbs2-0236" title="PontariMA , McNaughton‐CollinsM , O'LearyMP , CalhounEA , JangT , KusekJW , et al. A case‐control study of risk factors in men with chronic pelvic pain syndrome. BJU International2005;96(4):559‐65. [PUBMED: 16104910] ">Pontari 2005</a>). Nevertheless, the isolation of uropathogenic bacteria in prostatic fluids is similar to controls (<a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>). </p> </li> <li> <p>Inflammation/autoimmunity: elevated concentrations of pro‐inflammatory cytokines (interleukin 1, tumour necrosis factor, interferon‐γ) and of autoimmunity activity (T‐cell proliferation responses to prostate antigens) is found in men suffering from CP/CPPS and in animal models (<a href="./references#CD012552-bbs2-0235" title="PontariMA , RuggieriMR . Mechanisms in prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;172(3):839‐45. [PUBMED: 15310980] ">Pontari 2004</a>). </p> </li> <li> <p>Neuropsychological factors: the central nervous system might be involved through several mechanisms of pain sensitisation (<a href="./references#CD012552-bbs2-0227" title="MillerLJ , FischerKA , GoralnickSJ , LittM , BurlesonJA , AlbertsenP , et al. Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(4):603‐8. [PUBMED: 11927336] ">Miller 2002</a>; <a href="./references#CD012552-bbs2-0260" title="YangCC , LeeJC , KrommBG , CiolMA , BergerR . Pain sensitization in male chronic pelvic pain syndrome: why are symptoms so difficult to treat?. Journal of Urology2003;170(3):823‐6; discussion 826‐7. [PUBMED: 12913708] ">Yang 2003</a>). Increased stress burden, stress response, pain catastrophising cognitions, poor social functioning and psychiatric comorbidity (anxiety and depression) are contributing factors (<a href="./references#CD012552-bbs2-0242" title="RiegelB , BruenahlCA , AhyaiS , BingelU , FischM , LoweB . Assessing psychological factors, social aspects and psychiatric co‐morbidity associated with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men ‐‐ a systematic review. Journal of Psychosomatic Research2014;77(5):333‐50. [PUBMED: 25300538] ">Riegel 2014</a>). </p> </li> <li> <p>Dyssynergic voiding associated with bladder neck hypertrophy is detected in men suffering from refractory CP/CPPS (<a href="./references#CD012552-bbs2-0186" title="DellabellaM , MilaneseG , MuzzonigroG . Correlation between ultrasound alterations of the preprostatic sphincter and symptoms in patients with chronic prostatitis‐chronic pelvic pain syndrome. Journal of Urology2006;176(1):112‐8. [PUBMED: 16753384] ">Dellabella 2006</a>; <a href="./references#CD012552-bbs2-0207" title="HruzP , DanuserH , StuderUE , HochreiterWW . Non‐inflammatory chronic pelvic pain syndrome can be caused by bladder neck hypertrophy. European Urology2003;44(1):106‐10; discussion 110. [PUBMED: 12814683] ">Hruz 2003</a>). Intra‐prostatic urinary reflux and increased intra‐prostatic pressure is associated with inflammation in CP/CPPS (<a href="./references#CD012552-bbs2-0213" title="KirbyRS , LoweD , BultitudeMI , ShuttleworthKE . Intra‐prostatic urinary reflux: an aetiological factor in abacterial prostatitis. British Journal of Urology1982;54(6):729‐31. [PUBMED: 7150931] ">Kirby 1982</a>; <a href="./references#CD012552-bbs2-0226" title="MehikA , HellstromP , NickelJC , KilponenA , LeskinenM , SarpolaA , et al. The chronic prostatitis‐chronic pelvic pain syndrome can be characterized by prostatic tissue pressure measurements. Journal of Urology2002;167(1):137‐40. [PUBMED: 11743292] ">Mehik 2002</a>). </p> </li> <li> <p>Other theories described for this condition include: adrenal axis abnormalities (<a href="./references#CD012552-bbs2-0166" title="AndersonRU , OrenbergEK , ChanCA , MoreyA , FloresV . Psychometric profiles and hypothalamic‐pituitary‐adrenal axis function in men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2008;179(3):956‐60. [PUBMED: 18207189] ">Anderson 2008</a>), pelvic floor muscles dysfunction (<a href="./references#CD012552-bbs2-0199" title="HetrickDC , GlazerH , LiuYW , TurnerJA , FrestM , BergerRE . Pelvic floor electromyography in men with chronic pelvic pain syndrome: a case‐control study. Neurourology and Urodynamics2006;25(1):46‐9. [PUBMED: 16167354] ">Hetrick 2006</a>; <a href="./references#CD012552-bbs2-0248" title="ShoskesDA , BergerR , ElmiA , LandisJR , PropertKJ , ZeitlinS . Muscle tenderness in men with chronic prostatitis/chronic pelvic pain syndrome: the chronic prostatitis cohort study. Journal of Urology2008;179(2):556‐60. [PUBMED: 18082223] ">Shoskes 2008a</a>), pelvic nerves entrapment (<a href="./references#CD012552-bbs2-0168" title="AntolakSJJr , HoughDM , PawlinaW , SpinnerRJ . Anatomical basis of chronic pelvic pain syndrome: the ischial spine and pudendal nerve entrapment. Medical Hypotheses2002;59(3):349‐53. [PUBMED: 12208168] ">Antolak 2002</a>), genetic predisposition to inflammation (<a href="./references#CD012552-bbs2-0247" title="ShoskesDA , AlbakriQ , ThomasK , CookD . Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome: association with diagnosis and treatment response. Journal of Urology2002;168(1):331‐5. [PUBMED: 12050565] ">Shoskes 2002</a>), and oxidative stress (<a href="./references#CD012552-bbs2-0170" title="ArisanED , ArisanS , KiremitMC , TigliH , CaskurluT , Palavan‐UnsalN , et al. Manganese superoxide dismutase polymorphism in chronic pelvic pain syndrome patients. Prostate Cancer and Prostatic Diseases2006;9(4):426‐31. [PUBMED: 16847469] ">Arisan 2006</a>). </p> </li> </ul> </p> </section> <section id="CD012552-sec-0032"> <h3 class="title" id="CD012552-sec-0032">Description of the intervention</h3> <p>There are a wide variety of interventions for treating CP/CPPS, each one addressing a different pathophysiological or symptomatic framework. The diversity of available interventions reflects the complexity of the condition and how little is known about its determinants. </p> <p>Management of CP/CPPS involves a multimodal and tailored approach (<a href="./references#CD012552-bbs2-0240" title="ReesJ , AbrahamsM , DobleA , CooperA . Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU International2015;116(4):509‐25. [PUBMED: 25711488] ">Rees 2015</a>; <a href="./references#CD012552-bbs2-0249" title="ShoskesDA , NickelJC , RackleyRR , PontariMA . Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer and Prostatic Diseases2008;12(2):177‐83. ">Shoskes 2008b</a>). Some of the strategies used alone or in combination are the following. </p> <section id="CD012552-sec-0033"> <h4 class="title">Pharmacological interventions:</h4> <p> <ul id="CD012552-list-0002"> <li> <p>Alpha blockers</p> </li> <li> <p>5‐alpha reductase inhibitors</p> </li> <li> <p>Antibiotic therapy (quinolones, tetracyclines and other agents)</p> </li> <li> <p>Anti‐inflammatories (nonsteroidal anti‐inflammatory drugs (NSAIDs), corticosteroids)</p> </li> <li> <p>Phytotherapy (pollen extract and bioflavonoids)</p> </li> <li> <p>Botulinum toxin A</p> </li> <li> <p>Allopurinol</p> </li> <li> <p>Traditional medicine (traditional Chinese medicine, etc.)</p> </li> <li> <p>Other pharmacological agents (e.g. pregabalin)</p> </li> </ul> </p> </section> <section id="CD012552-sec-0034"> <h4 class="title">Non‐pharmacological interventions:</h4> <p> <ul id="CD012552-list-0003"> <li> <p>Acupuncture and electroacupuncture</p> </li> <li> <p>Local thermotherapy</p> </li> <li> <p>Extracorporeal shockwave therapy</p> </li> <li> <p>Myofascial trigger point release</p> </li> <li> <p>Biofeedback</p> </li> <li> <p>Psychological support</p> </li> <li> <p>Prostatic surgery</p> </li> <li> <p>Other miscellaneous non‐pharmacological therapies</p> </li> </ul> </p> </section> <section id="CD012552-sec-0035"> <h4 class="title">Multimodal approaches:</h4> <p> <ul id="CD012552-list-0004"> <li> <p>Combination therapy: alpha blockers plus antibiotics, antibiotics plus analgesics, etc. </p> </li> </ul> </p> <section id="CD012552-sec-0036"> <h5 class="title">Adverse effects</h5> <p>Common side effects of pharmacological regimens include (<a href="./references#CD012552-bbs2-0174" title="BruntonLL , ChabnerBA , KnollmannBC . Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th Edition. McGraw‐Hill Education, 10 January 2011. ">Brunton 2011</a>) the following. </p> <p> <ul id="CD012552-list-0005"> <li> <p>Alpha blockers: hypotension, ejaculatory dysfunction, headache, dizziness, and nasal congestion </p> </li> <li> <p>5‐alpha‐reductase inhibitors: decreased libido, impotence, potentiation of hypotension (in combination with alpha blockers) </p> </li> <li> <p>Quinolones: gastrointestinal discomfort, headache, dizziness, rash, and tendinopathy</p> </li> <li> <p>Tetracyclines: gastrointestinal discomfort, rash, teeth discolouration, and hepatotoxicity</p> </li> <li> <p>NSAIDs: peripheral oedema, rash, dyspepsia, peptic ulcer and bleeding, renal and hepatic injury, and increased risk of adverse cardiovascular events </p> </li> <li> <p>Phytotherapy: gastrointestinal discomfort and allergic reactions</p> </li> </ul> </p> <p>The most common side effect in physical therapies is pain worsened during or immediately after the procedure (<a href="./references#CD012552-bbs2-0190" title="FitzgeraldMP , AndersonRU , PottsJ , PayneCK , PetersKM , ClemensJQ , et al. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. Journal of Urology2013;189(1 Suppl):S75‐85. [PUBMED: 23234638] ">Fitzgerald 2013</a>). </p> </section> </section> </section> <section id="CD012552-sec-0037"> <h3 class="title" id="CD012552-sec-0037">How the intervention might work</h3> <section id="CD012552-sec-0038"> <h4 class="title">Pharmacological interventions</h4> <p>Alpha blockers reduce the autonomic sympathetic tone in the bladder neck and prostate, improving urinary flow, and lower urinary tract symptoms. 5‐alpha‐reductase inhibitors reduce the production of dihydrotestosterone and consequently the size of the prostatic gland dependent on the stimulation of this hormone. This might reduce pain and impaired voiding (<a href="./references#CD012552-bbs2-0174" title="BruntonLL , ChabnerBA , KnollmannBC . Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th Edition. McGraw‐Hill Education, 10 January 2011. ">Brunton 2011</a>). </p> <p>NSAIDs are antagonists to the cyclo‐oxygenases enzymes (COX) type 1 and 2 and their pro‐inflammatory sub‐products (<a href="./references#CD012552-bbs2-0174" title="BruntonLL , ChabnerBA , KnollmannBC . Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th Edition. McGraw‐Hill Education, 10 January 2011. ">Brunton 2011</a>). Both nonselective and selective (COX‐2) inhibitors could therefore decrease inflammatory mediated pain in CP/CPPS. </p> <p>Phytotherapy includes the use of pollen extract and bioflavonoids that appear to have anti‐inflammatory properties, decreasing acinar cell proliferation and the production of interleukin‐6, tumour necrosis factor α, and other pro‐inflammatory cytokines (<a href="./references#CD012552-bbs2-0176" title="CapodiceJL , BemisDL , ButtyanR , KaplanSA , KatzAE . Complementary and alternative medicine for chronic prostatitis/chronic pelvic pain syndrome. Evidence‐Based Complementary and Alternative Medicine2005;2(4):495‐501. ">Capodice 2005</a>; <a href="./references#CD012552-bbs2-0211" title="KamijoT , SatoS , KitamuraT . Effect of cernitin pollen‐extract on experimental nonbacterial prostatitis in rats. Prostate2001;49(2):122‐31. [PUBMED: 11582591] ">Kamijo 2001</a>). </p> <p>Even if CP/CPPS is defined when no bacterial cause can be identified, antibiotics have been used to treat it on the assumption of the existence of an occult or under‐treated infection (<a href="./references#CD012552-bbs2-0206" title="HouDS , LongWM , ShenJ , ZhaoLP , PangXY , XuC . Characterisation of the bacterial community in expressed prostatic secretions from patients with chronic prostatitis/chronic pelvic pain syndrome and infertile men: a preliminary investigation. Asian Journal of Andrology2012;14(4):566‐73. [PUBMED: 22635162] ">Hou 2012</a>). </p> <p>Allopurinol would reduce the prostatic secretions of purine and pyrimidine base containing metabolites in urine. These metabolites could be responsible for prostatic inflammation through urinary reflux (<a href="./references#CD012552-bbs2-0225" title="McNaughtonC O , WiltT . Allopurinol for chronic prostatitis. Cochrane Database of Systematic Reviews2002, Issue 4. [DOI: 10.1002/14651858.CD001041] ">McNaughton 2002</a>). </p> <p>Botulinum toxin A has denervating properties and also causes reduction in pain mediators when applied to the prostate in animal models. It also causes apoptosis and involution of the prostate gland (<a href="./references#CD012552-bbs2-0179" title="ChuangYC , ChancellorMB . The application of botulinum toxin in the prostate. Journal of Urology2006;176(6 Pt 1):2375‐82. ">Chuang 2006</a>). </p> </section> <section id="CD012552-sec-0039"> <h4 class="title">Non‐pharmacological interventions</h4> <p>Acupuncture targets specific cutaneous points representing various internal organs using fine needle insertion and sometimes adding electric current to increase stimulation (electroacupuncture). In animal models electroacupuncture has anti‐inflammatory properties and activates analgesic neurotransmitters (<a href="./references#CD012552-bbs2-0212" title="KimHW , RohDH , YoonSY , KangSY , KwonYB , HanHJ , et al. The anti‐inflammatory effects of low‐ and high‐frequency electroacupuncture are mediated by peripheral opioids in a mouse air pouch inflammation model. Journal of Alternative and Complementary Medicine (New York, N.Y.)2006;12(1):39‐44. [PUBMED: 16494567] ">Kim 2006</a>). </p> <p>Locally‐induced hyperthermia, using transrectal or transurethral procedures, could decrease oxygen free radicals associated with prostatic inflammation (<a href="./references#CD012552-bbs2-0192" title="GaoM , DingH , ZhongG , LuJ , WangH , LiQ , et al. The effects of transrectal radiofrequency hyperthermia on patients with chronic prostatitis and the changes of MDA, NO, SOD, and Zn levels in pretreatment and posttreatment. Urology2012;79(2):391‐6. [PUBMED: 22100490] ">Gao 2012</a>). </p> <p>Myofascial trigger points release targets pelvic floor musculature dysfunction as a potential cause or contributor to CP/CPPS (<a href="./references#CD012552-bbs2-0190" title="FitzgeraldMP , AndersonRU , PottsJ , PayneCK , PetersKM , ClemensJQ , et al. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. Journal of Urology2013;189(1 Suppl):S75‐85. [PUBMED: 23234638] ">Fitzgerald 2013</a>). Biofeedback also addresses pelvic floor muscle through initial contraction in order to achieve further relaxation (<a href="./references#CD012552-bbs2-0176" title="CapodiceJL , BemisDL , ButtyanR , KaplanSA , KatzAE . Complementary and alternative medicine for chronic prostatitis/chronic pelvic pain syndrome. Evidence‐Based Complementary and Alternative Medicine2005;2(4):495‐501. ">Capodice 2005</a>). </p> <p>It has been suggested that psychological treatments could be helpful in all types of chronic pain syndromes and the psychiatric comorbidity associated with the condition (e.g. depression secondary to chronic pain) (<a href="./references#CD012552-bbs2-0242" title="RiegelB , BruenahlCA , AhyaiS , BingelU , FischM , LoweB . Assessing psychological factors, social aspects and psychiatric co‐morbidity associated with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men ‐‐ a systematic review. Journal of Psychosomatic Research2014;77(5):333‐50. [PUBMED: 25300538] ">Riegel 2014</a>). </p> </section> <section id="CD012552-sec-0040"> <h4 class="title">Clinical phenotyping</h4> <p>Clincal phenotyping is a strategy that was developed in order to deliver customised treatment in an aetiologic framework (<a href="./references#CD012552-bbs2-0249" title="ShoskesDA , NickelJC , RackleyRR , PontariMA . Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer and Prostatic Diseases2008;12(2):177‐83. ">Shoskes 2008b</a>). The UPOINT system addresses six domains: <b>U</b> rinary symptoms, <b>P</b> sychosocial dysfunction, <b>O</b> rgan‐specific findings, <b>I</b> nfection, <b>N</b> eurologic dysfunction, and <b>T</b> enderness of muscles, and offers an algorithmic approach to the use of the aforementioned interventions. The number of affected domains correlates significantly with the prostatitis symptoms score, and the addition of a <b>S</b>exual dysfunction domain (UPOINT(S)) improves accuracy in stratification of symptom severity (<a href="./references#CD012552-bbs2-0223" title="MagriV , WagenlehnerF , PerlettiG , SchneiderS , MarrasE , NaberKG , et al. Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. Journal of Urology2010;184(6):2339‐45. [PUBMED: 20952019] ">Magri 2010</a>). While in itself it is not an intervention, it serves as a screening tool to select the most appropriate intervention for each person. </p> </section> </section> <section id="CD012552-sec-0041"> <h3 class="title" id="CD012552-sec-0041">Why it is important to do this review</h3> <p>The Cochrane Urology Group undertook an extensive prioritisation exercise to identify a core portfolio of the most clinically important titles. This title was identified as a clinically important priority by the urology expert panel for development, maintenance, and investment of resources by the editorial base. </p> <p>CP/CPPS is a prevalent condition amongst men and it causes significant impairment of quality of life. There was a previous Cochrane Review on the same subject, but with a different methodological approach (<a href="./references#CD012552-bbs2-0265" title="McNaughton CollinsM , MacDonaldR , WiltTJ . Interventions for chronic abacterial prostatitis. Cochrane Database of Systematic Reviews1999, Issue 4. [DOI: 10.1002/14651858.CD002080] ">McNaughton Collins 1999</a>). Other non‐Cochrane systematic reviews were also undertaken in previous years: some of them focused on individual interventions (<a href="./references#CD012552-bbs2-0239" title="QinZ , WuJ , ZhouJ , LiuZ . Systematic review of acupuncture for chronic prostatitis/chronic pelvic pain syndrome. Medicine2016;95(11):e3095. [PUBMED: 26986148] ">Qin 2016</a>; <a href="./references#CD012552-bbs2-0261" title="YangG , WeiQ , LiH , YangY , ZhangS , DongQ . The effect of alpha‐adrenergic antagonists in chronic prostatitis/chronic pelvic pain syndrome: a meta‐analysis of randomized controlled trials. Journal of Andrology2006;27(6):847‐52. ">Yang 2006</a>; <a href="./references#CD012552-bbs2-0263" title="ZhuY , WangC , PangX , LiF , ChenW , TanW . Antibiotics are not beneficial in the management of category III prostatitis: a meta analysis. Urology Journal2014;11(2):1377‐85. [PUBMED: 24807747] ">Zhu 2014</a>), while others had a wider scope of interventions (<a href="./references#CD012552-bbs2-0167" title="AnothaisintaweeT , AttiaJ , NickelJC , ThammakraisornS , NumthavajP , McEvoyM , et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta‐analysis. JAMA2011;305(1):78‐86. ">Anothaisintawee 2011</a>; <a href="./references#CD012552-bbs2-0181" title="CohenJM , FaginAP , HaritonE , NiskaJR , PierceMW , KuriyamaA , et al. Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta‐analysis. PLoS One2012;7(8):e41941. ">Cohen 2012</a>; <a href="./references#CD012552-bbs2-0222" title="MagistroG , WagenlehnerFM , GrabeM , WeidnerW , StiefCG , NickelJC . Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. European Urology2016;69(2):286‐97. ">Magistro 2016</a>). We consider that a new and updated Cochrane Review is needed in order to critically summarise the body of evidence for this complex condition and using the GRADE approach, thus providing key information about the best estimate of the magnitude of the effect in relative terms and absolute differences for patient‐important outcomes. Previous systematic reviews did not use this approach and had variable adherence to the rigorous methodology recommended by Cochrane. </p> <p>The protocol for this review was first published in August 2016 with the title <i>Interventions for treating chronic prostatitis/chronic pelvic pain syndrome</i> (<a href="./references#CD012552-bbs2-0264" title="FrancoJVA , TirapeguiFI , TurkT , GarroteV , ViettoV . Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD012552] ">Franco 2017</a>). Due to the retrieval of a significant number of included studies, the review team and the Cochrane Urology Group decided to split the review into two more narrowly defined reviews: <i>Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome</i> (<a href="./references#CD012552-bbs2-0191" title="FrancoJV , TurkT , JungJH , XiaoYT , IakhnoS , GarroteV , et al. Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database of Systematic Reviews2018, Issue 5. [DOI: 10.1002/14651858.CD012551.pub3] ">Franco 2018</a>) and <i>Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome</i>. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012552-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012552-sec-0042">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012552-sec-0295">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012552-sec-0042"></div> <p>To assess the effects of pharmacological therapies for chronic prostatitis/chronic pelvic pain syndrome. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012552-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012552-sec-0043">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012552-sec-0296">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012552-sec-0043"></div> <section id="CD012552-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012552-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs). We included studies regardless of their publication status or language of publication. </p> </section> <section id="CD012552-sec-0046"> <h4 class="title">Types of participants</h4> <p>We included men of all ages, regardless of social condition or ethnic origin, suffering from chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), according with type III prostatitis of the NIH classification. </p> <p>If we identified studies in which only a subset of participants were relevant to this review, we included them if data were available separately for the relevant subset. </p> </section> <section id="CD012552-sec-0047"> <h4 class="title">Types of interventions</h4> <p>We planned to investigate the following comparisons of experimental intervention versus comparator intervention. Concomitant interventions have to be the same in the experimental and comparator groups to establish fair comparisons. We performed a condition‐based comprehensive bibliographic search in order to find all interventions tested so far for CP/CPPS; some of them therefore might not be listed in this section. </p> <section id="CD012552-sec-0048"> <h5 class="title">Pharmacological interventions:</h5> <p> <ul id="CD012552-list-0006"> <li> <p>Alpha blockers</p> </li> <li> <p>5‐alpha reductase inhibitors</p> </li> <li> <p>Antibiotic therapy (quinolones, tetracyclines and other agents)</p> </li> <li> <p>Anti‐inflammatories (nonsteroidal anti‐inflammatory drugs (NSAIDs), corticosteroids)</p> </li> <li> <p>Phytotherapy (pollen extract and bioflavonoids)</p> </li> <li> <p>Botulinum toxin A</p> </li> <li> <p>Allopurinol</p> </li> <li> <p>Traditional medicine (traditional Chinese medicine, etc.)</p> </li> <li> <p>Other pharmacological agents</p> </li> </ul> </p> </section> <section id="CD012552-sec-0049"> <h5 class="title">Multimodal approaches:</h5> <p> <ul id="CD012552-list-0007"> <li> <p>Combination pharmacological therapy: e.g. alpha blockers plus antibiotics, antibiotics plus analgesics, etc. </p> </li> </ul> </p> </section> <section id="CD012552-sec-0050"> <h5 class="title">Comparator interventions</h5> <p> <ul id="CD012552-list-0008"> <li> <p>Placebo</p> </li> <li> <p>No treatment</p> </li> <li> <p>Other types of pharmacological interventions</p> </li> </ul> </p> </section> <section id="CD012552-sec-0051"> <h5 class="title">Comparisons</h5> <p>We perform head‐to‐head comparisons or intervention versus placebo/no‐treatment comparisons. Pharmacological treatments are compared by drug and by class. For example: </p> <p> <ul id="CD012552-list-0009"> <li> <p>Alpha blockers versus placebo</p> </li> <li> <p>Alpha blockers plus quinolones versus placebo</p> </li> </ul> </p> <p>And also</p> <p> <ul id="CD012552-list-0010"> <li> <p>Tamsulosin versus placebo</p> </li> <li> <p>Tamsulosin plus ciprofloxacin versus placebo</p> </li> </ul> </p> <p>We have not included in this review those studies evaluating the comparison between pharmacological and non‐pharmacological interventions, and those which combine non‐pharmacological and pharmacological interventions in the same arm; this is to prevent overlapping with the review <i>Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (</i><a href="./references#CD012552-bbs2-0191" title="FrancoJV , TurkT , JungJH , XiaoYT , IakhnoS , GarroteV , et al. Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database of Systematic Reviews2018, Issue 5. [DOI: 10.1002/14651858.CD012551.pub3] ">Franco 2018</a>). </p> </section> </section> <section id="CD012552-sec-0052"> <h4 class="title">Types of outcome measures</h4> <p>We have not used the measurement of the outcomes assessed in this review as an eligibility criterion. </p> <section id="CD012552-sec-0053"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012552-list-0011"> <li> <p>Prostatitis symptoms</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </section> <section id="CD012552-sec-0054"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012552-list-0012"> <li> <p>Sexual dysfunction</p> </li> <li> <p>Quality of life (QoL)</p> </li> <li> <p>Depression and anxiety</p> </li> <li> <p>Urinary symptoms</p> </li> </ul> </p> <section id="CD012552-sec-0055"> <h6 class="title">Method and timing of outcome measurement</h6> <p>We used the clinically important difference for the review outcomes, to rate the overall quality of the evidence in 'Summary of finding' tables (<a href="./references#CD012552-bbs2-0210" title="JohnstonBC , ThorlundK , SchünemannHJ , XieF , MuradMH , MontoriVM , et al. Improving the interpretation of quality of life evidence in meta‐analyses: the application of minimal important difference units. Health and Quality of Life Outcomes2010;8:116. ">Johnston 2010</a>). When the mean difference (MD) or risk ratio (RR) was equal to or larger than the minimal clinically important difference (MCID), we assumed that many participants may have gained clinically meaningful improvement from treatment; when the MD was at least half of the MCID but less than the MCID, an appreciable number of participants had probably achieved a clinically meaningful improvement; and when the MD was less than one‐half of the MCID, it was unlikely that an appreciable number of participants achieved clinically meaningful improvement (<a href="./references#CD012552-bbs2-0210" title="JohnstonBC , ThorlundK , SchünemannHJ , XieF , MuradMH , MontoriVM , et al. Improving the interpretation of quality of life evidence in meta‐analyses: the application of minimal important difference units. Health and Quality of Life Outcomes2010;8:116. ">Johnston 2010</a>). </p> <section id="CD012552-sec-0056"> <p><b>Prostatitis symptoms</b></p> <p> <ul id="CD012552-list-0013"> <li> <p>Measured by the National Institutes of Health ‐ Chronic Prostatitis Symptom Index (NIH‐CPSI) as total score and sub‐score measurements, when possible, and other validated scales. </p> </li> <li> <p>We considered an MCID in NIH‐CPSI score as a 25% decrease or a six‐point reduction from baseline (<a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. ">Nickel 2003b</a>). This threshold was used to measure the 'responders rate' (<a href="./references#CD012552-bbs2-0177" title="CatesC , KarnerC . Clinical importance cannot be ruled out using mean difference alone. BMJ (Clinical Research Ed.)2015;351:h5496. [PUBMED: 26588935] ">Cates 2015</a>). </p> </li> </ul> </p> </section> <section id="CD012552-sec-0057"> <p><b>Adverse events</b></p> <p> <ul id="CD012552-list-0014"> <li> <p>Defined as treatment intolerance, adverse effects of the interventions at any time after participants were randomised to intervention/comparator groups </p> </li> <li> <p>There was no established threshold for adverse events. We considered the clinically important differences of adverse events above as a relative risk reduction of at least 25% (<a href="./references#CD012552-bbs2-0197" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. ">Guyatt 2011a</a>) </p> </li> </ul> </p> </section> <section id="CD012552-sec-0058"> <p><b>Sexual dysfunction</b></p> <p> <ul id="CD012552-list-0015"> <li> <p>Measured by validated scales (e.g. International Index of Erectile Function (IIEF))</p> </li> <li> <p>We considered the MCID in the erectile function domain score of the IIEF to be four (<a href="./references#CD012552-bbs2-0244" title="RosenRC , AllenKR , NiX , AraujoAB . Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology2011;60(5):1010‐6. ">Rosen 2011</a>). We planned to use different thresholds of MCID based on the severity of erectile dysfunction, with a threshold of two for men with mild erectile dysfunction, five with moderate erectile dysfunction and seven with severe erectile dysfunction (<a href="./references#CD012552-bbs2-0244" title="RosenRC , AllenKR , NiX , AraujoAB . Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology2011;60(5):1010‐6. ">Rosen 2011</a>). We also considered an IIEF‐5 of over five points as the MCID (<a href="./references#CD012552-bbs2-0252" title="SpalivieroM , StromKH , GuX , ArakiM , CulkinDJ , WongC . Does Greenlight HPS (™) laser photoselective vaporization prostatectomy affect sexual function?. Journal of Endourology2010;24(12):2051‐7. ">Spaliviero 2010</a>). </p> </li> </ul> </p> </section> <section id="CD012552-sec-0059"> <p><b>Quality of life</b></p> <p> <ul id="CD012552-list-0016"> <li> <p>Assessed by the Medical Outcomes Study Short Form 12 (SF‐12) or other validated scales</p> </li> <li> <p>We considered an MCID of SF‐12 physical component score to be eight and SF‐12 mental component score to be four (<a href="./references#CD012552-bbs2-0233" title="ParkerSL , GodilSS , ShauDN , MendenhallSK , McGirtMJ . Assessment of the minimum clinically important difference in pain, disability, and quality of life after anterior cervical discectomy and fusion: clinical article. Journal of Neurosurgery Spine2013;18(2):154‐60. ">Parker 2013</a>) </p> </li> </ul> </p> </section> <section id="CD012552-sec-0060"> <p><b>Depression and anxiety</b></p> <p> <ul id="CD012552-list-0017"> <li> <p>Assessed by Beck Depression Inventory, State Anxiety Inventory‐Y or other validated scales </p> </li> <li> <p>We considered an MCID of Beck Depression Inventory to be 11 and State Anxiety Inventory‐Y to be 10 (<a href="./references#CD012552-bbs2-0175" title="ButtonKS , KounaliD , ThomasL , WilesNJ , PetersTJ , WeltonNJ , et al. Minimal clinically important difference on the Beck Depression Inventory‐II according to the patient's perspective. Psychological Medicine2015;45(14):3269‐79. ">Button 2015</a>; <a href="./references#CD012552-bbs2-0183" title="CorsalettiBF , ProençaMD , BiscaGK , LeiteJC , BellinettiLM , PittaF . Minimal important difference for anxiety and depression surveys after intervention to increase daily physical activity in smokers. Fisioterapia e Pesquisa2014;21:359‐64. ">Corsaletti 2014</a>) </p> </li> <li> <p>We considered an MCID of Hospital Anxiety and Depression scale to be 1.6 (<a href="./references#CD012552-bbs2-0238" title="PuhanMA , FreyM , BüchiS , SchünemannHJ . The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health and Quality of Life Outcomes2008;6:46. [DOI: 10.1186/1477‐7525‐6‐46] ">Puhan 2008</a>) </p> </li> </ul> </p> </section> <section id="CD012552-sec-0061"> <p><b>Urinary symptoms</b></p> <p> <ul id="CD012552-list-0018"> <li> <p>Measured by International Prostate Symptom Score (IPSS) or American Urological Association Symptom Score (AUASS) </p> </li> <li> <p>We considered improvement of the IPSS score of three points as an MCID to assess efficacy and comparative effectiveness (<a href="./references#CD012552-bbs2-0172" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesK , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154(5):1770‐4. ">Barry 1995</a>). We planned to use different thresholds of MCID based on the severity of IPSS, with a threshold of three for men with mild lower urinary tract symptomatology (LUTS), five for moderate LUTS and eight for severe LUTS (<a href="./references#CD012552-bbs2-0172" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesK , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154(5):1770‐4. ">Barry 1995</a>). </p> </li> </ul> </p> <p>We considered outcomes measured up to and including 12 months after randomisation as short‐term, and later than 12 months as long‐term. </p> </section> </section> <section id="CD012552-sec-0062"> <h6 class="title">Main outcomes for 'Summary of findings' tables</h6> <p>We present 'Summary of findings' tables reporting the following outcomes, listed according to priority. </p> <p> <ul id="CD012552-list-0019"> <li> <p>Prostatitis symptoms</p> </li> <li> <p>Adverse events</p> </li> <li> <p>Sexual dysfunction</p> </li> <li> <p>QoL</p> </li> <li> <p>Depression and anxiety</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012552-sec-0063"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs meeting our stated inclusion/exclusion criteria, without restrictions by language, publication date or publication status, and in consultation with the Cochrane Urology Group Information Specialist. </p> <section id="CD012552-sec-0064"> <h4 class="title">Electronic searches</h4> <p>We identified published, unpublished and ongoing studies by searching the following databases from their inception: </p> <p> <ul id="CD012552-list-0020"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; latest issue in 10 July 2019) in the Cochrane Library; </p> </li> <li> <p>PubMed (1946 to 10 July 2019);</p> </li> <li> <p>Embase Elsevier (1947 to 10 July 2019);</p> </li> <li> <p>PsycINFO OVID (1887 to 10 July 2019);</p> </li> <li> <p>CINAHL EBSCO (1937 to 10 July 2019);</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>, 10 July 2019); </p> </li> <li> <p>ISRCTN Registry (BioMed Central; <a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>, 10 July 2019); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>, 10 July 2019). </p> </li> </ul> </p> <p>We modelled the search strategies for databases on the search strategy designed for PubMed (<a href="./appendices#CD012552-sec-0259">Appendix 1</a>; <a href="./appendices#CD012552-sec-0260">Appendix 2</a>; <a href="./appendices#CD012552-sec-0261">Appendix 3</a>; <a href="./appendices#CD012552-sec-0262">Appendix 4</a>; <a href="./appendices#CD012552-sec-0263">Appendix 5</a>; <a href="./appendices#CD012552-sec-0264">Appendix 6</a>). The PubMed search used the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity maximising version (2008 revision; <a href="./references#CD012552-bbs2-0218" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). The Embase search used the trial filter for therapy, maximising sensitivity developed by the Health Information Research Unit (HIRU) at McMaster University, adapted from OVID to the Elsevier interface (<a href="./references#CD012552-bbs2-0205" title="Health Information Research Unit (HIRU). Evidence‐Based Health Informatics. Search strategies for PsycINFO in OVID syntax. Hamilton (ON): McMaster University; 2015. Available from: hiru.mcmaster.ca/hiru/HIRU_Hedges_EMBASE_Strategies.aspx 2015 (14 December 2015). ">HIRU 2015</a>). For CENTRAL and clinical trials registries filters are not applicable. We did not use filters for PsycINFO and CINAHL because the results likely to be obtained were very few. </p> </section> <section id="CD012552-sec-0065"> <h4 class="title">Searching other resources</h4> <p>We tried to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials and relevant reviews, meta‐analyses and health technology assessment reports. We also contacted authors of included studies to identify any further studies that we may have missed. We contacted drug and device manufacturers for ongoing or unpublished trials. We searched abstract proceedings of the American Urological Association, European Association of Urology and Society of Sexual Medicine of the last three years for unpublished studies (<a href="./appendices#CD012552-sec-0265">Appendix 7</a>). </p> <p>We also searched other grey literature sources such as:</p> <p> <ul id="CD012552-list-0021"> <li> <p>Open Grey (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu/</a>); </p> </li> <li> <p>New York Academy of Medicine Grey Literature Report (<a href="http://www.greylit.org/" target="_blank">www.greylit.org/</a>); </p> </li> <li> <p>Google Scholar.</p> </li> </ul> </p> </section> </section> <section id="CD012552-sec-0066"> <h3 class="title" id="CD012552-sec-0066">Data collection and analysis</h3> <section id="CD012552-sec-0067"> <h4 class="title">Selection of studies</h4> <p>We used reference management software (<a href="./references#CD012552-bbs2-0187" title="Clarivate Analytics. EndNote. Version 7.5. Clarivate Analytics, 2016. ">EndNote</a>) and <a href="./references#CD012552-bbs2-0184" title="Veritas Health Innovation. Covidence: systematic review software. Melbourne, Australia: Veritas Health Innovation, 2013. ">Covidence</a> to identify and remove duplicate records. Three review authors (JVAF, TT, VV) working in pairs, independently scanned the abstract, title, or both, of remaining records retrieved, to determine which studies should be assessed further. Five review authors (JVAF, SI, TT, VV, YX) investigated all potentially relevant records in full text, mapped records to studies, and classified studies as included studies, excluded studies, studies awaiting classification or ongoing studies, in accordance with the criteria for each provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012552-bbs2-0202" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011]) The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We used <a href="./references#CD012552-bbs2-0184" title="Veritas Health Innovation. Covidence: systematic review software. Melbourne, Australia: Veritas Health Innovation, 2013. ">Covidence</a> for title/abstract and full‐text screening. We resolved any discrepancies through consensus or by recourse to a third review author (JHJ). If we could not resolve disagreements, we designated the study as 'awaiting classification' (<a href="./references#CD012552-sec-0281" title="">Characteristics of studies awaiting classification</a>) and we contacted study authors for clarification. We documented reasons for the exclusion of studies that may have reasonably been expected to be included in the review in a <a href="./references#CD012552-sec-0280" title="">Characteristics of excluded studies</a> table. We present an adapted PRISMA flow diagram showing the process of study selection (<a href="./references#CD012552-bbs2-0220" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100] ">Liberati 2009</a>). </p> </section> <section id="CD012552-sec-0068"> <h4 class="title">Data extraction and management</h4> <p>We developed a dedicated data abstraction form that we piloted ahead of time.</p> <p>For studies that fulfilled our inclusion criteria, seven review authors (FIT, JHJ, JVAF, SI, TT, VV, YX), working in pairs, independently abstracted the following information, which is provided in the <a href="./references#CD012552-sec-0279" title="">Characteristics of included studies</a> table. </p> <p> <ul id="CD012552-list-0022"> <li> <p>Study design;</p> </li> <li> <p>Study dates (if dates are not available then this will be reported as such);</p> </li> <li> <p>Study settings and country;</p> </li> <li> <p>Participant inclusion and exclusion criteria;</p> </li> <li> <p>Participant details, baseline demographics;</p> </li> <li> <p>The number of participants by study and by study arm;</p> </li> <li> <p>Details of relevant experimental and comparator interventions, such as dose, route, frequency, and duration; </p> </li> <li> <p>Definitions of relevant outcomes, and method and timing of outcome measurement, as well as any relevant subgroups; </p> </li> <li> <p>Study funding sources;</p> </li> <li> <p>Declarations of interest by primary investigators.</p> </li> </ul> </p> <p>We further summarise some of the characteristics of the studies, participants and interventions in additional tables (<a href="#CD012552-tbl-0009">Table 1</a>; <a href="#CD012552-tbl-0010">Table 2</a>). </p> <div class="table" id="CD012552-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of the interventions by study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose for comparison</b> </p> <p><b>Co‐interventions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. "><b>Abdalla 2018</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tadalafil study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both arms received levofloxacin 500 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] "><b>Alexander 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciprofloxacin + tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciprofloxacin 500 mg twice daily, tamsulosin 0.4 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Ciprofloxacin</p> <p>C2: Tamsulosin</p> <p>C3: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>They used double placebo (factorial design)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. "><b>Apolikhin 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cernilton® (pollen extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 pills, 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cernilton® (pollen extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pill, 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. "><b>Bates 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg once daily and then tapered to 5 mg in 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. "><b>Breusov 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prolit super (plant extracts)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 capsules a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0006" title="CaiT , WagenlehnerFM , LucianiLG , TiscioneD , MalossiniG , VerzeP , et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine2014;8(4):1032‐8. "><b>Cai 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deprox ® (pollen extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 capsules a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg three times daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. "><b>Cai 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deprox ® (pollen extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 capsules a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromelain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 tablets a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0008" title="CavalliniG . Mepartricin in the treatment of male pelvic pain syndrome secondary to chronic nonbacterial prostatitis/prostatodynia. Minerva Urologica e Nefrologica [Italian Journal of Urology and Nephrology]2001;53(1):13‐7. "><b>Cavallini 2001</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepatricin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin C (as placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. "><b>Cha 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfusozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Terpene mixture 1 capsule three times a day</p> <p>C2: Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received levofloxacin 300 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. "><b>Cheah 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Titrated from 1 to 5 mg daily in two weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. "><b>Chen 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qiantongding decoction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mix of herbal medications (oral infusion), twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XiaoYanTong</p> <p>(Indometacin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg tablet three times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. "><b>Chen 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0013" title="ChengC‐H , LaiY‐W , HsuehT‐Y , ChiuY‐C , ChenS‐S , LuS‐H , et al. The efficacy of levofloxacin or ciprofloxacin in the management of chronic non‐bacterial prostatitis. International Journal of Urology2010;17:A335. LaiY , ChengC , HsuehT , ChiuY , ChenS , ChiuA . The efficacy of levofloxacin or ciprofloxacin in management of chronic non‐bacterial prostatitis. Urology2012;80(3):S154. "><b>Cheng 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Ciprofloxacin 500 mg daily</p> <p>C2: Levofloxacin 1 g daily</p> <p>C3: No antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. "><b>Choe 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Ciprofloxacin 1g daily</p> <p>C2: Aceclofenac 200 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0015" title="ChurakovAA , KolesnikovAI , BliumbergBI , PopkovVM . Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction. Urologiia2012;5:64‐6, 68. "><b>Churakov 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cytoflavin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 ml intravenously for 10 days, then 4 pills a day for 20 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cytoflavin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both arms received:</p> <p>α‐blockers ‐ 1 month</p> <p>anti‐inflammatory drugs – 2 weeks</p> <p>prostate massage and vibrovacuum fallostimulation – 10 times</p> <p>antibiotics – 10 day<i>s</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0016" title="DeRoseAF , GalloF , GiglioM , CarmignaniG . Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo‐controlled trial. Urology2004;63(1):13‐6. DeRoseAF , TraversoP , MontanaroT , CarmignaniG . The role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS): A randomized prospective placebo‐controlled trial. Journal of Urology2010;183(4):e311. "><b>De Rose 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepartricin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg daily for 60 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. "><b>Dunzendorfer 1983</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenoxybenzamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. "><b>Elist 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pollen extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 mg in Prolit® capsules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0019" title="ElshawafH . Chemodenervation of the rhabdosphincter (EUS) alone versus combined injection of both EUS &amp; prostate in patients with prostatitis and chronic pelvic pain syndrome type III. Prospective randomized controlled trial. (Abstract number 394). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. "><b>Elshawaf 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 units applied in the external urethral sphincter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 units applied to the prostate and sphincter</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. "><b>Erdemir 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quinolone + ibuprofen + terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg, 400 mg and 5 mg respectively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Terazosin 5 mg</p> <p>C2: Quinolone 500 mg + ibuprofen 400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. "><b>Falahatkar 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 units applied to the prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0022" title="GiammussoB , DiMauroR , BernardiniR . The efficacy of an association of palmitoylethanolamide and alpha‐lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Archivio Italiano di Urologia e Andrologia2017;89(1):17‐21. "><b>Giammusso 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palmitoylethanolamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg in Penease® capsules twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serenoa repens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 mg 1 capsule daily</p> <p>[All] "patients received a full course of pharmacological therapy" before allocation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. "><b>Giannantoni 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duloxetin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 mg, escalated during the first 15 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐interventions included Serenoa repens and tamsulosin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. "><b>Goldmeier 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zafirlukast</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> <p>Both arms received doxycycline 100 mg twice daily for 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. "><b>Gottsch 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 units applied to pelvic floor muscles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0026" title="GülO , ErogluM , OzokU . Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. International Urology and Nephrology2001;32(3):433‐6. "><b>Gül 2001</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terasozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. "><b>Hu 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bazheng decoction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320 mL daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Co‐intervention: tamsulosin 0.2 mg a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. "><b>Iwamura 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pollen extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 mg 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eviprostat® (herbal extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 capsule 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. "><b>Jeong 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Doxazosin</p> <p>C2: Levofloxacin + Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. "><b>Jiang 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Desketoprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5 mg 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Indomethacin 25 mg 3 times a day</p> <p>C2: Only co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received terazosin 2 mg daily for 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. "><b>Jung 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 ‐ 4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received levofloxacin 300 mg/day, tamiflunate 3 tablets/day for 12 weeks </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0032" title="KaplanSA , VolpeMA , TeAE . A prospective, 1‐year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(1):284‐8. "><b>Kaplan 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serenoa repens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finasteride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. "><b>Kim 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Ibuprofen + Misoprostol</p> <p>C2: Tamsulosin + ibuprofen + misoprostol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg ibuprofen three 3 times a day, 300 mcg misoprostol 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. "><b>Kim 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received gatifloxacin 200 mg twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. "><b>Kim 2011a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Diclofenac</p> <p>C2: Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg twice daily</p> <p>Both groups received tamsulosin 0.2 mg daily for 12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. "><b>Kim 2011b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received ciprofloxacin 1000 mg daily for 8 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. "><b>Kong 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mirodenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 500 mg daily for 6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. "><b>Kulovac 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Ciprofloxacin</p> <p>C2: Doxazosin + ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg twice a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. "><b>Lacquaniti 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Tamsulosin</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. "><b>Lee 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0041" title="LeeCB , HaUS , LeeSJ , KimSW , ChoYH . Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World Journal of Urology2006;24(1):55‐60. "><b>Lee 2006a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terpene mixture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rowatinex® 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. "><b>Leskinen 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finasteride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> <p>Ketoprofene was provided to both group for pain relief</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. "><b>Li 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QianLieAnShuan (Prostat, 前列安栓)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal suppository each night</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo suppository</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. "><b>Li 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiaoshen Tonglin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mix of herbal medications (oral 150 ml infusion) daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. "><b>Li 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qianlieping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 g herbal capsule 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Tamsulosin</p> <p>C2: Qianlieping + Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. "><b>Lin 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg daily before sexual intercourse (from week 5 onwards)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received traditional Chinese medicine</p> <p>(Huafenqinutang oral dose for 8 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. "><b>Lu 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenoxybenzamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Flavoxate</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. "><b>Macchione 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deprox ® (pollen extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 tablets a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serenoa repens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0049" title="MauriziA , DeLucaF , ZanghiA , ManziE , LeonardoC , GuidottiM , et al. The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica2019;90(4):260‐4. [PUBMED: 30655636] "><b>Maurizi 2019</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deprox ® (pollen extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 tablets a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quercetin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mg twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. "><b>Mehik 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfusozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> <p>Both groups "were allowed to take analgesics (ibuprofen, ketoprofen, diclofenac)"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0051" title="MoKI , LeeKS , KimDG . Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2006;47(5):536‐40. "><b>Mo 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfusozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 100mg 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. "><b>Morgia 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Profluss ® (Serenoa repens + lycopene + seleniated sodium)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serenoa repens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. "><b>Morgia 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Curcumin‐calendula</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>350 mg curcumin and 80 mg calendula in rectal suppositories daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. "><b>Nickel 2003a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. "><b>Nickel 2003b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rofecoxib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg and 25 mg doses daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Rofecoxib</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants had the same regimen</p> <p>All participants were permitted to take up to 2.6 g of paracetamol for rescue analgesia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0056" title="NickelJC , DowneyJ , PontariMA , ShoskesD A , ZeitlinSI . A randomized placebo‐controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU International2004;93(7):991‐5. "><b>Nickel 2004a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finasteride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. "><b>Nickel 2004b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0058" title="NickelJC , ForrestJB , TomeraK , Hernandez‐GraulauJ , MoonTD , SchaefferAJ , et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. Journal of Urology2005;173(4):1252‐5. "><b>Nickel 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pentosan polysulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. "><b>Nickel 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfusozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. "><b>Nickel 2011a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Silodosin (4 mg)</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. "><b>Nickel 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanezumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg intravenous single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. "><b>Okada 1985</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PPC (aminoacid preparation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 capsules a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pollen extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. "><b>Park 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cranberry juice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 ml twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants underwent an 8 week‐run‐in period with levofloxacin 100mg 3 times a day, NSAID, alpha blocker, behaviour therapy, and hot sitz bath; for non‐responder, 4 additional weeks of same treatments were added </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. "><b>Park 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 500 mg daily for 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0065" title="ParkHJ , ParkNC , MoonDG , KimTN , NamJK , ParkSW . Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction. European Urology Supplements2017;16(3):e453. "><b>Park 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 500 mg daily for six weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. "><b>Peng 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antiphlogistic agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixture of herbal remedies 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Antiphlogistic + enema</p> <p>C2: Antiphlogistic + suppository</p> <p>C3: Antiphlogistic + "rectal fumigation"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. "><b>Persson 1996</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allopurinol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Allopurinol 300 mg + placebo</p> <p>C2: Placebo twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received the same number of pills</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. "><b>Pontari 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pregabalin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Titrated from 150 to 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0069" title="ReissiglA , DjavanB , PointnerJ . Prospective placebo‐controlled multicenter trial on safety and efficacy of phytotherapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(61):Abstract 233. [MEDLINE: 14665844] "><b>Reissigl 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serenoa repens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No description on dose or regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No description on dose or regimen</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. "><b>Ryu 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfusozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received tosufloxacin 150mg 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. "><b>Shi 1994</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QianLieAnWan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal ball‐shaped formulation, 9g 2 ‐ 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: QianLieKang</p> <p>C2: Pollen extract capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. "><b>Shoskes 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quercetin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. "><b>Singh 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 500 mg for 6 weeks and alfuzosin 10 mg for 6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. "><b>Sivkov 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Titrated to 5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. "><b>Sun 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QianLieAnTong</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal capsule 0.38 g four tables 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No QianLieAnTong</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received terazosin 2 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. "><b>Tan 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QianLieAnShuan (Prostat, 前列安栓)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal suppository each night</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No QuanLieAnShuan (Prostant)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received alpha blockers (tamsulosin or terazosin)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0077" title="TucuV , TasciAI , FazlioluA , OdunctemurA , OzbekE , CekM . Comparison of the efficiency of mono and triple theraphy in chronic pelvic pain syndrome. Turk Urol. Derg.2006;32(3):393‐7. "><b>Tugcu 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiocolchicoside + ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 (sic) and 1200 mg respectively, daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received terazosin 5 mg a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. "><b>Tuğcu 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiocolchicoside + ibuprofen + doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 mg + 400 mg + 4 mg respectively, daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Doxazosin</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Doxazosin 4 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. "><b>Turkington 2002</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluvoxamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. "><b>Wagenlehner 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pollen extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 mg carnitine twice a day, daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> <p>Both groups were pretreated with azithromycin (250 mg every 6 hours for 1 day)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. "><b>Wagenlehner 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐89 (E. coli lysate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg from 18 strains</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> <p>Other medications were allowed in both groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. "><b>Wang 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chuanshentong</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sage and carrot‐family herbal extracts, injected in the prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo injection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. "><b>Wang 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Levofloxacin</p> <p>C2: Terazosin + Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levofloxacin dose: 200 mg twice daily</p> <p>Both groups received dietary advice and prostatic massage once a week and were advised to take warm baths </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0084" title="WedrenH . Effects of sodium pentosanpolysulphate on symptoms related to chronic non‐bacterial prostatitis. A double‐blind randomized study. Scandinavian Jpurnal of Urology and Nephrology1987;21(2):81‐8. "><b>Wedren 1987</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pentosan polysulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. "><b>Wu 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Diclofenac</p> <p>C2: Doxazosin + diclofenac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. "><b>Xia 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YuLeShu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal mixture 20 ml 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 0.2g twice a day, doxazosin 2 mg daily, QianLieTongYu 3 times a day, 4 capsules each time and weekly prostate massage </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. "><b>Xu 2000</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pollen extract (普适泰 = 舍尼通)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.375 g 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfamethoxazole 2 tablets, twice daily 10 days, ofloxacin 0.2 g, twice daily 10 days, minocycline 0.1 g twice daily, 10 days, sequentially, repeated monthly for 3 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. "><b>Yang 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 100 mg twice a day for 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0089" title="MinggenY , ZhoudaZ , ZhimingZ , HailiL , ZhenqiangX , ChaoxianZ , et al. Tamsulosin therapy for chronic nonbacterial prostatitis: A randomized double‐blind placebo controlled clinical trial. Chinese Journal of Andrology2010;24(12):32‐5. "><b>Yang 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Tamsulosin</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. "><b>Ye 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pollen extract (普适泰 = 舍尼通)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.375 g twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 100 mg twice a day for 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. "><b>Ye 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Levofloxacin</p> <p>C2: Tamsulosin + levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levofloxacin 0.2 g daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0092" title="YounCW , SonK‐C , ChoiH‐S , KwonDD , ParkK , RyuSB . Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha‐blocker combination therapy for patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome. Korean Journal of Urology2008;49(1):72‐6. "><b>Youn 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose was not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received gatifloxacin 200mg twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0093" title="ZengX , YeZ , YangW , LiuJ , ZhangX , ZhouX , et al. Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis. Zhonghua Nan Ke Xue2004;10(4):278‐81. "><b>Zeng 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Celecoxib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Celecoxib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. "><b>Zhang 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aike decoction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Bazhengsan decoction</p> <p>C2: Prostatitis decoction</p> <p>C3: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All decoctions were administered twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. "><b>Zhang 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Titrated from 50 to 100 mg individually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1:Duloxetine</p> <p>C2: Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duloxeine titrated from 30 to 120 mg individually</p> <p>All participants received doxazosin 4 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. "><b>Zhao 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Celecoxib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. "><b>Zhou 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo was "Vitamin B"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0099" title="ZiaeeAM , AkhavizadeganH , KarbakhshM . Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. International Brazilian Journal of Urology2006;32(2):181‐6. "><b>Ziaee 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allopurinol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>C1, C2, C3</b> were used to refer to multiple treatment arms. <b>NSAID</b>: Nonsteroidal anti‐inflammatory drugs. Blank cells indicate that dosing is described in the adjacent cell and co‐interventions were not described. </p> </div> </div> <div class="table" id="CD012552-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Description of studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration ‐ Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age (years)</b> </p> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Previous treatments</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean NIH‐CPSI score</b> </p> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Funding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. "><b>Abdalla 2018</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saudi Arabia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] "><b>Alexander 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001 ‐ 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA and Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government + Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. "><b>Apolikhin 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. "><b>Bates 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000 ‐ 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. "><b>Breusov 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0006" title="CaiT , WagenlehnerFM , LucianiLG , TiscioneD , MalossiniG , VerzeP , et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine2014;8(4):1032‐8. "><b>Cai 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. "><b>Cai 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0008" title="CavalliniG . Mepartricin in the treatment of male pelvic pain syndrome secondary to chronic nonbacterial prostatitis/prostatodynia. Minerva Urologica e Nefrologica [Italian Journal of Urology and Nephrology]2001;53(1):13‐7. "><b>Cavallini 2001</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. "><b>Cha 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. "><b>Cheah 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> <p>14 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000 ‐ 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malaysia and US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. "><b>Chen 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. "><b>Chen 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> <p>120 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003 ‐ 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0013" title="ChengC‐H , LaiY‐W , HsuehT‐Y , ChiuY‐C , ChenS‐S , LuS‐H , et al. The efficacy of levofloxacin or ciprofloxacin in the management of chronic non‐bacterial prostatitis. International Journal of Urology2010;17:A335. LaiY , ChengC , HsuehT , ChiuY , ChenS , ChiuA . The efficacy of levofloxacin or ciprofloxacin in management of chronic non‐bacterial prostatitis. Urology2012;80(3):S154. "><b>Cheng 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taiwan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. "><b>Choe 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0015" title="ChurakovAA , KolesnikovAI , BliumbergBI , PopkovVM . Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction. Urologiia2012;5:64‐6, 68. "><b>Churakov 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not ANLZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0016" title="DeRoseAF , GalloF , GiglioM , CarmignaniG . Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo‐controlled trial. Urology2004;63(1):13‐6. DeRoseAF , TraversoP , MontanaroT , CarmignaniG . The role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS): A randomized prospective placebo‐controlled trial. Journal of Urology2010;183(4):e311. "><b>De Rose 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001 ‐ 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. "><b>Dunzendorfer 1983</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. "><b>Elist 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0019" title="ElshawafH . Chemodenervation of the rhabdosphincter (EUS) alone versus combined injection of both EUS &amp; prostate in patients with prostatitis and chronic pelvic pain syndrome type III. Prospective randomized controlled trial. (Abstract number 394). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. "><b>Elshawaf 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. "><b>Erdemir 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> <p>20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. "><b>Falahatkar 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011 ‐ 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0022" title="GiammussoB , DiMauroR , BernardiniR . The efficacy of an association of palmitoylethanolamide and alpha‐lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Archivio Italiano di Urologia e Andrologia2017;89(1):17‐21. "><b>Giammusso 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014 ‐ 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. "><b>Giannantoni 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009 ‐ 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. "><b>Goldmeier 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. "><b>Gottsch 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0026" title="GülO , ErogluM , OzokU . Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. International Urology and Nephrology2001;32(3):433‐6. "><b>Gül 2001</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSSI</p> <p>9.61/9.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1997 ‐ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. "><b>Hu 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012 ‐ 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. "><b>Iwamura 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009 ‐ 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. "><b>Jeong 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. "><b>Jiang 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. "><b>Jung 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004 ‐ 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0032" title="KaplanSA , VolpeMA , TeAE . A prospective, 1‐year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(1):284‐8. "><b>Kaplan 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. "><b>Kim 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001 ‐ 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. "><b>Kim 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. "><b>Kim 2011a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 ‐ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. "><b>Kim 2011b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. "><b>Kong 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. "><b>Kulovac 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bosnia and Herzegovina</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. "><b>Lacquaniti 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1997 ‐ 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. "><b>Lee 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSS</p> <p>23.4/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NGO</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0041" title="LeeCB , HaUS , LeeSJ , KimSW , ChoYH . Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World Journal of Urology2006;24(1):55‐60. "><b>Lee 2006a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003 ‐ 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. "><b>Leskinen 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. "><b>Li 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. "><b>Li 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004 ‐ 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. "><b>Li 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010 ‐ 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. "><b>Lin 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. "><b>Lu 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000 ‐ 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government + Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. "><b>Macchione 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0049" title="MauriziA , DeLucaF , ZanghiA , ManziE , LeonardoC , GuidottiM , et al. The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica2019;90(4):260‐4. [PUBMED: 30655636] "><b>Maurizi 2019</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. "><b>Mehik 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0051" title="MoKI , LeeKS , KimDG . Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2006;47(5):536‐40. "><b>Mo 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004 ‐ 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. "><b>Morgia 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 ‐ 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. "><b>Morgia 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015 ‐ 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. "><b>Nickel 2003a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government + Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. "><b>Nickel 2003b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA and Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0056" title="NickelJC , DowneyJ , PontariMA , ShoskesD A , ZeitlinSI . A randomized placebo‐controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU International2004;93(7):991‐5. "><b>Nickel 2004a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government + Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. "><b>Nickel 2004b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000 ‐ 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0058" title="NickelJC , ForrestJB , TomeraK , Hernandez‐GraulauJ , MoonTD , SchaefferAJ , et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. Journal of Urology2005;173(4):1252‐5. "><b>Nickel 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA and Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. "><b>Nickel 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, Canada and Malaysia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government + Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. "><b>Nickel 2011a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 ‐ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. "><b>Nickel 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009 ‐ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, Canada, France, Sweden and Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. "><b>Okada 1985</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not ANLZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. "><b>Park 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002 ‐ 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. "><b>Park 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0065" title="ParkHJ , ParkNC , MoonDG , KimTN , NamJK , ParkSW . Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction. European Urology Supplements2017;16(3):e453. "><b>Park 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. "><b>Peng 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not ANLZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999 ‐ 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. "><b>Persson 1996</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. "><b>Pontari 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 ‐ 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government + Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0069" title="ReissiglA , DjavanB , PointnerJ . Prospective placebo‐controlled multicenter trial on safety and efficacy of phytotherapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(61):Abstract 233. [MEDLINE: 14665844] "><b>Reissigl 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. "><b>Ryu 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. "><b>Shi 1994</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not ANLZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. "><b>Shoskes 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. "><b>Singh 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61‐65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. "><b>Sivkov 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. "><b>Sun 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. "><b>Tan 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0077" title="TucuV , TasciAI , FazlioluA , OdunctemurA , OzbekE , CekM . Comparison of the efficiency of mono and triple theraphy in chronic pelvic pain syndrome. Turk Urol. Derg.2006;32(3):393‐7. "><b>Tugcu 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003 ‐ 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. "><b>Tuğcu 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004 ‐ 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. "><b>Turkington 2002</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. "><b>Wagenlehner 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999 ‐ 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. "><b>Wagenlehner 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 ‐ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austria, Germany, Poland and Portugal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. "><b>Wang 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002 ‐ 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. "><b>Wang 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011 ‐ 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0084" title="WedrenH . Effects of sodium pentosanpolysulphate on symptoms related to chronic non‐bacterial prostatitis. A double‐blind randomized study. Scandinavian Jpurnal of Urology and Nephrology1987;21(2):81‐8. "><b>Wedren 1987</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1984 ‐ 1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. "><b>Wu 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 ‐ 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. "><b>Xia 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011 ‐ 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. "><b>Xu 2000</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not ANLZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1998 ‐ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. "><b>Yang 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0089" title="MinggenY , ZhoudaZ , ZhimingZ , HailiL , ZhenqiangX , ChaoxianZ , et al. Tamsulosin therapy for chronic nonbacterial prostatitis: A randomized double‐blind placebo controlled clinical trial. Chinese Journal of Andrology2010;24(12):32‐5. "><b>Yang 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. "><b>Ye 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005 ‐ 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. "><b>Ye 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002 ‐ 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0092" title="YounCW , SonK‐C , ChoiH‐S , KwonDD , ParkK , RyuSB . Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha‐blocker combination therapy for patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome. Korean Journal of Urology2008;49(1):72‐6. "><b>Youn 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005 ‐ 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0093" title="ZengX , YeZ , YangW , LiuJ , ZhangX , ZhouX , et al. Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis. Zhonghua Nan Ke Xue2004;10(4):278‐81. "><b>Zeng 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. "><b>Zhang 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005 ‐ 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. "><b>Zhang 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011 ‐ 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. "><b>Zhao 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0097" title="ChiCTR1800019441 . A clinical observation of dapoxetine combined with tamsulosin in treatment of type III prostatitis with premature ejaculation. http://www.chictr.org.cn/showproj.aspx?proj=28436 (Date of Registration: 2018‐11‐11). ZhaoL , TianR , LiangC , ZhangL , SongW , ZhaoJ , et al. Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation. Andrologia2019;51(8):e13319. [PUBMED: 31131928] "><b>Zhao 2019</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. "><b>Zhou 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005 ‐ 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0099" title="ZiaeeAM , AkhavizadeganH , KarbakhshM . Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. International Brazilian Journal of Urology2006;32(2):181‐6. "><b>Ziaee 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002 ‐ 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>N/A</b> : not applicable; <b>NGO</b> : non‐governmental organization; <b>NIH‐CPSI</b> : National Institutes of Health Chronic Prostatitis Symptom Index; <b>PSS</b> : Prostatitis Severity Score; <b>PSSI</b> : Prostatitis Symptoms Severity Index; <b>USA</b>: United States of America. Duration and follow‐up are differentiated when data were available. </p> </div> </div> <p>We extracted outcome data relevant to this Cochrane Review as needed for calculation of summary statistics and measures of variance. For dichotomous outcomes, we attempted to obtain numbers of events and totals of population for a 2 × 2 table, as well as summary statistics with corresponding measures of variance. For continuous outcomes, we attempted to obtain means and standard deviations, or data necessary to calculate this information. We resolved any disagreements by discussion, or, if required, by consultation with a third review author (SI or JHJ). </p> <p>We attempted to contact authors of included studies to obtain key missing data as needed. </p> <p>We provide information, including trial identifier, about potentially relevant ongoing studies in a <a href="./references#CD012552-sec-0282" title="">Characteristics of ongoing studies</a> table. </p> <section id="CD012552-sec-0069"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents or multiple reports of a primary study, we maximised yield of information by mapping all publications to unique studies and collating all available data. We used the most complete data set aggregated across all known publications. In case of doubt, we gave priority to the publication reporting the longest follow‐up associated with our primary or secondary outcomes. </p> </section> </section> <section id="CD012552-sec-0070"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Six review authors (JHJ, JVAF, SI, TT, VV, YX), working in pairs, independently assessed the risks of bias of each included study. We resolved disagreements by consensus, or by consultation with a third review author (JVAF or VV). </p> <p>We assessed risks of bias using Cochrane's 'Risk of bias' assessment tool (<a href="./references#CD012552-bbs2-0204" title="HigginsJP , AltmanDG , SterneJA , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). We assessed the following domains: </p> <p> <ul id="CD012552-list-0023"> <li> <p>Random sequence generation (selection bias);</p> </li> <li> <p>Allocation concealment (selection bias);</p> </li> <li> <p>Blinding of participants and personnel (performance bias);</p> </li> <li> <p>Blinding of outcome assessment (detection bias);</p> </li> <li> <p>Incomplete outcome data (attrition bias);</p> </li> <li> <p>Selective reporting (reporting bias);</p> </li> <li> <p>Other potential sources of bias.</p> </li> </ul> </p> <p>We judged 'Risk of bias' domains as being at low risk, high risk or unclear risk and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012552-bbs2-0204" title="HigginsJP , AltmanDG , SterneJA , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). We present 'Risk of bias' summary figures to illustrate these findings. </p> <p>For performance bias (blinding of participants and personnel) and detection bias (blinding of outcome assessment), we evaluated the risks of bias separately for each outcome, and we grouped outcomes according to whether they were measured subjectively or objectively when reporting our findings in the 'Risk of bias' tables. </p> <p>We also assessed attrition bias (incomplete outcome data) on an outcome‐specific basis, and grouped outcomes with similar judgements when reporting our findings in the 'Risk of bias' tables. </p> <p>We further summarised the risks of bias across domains for each outcome in each included study, as well as across studies and domains for each outcome. </p> <p>All endpoints are subjective outcomes.</p> </section> <section id="CD012552-sec-0071"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs). We expressed continuous data as mean differences (MDs) with 95% CIs unless different studies used different measures to assess the same outcome, in which case we expressed data as standardised mean differences (SMDs) with 95% CIs. </p> </section> <section id="CD012552-sec-0072"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. If we identified cross‐over trials, cluster‐randomised trials or trials with more than two intervention groups for inclusion in the review, we handled these in accordance with guidance provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012552-bbs2-0203" title="HigginsJP , DeeksJJ , AltmanDG , editor(s) . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> </section> <section id="CD012552-sec-0073"> <h4 class="title">Dealing with missing data</h4> <p>We obtained missing data from study authors, if feasible, and performed intention‐to‐treat analyses if data were available; otherwise, we performed available‐case analyses. We investigated attrition rates, such as dropouts, losses to follow‐up and withdrawals, and we critically appraised issues of missing data. We did not impute missing data. In studies where results were available only graphically we estimated the measurements of the primary outcomes using software in order to describe them in a narrative fashion (<a href="./references#CD012552-bbs2-0209" title="Jelicic KadicA , VucicK , DosenovicS , SapunarD , PuljakL . Extracting data from figures with software was faster, with higher interrater reliability than manual extraction. Journal of Clinical Epidemiology2016;74:119‐23. [PUBMED: 26780258] ">Jelicic 2016</a>; <a href="./references#CD012552-bbs2-0234" title="SourceForge. Plot Digitalizer. Version 2.6.8. SourceForge, 2015. [plotdigitizer.sourceforge.net/] ">PlotDigitalizer</a>). </p> </section> <section id="CD012552-sec-0074"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of excessive heterogeneity unexplained by subgroup analyses, we did not report outcome results as the pooled effect estimate in a meta‐analysis, but have provided a narrative description of the results of each study. </p> <p>We identified heterogeneity (inconsistency) through visual inspection of the forest plots to assess the amount of overlap of CIs, and the I<sup>2</sup> statistic, which quantifies inconsistency across studies, to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD012552-bbs2-0200" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. [DOI: 10.1002/sim.1186] ">Higgins 2002</a>; <a href="./references#CD012552-bbs2-0201" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.)2003;327(7414):557‐60. [DOI: 10.1136/bmj.327.7414.557] ">Higgins 2003</a>). We interpreted the I<sup>2</sup> statistic as follows. </p> <p> <ul id="CD012552-list-0024"> <li> <p>0% to 40%: may not be important.</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity.</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>When we found heterogeneity, we attempted to determine possible reasons for it by examining individual study and subgroup characteristics. </p> </section> <section id="CD012552-sec-0075"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to obtain study protocols to assess for selective outcome reporting.</p> <p>When we included 10 studies or more investigating a particular outcome, we used funnel plots to assess small‐study effects. Several explanations can be offered for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials) and publication bias. We therefore interpreted the results cautiously. </p> </section> <section id="CD012552-sec-0076"> <h4 class="title">Data synthesis</h4> <p>Unless there was good evidence for homogeneous effects across studies, we summarised data using a random‐effects model. We interpreted random‐effects meta‐analyses with due consideration of the whole distribution of effects. We also performed statistical analyses according to the statistical guidelines contained in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012552-bbs2-0202" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011]) The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). For dichotomous outcomes, we used the Mantel‐Haenszel method; for continuous outcomes, we used the inverse variance method. We used Review Manager 5 (<a href="./references#CD012552-bbs2-0241" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) software to perform analyses. </p> </section> <section id="CD012552-sec-0077"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity, and planned to carry out subgroup analyses with investigation of interactions. </p> <p> <ul id="CD012552-list-0025"> <li> <p>Participants' characteristics: symptom severity at recruitment, age, presence of clinical comorbidities (irritable bowel syndrome, fibromyalgia, interstitial cystitis). </p> </li> <li> <p>Duration of the intervention: measured in weeks (e.g. less than 12 weeks or more than 12 weeks). </p> </li> <li> <p>Presence of combined therapy due to the presence of co‐interventions: e.g. alpha blockers versus placebo, compared to alpha blockers + co‐interventions (antibiotics or analgesics or both) versus co‐interventions alone or in combination with placebo. </p> </li> </ul> </p> <p>We planned to use the test for subgroup differences in Review Manager 5 to compare subgroup analyses if there had been sufficient studies (<a href="./references#CD012552-bbs2-0241" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD012552-sec-0078"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes. </p> <p> <ul id="CD012552-list-0026"> <li> <p>Restricting the analysis by taking into account risk of bias, by excluding studies at high risk or unclear risk in at least one domain. </p> </li> <li> <p>Explore the impact of re‐expressing symptom severity as a dichotomous outcome.</p> </li> <li> <p>Excluding studies that included participants with a diagnosis of chronic non‐bacterial prostatitis or prostatodynia, not meeting the criteria of the 1999 Research Consensus (<a href="./references#CD012552-bbs2-0230" title="NickelJC , NybergLM , HennenfentM . Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology1999;54(2):229‐33. [PUBMED: 10443716] ">Nickel 1999</a>). </p> </li> </ul> </p> <section id="CD012552-sec-0079"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented the overall quality of the evidence for each outcome according to the GRADE approach, which takes into account five criteria related to internal validity (risk of bias, inconsistency, imprecision, publication bias), and external validity, such as directness of results (<a href="./references#CD012552-bbs2-0196" title='GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , SchünemannHJ , et al. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.)2008;336(7651):995‐8. [DOI: 10.1136/bmj.39490.551019.BE] '>Guyatt 2008</a>)<i>.</i> For each comparison, two review authors (JHJ, JVAF) independently rated the quality of evidence for each outcome as 'high,' 'moderate,' 'low' or 'very low', using <a href="./references#CD012552-bbs2-0195" title="GRADE Working Group, McMaster University. GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from www.gradepro.org. Hamilton (ON): GRADE Working Group, McMaster University, 2015. ">GRADEpro GDT</a>. We resolved any discrepancies by consensus, or if needed by arbitration by a third review author (VV). We present a summary of the evidence for the main outcomes in the 'Summary of findings' tables, which provide key information about: the best estimate of the magnitude of the effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence in effect estimates for each outcome (<a href="./references#CD012552-bbs2-0198" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [DOI: 10.1016/j.jclinepi.2010.04.026] ">Guyatt 2011b</a>; <a href="./references#CD012552-bbs2-0246" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>). If meta‐analysis was not possible, we present results in a narrative 'Summary of findings' table. We initially planned to present 'Summary of findings' tables for all comparisons, but given their multiplicity, we have presented only those most related to clinical practice in order to highlight the evidence most relevant to clinicians, patients and other stakeholders (see <a href="#CD012552-sec-0271">Differences between protocol and review</a>). Nevertheless, we assessed all comparisons using the GRADE approach and they are available under the section <a href="#CD012552-sec-0102">Effects of interventions</a>. </p> <p>We used the controlled vocabulary suggested by <a href="./references#CD012552-bbs2-0194" title="GlentonC , SantessoN , RosenbaumS , NilsenES , RaderT , CiapponiA , et al. Presenting the results of Cochrane systematic reviews to a consumer audience: a qualitative study. Medical Decision Making2010;30(5):566‐77. [PUBMED: 20643912] ">Glenton 2010</a> to summarise the findings of the 'Summary of findings' tables in the 'Plain language summary.' </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012552-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012552-sec-0080"></div> <section id="CD012552-sec-0081"> <h3 class="title">Description of studies</h3> <section id="CD012552-sec-0082"> <h4 class="title">Results of the search</h4> <p>For detailed information about the results of the search see <a href="#CD012552-fig-0001">Figure 1</a>. This review shares the search strategy for the review of non‐pharmacological Interventions for treating chronic prostatitis/chronic pelvic pain syndrome (<a href="./references#CD012552-bbs2-0191" title="FrancoJV , TurkT , JungJH , XiaoYT , IakhnoS , GarroteV , et al. Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database of Systematic Reviews2018, Issue 5. [DOI: 10.1002/14651858.CD012551.pub3] ">Franco 2018</a>). In this section we describe the study flow for the studies relevant to the review question. For this review we screened 1725 records. We included four studies from other systematic reviews on this topic (<a href="./references#CD012552-bbs2-0224" title="McNaughton CollinsM , MacDonaldR , WiltTJ . Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. Annals of Internal Medicine2000;133(5):367‐81. ">McNaughton 2000</a>; <a href="./references#CD012552-bbs2-0262" title="YangM , ZhaoX , HouY . Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): A systematic review and meta‐analysis of randomized controlled trials (RCTs). Chinese Journal of Andrology2008;22(4):20‐6. ">Yang 2008</a>). We discounted 1536 records and obtained the full text for 189 records. We excluded 54 studies (57 records) after full‐text assessment; their characteristics are given in <a href="./references#CD012552-sec-0280" title="">Characteristics of excluded studies</a> tables. We found five studies that could have been completed according to the clinical trial registries but there was no publication available and a two‐stage study with an incomplete report of the conduct of the clinical trial stage (<a href="./references#CD012552-sec-0281" title="">Characteristics of studies awaiting classification</a>). We identified four ongoing studies (see <a href="./references#CD012552-sec-0282" title="">Characteristics of ongoing studies</a>). We included 99 studies (122 records) in this review. </p> <div class="figure" id="CD012552-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012552-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012552-sec-0083"> <h4 class="title">Included studies</h4> <p>We included 99 studies with 9119 participants (see <a href="./references#CD012552-sec-0279" title="">Characteristics of included studies</a>; <a href="#CD012552-tbl-0009">Table 1</a>; <a href="#CD012552-tbl-0010">Table 2</a>). </p> <section id="CD012552-sec-0084"> <h5 class="title">Design</h5> <p>All the included studies were RCTs.</p> </section> <section id="CD012552-sec-0085"> <h5 class="title">Sample sizes</h5> <p>Median sample size was 76 (interquartile range 55.5 to 107.5). The smallest sample size was 14 and the largest sample size was 324. Sample size was not specified in one study (<a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. ">Macchione 2017</a>). </p> </section> <section id="CD012552-sec-0086"> <h5 class="title">Setting</h5> <p>Since CP/CPPS is usually treated in an outpatient setting, most studies offered ambulatory care. </p> <p>Twenty‐eight studies were conducted in China (<a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. ">Chen 2009</a>; <a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. ">Hu 2015</a>; <a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. ">Jiang 2009</a>; <a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. ">Li 2003</a>; <a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. ">Li 2007</a>; <a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. ">Li 2012</a>; <a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. ">Lin 2007</a>; <a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>; <a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. ">Peng 2003</a>; <a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. ">Shi 1994</a>; <a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. ">Sun 2008</a>; <a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. ">Tan 2009</a>; <a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. ">Wang 2004</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. ">Xia 2014</a>; <a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. ">Xu 2000</a>; <a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. ">Yang 2009</a>; <a href="./references#CD012552-bbs2-0089" title="MinggenY , ZhoudaZ , ZhimingZ , HailiL , ZhenqiangX , ChaoxianZ , et al. Tamsulosin therapy for chronic nonbacterial prostatitis: A randomized double‐blind placebo controlled clinical trial. Chinese Journal of Andrology2010;24(12):32‐5. ">Yang 2010</a>; <a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. ">Ye 2006</a>; <a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. ">Ye 2008</a>; <a href="./references#CD012552-bbs2-0093" title="ZengX , YeZ , YangW , LiuJ , ZhangX , ZhouX , et al. Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis. Zhonghua Nan Ke Xue2004;10(4):278‐81. ">Zeng 2004</a>; <a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. ">Zhang 2007</a>; <a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. ">Zhang 2017</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>; <a href="./references#CD012552-bbs2-0097" title="ChiCTR1800019441 . A clinical observation of dapoxetine combined with tamsulosin in treatment of type III prostatitis with premature ejaculation. http://www.chictr.org.cn/showproj.aspx?proj=28436 (Date of Registration: 2018‐11‐11). ZhaoL , TianR , LiangC , ZhangL , SongW , ZhaoJ , et al. Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation. Andrologia2019;51(8):e13319. [PUBMED: 31131928] ">Zhao 2019</a>; <a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. ">Zhou 2008</a>), 16 studies were conducted in South Korea (<a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. ">Cha 2009</a>; <a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. ">Choe 2014</a>; <a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. ">Jeong 2008</a>; <a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. ">Jung 2006</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. ">Kim 2008</a>; <a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>; <a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. ">Kim 2011b</a>; <a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. ">Kong 2014</a>; <a href="./references#CD012552-bbs2-0041" title="LeeCB , HaUS , LeeSJ , KimSW , ChoYH . Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World Journal of Urology2006;24(1):55‐60. ">Lee 2006a</a>; <a href="./references#CD012552-bbs2-0051" title="MoKI , LeeKS , KimDG . Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2006;47(5):536‐40. ">Mo 2006</a>; <a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. ">Park 2005</a>; <a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. ">Park 2012</a>; <a href="./references#CD012552-bbs2-0065" title="ParkHJ , ParkNC , MoonDG , KimTN , NamJK , ParkSW . Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction. European Urology Supplements2017;16(3):e453. ">Park 2017</a>; <a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. ">Ryu 2007</a>; <a href="./references#CD012552-bbs2-0092" title="YounCW , SonK‐C , ChoiH‐S , KwonDD , ParkK , RyuSB . Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha‐blocker combination therapy for patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome. Korean Journal of Urology2008;49(1):72‐6. ">Youn 2008</a>), 11 studies were conducted in Italy (<a href="./references#CD012552-bbs2-0006" title="CaiT , WagenlehnerFM , LucianiLG , TiscioneD , MalossiniG , VerzeP , et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine2014;8(4):1032‐8. ">Cai 2014</a>; <a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. ">Cai 2017</a>; <a href="./references#CD012552-bbs2-0008" title="CavalliniG . Mepartricin in the treatment of male pelvic pain syndrome secondary to chronic nonbacterial prostatitis/prostatodynia. Minerva Urologica e Nefrologica [Italian Journal of Urology and Nephrology]2001;53(1):13‐7. ">Cavallini 2001</a>; <a href="./references#CD012552-bbs2-0016" title="DeRoseAF , GalloF , GiglioM , CarmignaniG . Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo‐controlled trial. Urology2004;63(1):13‐6. DeRoseAF , TraversoP , MontanaroT , CarmignaniG . The role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS): A randomized prospective placebo‐controlled trial. Journal of Urology2010;183(4):e311. ">De Rose 2004</a>; <a href="./references#CD012552-bbs2-0022" title="GiammussoB , DiMauroR , BernardiniR . The efficacy of an association of palmitoylethanolamide and alpha‐lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Archivio Italiano di Urologia e Andrologia2017;89(1):17‐21. ">Giammusso 2017</a>; <a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. ">Giannantoni 2014</a>; <a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. ">Lacquaniti 1999</a>; <a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. ">Macchione 2017</a>; <a href="./references#CD012552-bbs2-0049" title="MauriziA , DeLucaF , ZanghiA , ManziE , LeonardoC , GuidottiM , et al. The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica2019;90(4):260‐4. [PUBMED: 30655636] ">Maurizi 2019</a><a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. ">Morgia 2010</a>; <a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. ">Morgia 2017</a>), seven studies were conducted in the USA (<a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a>; <a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a>; <a href="./references#CD012552-bbs2-0032" title="KaplanSA , VolpeMA , TeAE . A prospective, 1‐year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(1):284‐8. ">Kaplan 2004</a>; <a href="./references#CD012552-bbs2-0056" title="NickelJC , DowneyJ , PontariMA , ShoskesD A , ZeitlinSI . A randomized placebo‐controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU International2004;93(7):991‐5. ">Nickel 2004a</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>; <a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. ">Shoskes 1999</a>) and seven studies were conducted in more than one country (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. ">Cheah 2003</a>; <a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. ">Nickel 2003b</a>; <a href="./references#CD012552-bbs2-0058" title="NickelJC , ForrestJB , TomeraK , Hernandez‐GraulauJ , MoonTD , SchaefferAJ , et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. Journal of Urology2005;173(4):1252‐5. ">Nickel 2005</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. ">Nickel 2016</a>; <a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. ">Wagenlehner 2014</a>). The remaining studies were conducted in Austria (<a href="./references#CD012552-bbs2-0069" title="ReissiglA , DjavanB , PointnerJ . Prospective placebo‐controlled multicenter trial on safety and efficacy of phytotherapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(61):Abstract 233. [MEDLINE: 14665844] ">Reissigl 2004</a>), Bosnia‐Herzegovina (<a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. ">Kulovac 2007</a>), Canada (<a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>), Egypt (<a href="./references#CD012552-bbs2-0019" title="ElshawafH . Chemodenervation of the rhabdosphincter (EUS) alone versus combined injection of both EUS &amp; prostate in patients with prostatitis and chronic pelvic pain syndrome type III. Prospective randomized controlled trial. (Abstract number 394). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. ">Elshawaf 2009</a>), Finland (<a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. ">Leskinen 1999</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>), Germany (<a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>), India (<a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>), Iran (<a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>; <a href="./references#CD012552-bbs2-0099" title="ZiaeeAM , AkhavizadeganH , KarbakhshM . Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. International Brazilian Journal of Urology2006;32(2):181‐6. ">Ziaee 2006</a>), Japan (<a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. ">Iwamura 2015</a>; <a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. ">Okada 1985</a>), Russia (<a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. ">Apolikhin 2010</a>; <a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>; <a href="./references#CD012552-bbs2-0015" title="ChurakovAA , KolesnikovAI , BliumbergBI , PopkovVM . Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction. Urologiia2012;5:64‐6, 68. ">Churakov 2012</a>; <a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. ">Sivkov 2005</a>), Sweden (<a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. ">Persson 1996</a>; <a href="./references#CD012552-bbs2-0084" title="WedrenH . Effects of sodium pentosanpolysulphate on symptoms related to chronic non‐bacterial prostatitis. A double‐blind randomized study. Scandinavian Jpurnal of Urology and Nephrology1987;21(2):81‐8. ">Wedren 1987</a>), Taiwan (<a href="./references#CD012552-bbs2-0013" title="ChengC‐H , LaiY‐W , HsuehT‐Y , ChiuY‐C , ChenS‐S , LuS‐H , et al. The efficacy of levofloxacin or ciprofloxacin in the management of chronic non‐bacterial prostatitis. International Journal of Urology2010;17:A335. LaiY , ChengC , HsuehT , ChiuY , ChenS , ChiuA . The efficacy of levofloxacin or ciprofloxacin in management of chronic non‐bacterial prostatitis. Urology2012;80(3):S154. ">Cheng 2010</a>), Turkey (<a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. ">Erdemir 2010</a>; <a href="./references#CD012552-bbs2-0026" title="GülO , ErogluM , OzokU . Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. International Urology and Nephrology2001;32(3):433‐6. ">Gül 2001</a>; <a href="./references#CD012552-bbs2-0077" title="TucuV , TasciAI , FazlioluA , OdunctemurA , OzbekE , CekM . Comparison of the efficiency of mono and triple theraphy in chronic pelvic pain syndrome. Turk Urol. Derg.2006;32(3):393‐7. ">Tugcu 2006</a>; <a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>), Saudi Arabia (<a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. ">Abdalla 2018</a>) and the UK (<a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. ">Bates 2007</a>; <a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. ">Goldmeier 2005</a>; <a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. ">Lee 2005</a>; <a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. ">Turkington 2002</a>). </p> <p>There was a wide variety of languages in the included studies. Twenty‐one studies were written in Chinese (<a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. ">Chen 2009</a>; <a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. ">Hu 2015</a>; <a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. ">Jiang 2009</a>; <a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. ">Li 2003</a>; <a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. ">Li 2007</a>; <a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. ">Li 2012</a>; <a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. ">Lin 2007</a>; <a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>; <a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. ">Peng 2003</a>; <a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. ">Shi 1994</a>; <a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. ">Sun 2008</a>; <a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. ">Tan 2009</a>; <a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. ">Wang 2004</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. ">Xia 2014</a>; <a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. ">Xu 2000</a>; <a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. ">Yang 2009</a>; <a href="./references#CD012552-bbs2-0089" title="MinggenY , ZhoudaZ , ZhimingZ , HailiL , ZhenqiangX , ChaoxianZ , et al. Tamsulosin therapy for chronic nonbacterial prostatitis: A randomized double‐blind placebo controlled clinical trial. Chinese Journal of Andrology2010;24(12):32‐5. ">Yang 2010</a>; <a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. ">Ye 2006</a>; <a href="./references#CD012552-bbs2-0093" title="ZengX , YeZ , YangW , LiuJ , ZhangX , ZhouX , et al. Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis. Zhonghua Nan Ke Xue2004;10(4):278‐81. ">Zeng 2004</a>; <a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. ">Zhang 2007</a>), four studies were in Russian (<a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>; <a href="./references#CD012552-bbs2-0015" title="ChurakovAA , KolesnikovAI , BliumbergBI , PopkovVM . Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction. Urologiia2012;5:64‐6, 68. ">Churakov 2012</a>; <a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. ">Apolikhin 2010</a>; <a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. ">Sivkov 2005</a>); eight studies in Korean (<a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. ">Cha 2009</a>; <a href="./references#CD012552-bbs2-0092" title="YounCW , SonK‐C , ChoiH‐S , KwonDD , ParkK , RyuSB . Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha‐blocker combination therapy for patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome. Korean Journal of Urology2008;49(1):72‐6. ">Youn 2008</a>; <a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. ">Kim 2008</a>; <a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. ">Ryu 2007</a>; <a href="./references#CD012552-bbs2-0051" title="MoKI , LeeKS , KimDG . Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2006;47(5):536‐40. ">Mo 2006</a>; <a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. ">Jung 2006</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. ">Park 2005</a>); two in Italian (<a href="./references#CD012552-bbs2-0008" title="CavalliniG . Mepartricin in the treatment of male pelvic pain syndrome secondary to chronic nonbacterial prostatitis/prostatodynia. Minerva Urologica e Nefrologica [Italian Journal of Urology and Nephrology]2001;53(1):13‐7. ">Cavallini 2001</a>; <a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. ">Lacquaniti 1999</a>), two in Turkish (<a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. ">Erdemir 2010</a>; <a href="./references#CD012552-bbs2-0077" title="TucuV , TasciAI , FazlioluA , OdunctemurA , OzbekE , CekM . Comparison of the efficiency of mono and triple theraphy in chronic pelvic pain syndrome. Turk Urol. Derg.2006;32(3):393‐7. ">Tugcu 2006</a>) one in Japanese (<a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. ">Okada 1985</a>) and one in German (<a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a>). This posed some limitations on our review (see <a href="#CD012552-sec-0249">Potential biases in the review process</a>). The remaining RCTs were written in English. </p> </section> <section id="CD012552-sec-0087"> <h5 class="title">Participants</h5> <p>The median age of participants was 38 years (interquartile range 33 to 41). Seventeen studies did not provide information on age (<a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>; <a href="./references#CD012552-bbs2-0013" title="ChengC‐H , LaiY‐W , HsuehT‐Y , ChiuY‐C , ChenS‐S , LuS‐H , et al. The efficacy of levofloxacin or ciprofloxacin in the management of chronic non‐bacterial prostatitis. International Journal of Urology2010;17:A335. LaiY , ChengC , HsuehT , ChiuY , ChenS , ChiuA . The efficacy of levofloxacin or ciprofloxacin in management of chronic non‐bacterial prostatitis. Urology2012;80(3):S154. ">Cheng 2010</a>; <a href="./references#CD012552-bbs2-0015" title="ChurakovAA , KolesnikovAI , BliumbergBI , PopkovVM . Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction. Urologiia2012;5:64‐6, 68. ">Churakov 2012</a>; <a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. ">Jung 2006</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. ">Kim 2011b</a>; <a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. ">Lee 2005</a>; <a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. ">Macchione 2017</a>; <a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. ">Okada 1985</a>; <a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. ">Park 2012</a>; <a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. ">Persson 1996</a>; <a href="./references#CD012552-bbs2-0069" title="ReissiglA , DjavanB , PointnerJ . Prospective placebo‐controlled multicenter trial on safety and efficacy of phytotherapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(61):Abstract 233. [MEDLINE: 14665844] ">Reissigl 2004</a>; <a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. ">Shi 1994</a>; <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>; <a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. ">Sivkov 2005</a>; <a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. ">Ye 2008</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>). Most studies did not include participants over 50 years old, to avoid symptom overlap with benign prostate hyperplasia. Three studies (<a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a>; <a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. ">Iwamura 2015</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>) included older participants (mean age 50 or older). Median symptoms severity, measured by NIH‐CPSI scores, was 24, with a narrow interquartile range of 22 to 26. Only two studies included participants with a NIH‐CPSI score greater than 30 (<a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. ">Li 2003</a>; <a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>). </p> <p>All studies referred to diagnostic criteria aimed at the differentiation of CP/CPPS from other forms of prostatitis and other urological diseases. Participants underwent digital rectal examination, urine cultures and two‐ or four‐glass Meares‐Stamey test. They excluded participants who had recently undergone prostatic biopsy or surgery, participants with prostate cancer, participants with a recent history of sexually‐transmitted diseases and participants with concomitant neurological disorders or severe systemic disorders. </p> <p>Thirteen studies included participants who had not received other previous treatment (<a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. ">Chen 2009</a>; <a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. ">Iwamura 2015</a>; <a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. ">Jeong 2008</a>; <a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. ">Jiang 2009</a>; <a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. ">Morgia 2010</a>; <a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. ">Morgia 2017</a>; <a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. ">Sun 2008</a>; <a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. ">Zhang 2017</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>). Ten studies specified that participants had previously received medical treatment with antibiotics or alpha blockers (or both) and had not had a positive response (<a href="./references#CD012552-bbs2-0013" title="ChengC‐H , LaiY‐W , HsuehT‐Y , ChiuY‐C , ChenS‐S , LuS‐H , et al. The efficacy of levofloxacin or ciprofloxacin in the management of chronic non‐bacterial prostatitis. International Journal of Urology2010;17:A335. LaiY , ChengC , HsuehT , ChiuY , ChenS , ChiuA . The efficacy of levofloxacin or ciprofloxacin in management of chronic non‐bacterial prostatitis. Urology2012;80(3):S154. ">Cheng 2010</a>; <a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a>; <a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a>; <a href="./references#CD012552-bbs2-0019" title="ElshawafH . Chemodenervation of the rhabdosphincter (EUS) alone versus combined injection of both EUS &amp; prostate in patients with prostatitis and chronic pelvic pain syndrome type III. Prospective randomized controlled trial. (Abstract number 394). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. ">Elshawaf 2009</a>; <a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>; <a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a>; <a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. ">Leskinen 1999</a>; <a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. ">Park 2005</a>; <a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>; <a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. ">Zhou 2008</a>). The other studies did not specify whether the participants had received previous treatments for this condition. Nevertheless, a common inclusion criterion was a wash‐out period, as stated in a protocol for medical therapy often cited as a consensus for inclusion/exclusion criteria (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>). </p> </section> <section id="CD012552-sec-0088"> <h5 class="title">Interventions</h5> <p>We included studies assessing a wide variety of pharmacological interventions.</p> <p> <ul id="CD012552-list-0027"> <li> <p>Alpha blockers (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. ">Cha 2009</a>; <a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. ">Cheah 2003</a>; <a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a>; <a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. ">Erdemir 2010</a>; <a href="./references#CD012552-bbs2-0026" title="GülO , ErogluM , OzokU . Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. International Urology and Nephrology2001;32(3):433‐6. ">Gül 2001</a>; <a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. ">Jeong 2008</a>; <a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. ">Jung 2006</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. ">Kulovac 2007</a>; <a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. ">Lacquaniti 1999</a>; <a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>; <a href="./references#CD012552-bbs2-0051" title="MoKI , LeeKS , KimDG . Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2006;47(5):536‐40. ">Mo 2006</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>; <a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. ">Ryu 2007</a>; <a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. ">Sivkov 2005</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0089" title="MinggenY , ZhoudaZ , ZhimingZ , HailiL , ZhenqiangX , ChaoxianZ , et al. Tamsulosin therapy for chronic nonbacterial prostatitis: A randomized double‐blind placebo controlled clinical trial. Chinese Journal of Andrology2010;24(12):32‐5. ">Yang 2010</a>; <a href="./references#CD012552-bbs2-0092" title="YounCW , SonK‐C , ChoiH‐S , KwonDD , ParkK , RyuSB . Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha‐blocker combination therapy for patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome. Korean Journal of Urology2008;49(1):72‐6. ">Youn 2008</a>). </p> </li> <li> <p>5‐alpha reductase inhibitors (<a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. ">Leskinen 1999</a>; <a href="./references#CD012552-bbs2-0056" title="NickelJC , DowneyJ , PontariMA , ShoskesD A , ZeitlinSI . A randomized placebo‐controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU International2004;93(7):991‐5. ">Nickel 2004a</a>). </p> </li> <li> <p>Antibiotic therapy (<a href="./references#CD012552-bbs2-0013" title="ChengC‐H , LaiY‐W , HsuehT‐Y , ChiuY‐C , ChenS‐S , LuS‐H , et al. The efficacy of levofloxacin or ciprofloxacin in the management of chronic non‐bacterial prostatitis. International Journal of Urology2010;17:A335. LaiY , ChengC , HsuehT , ChiuY , ChenS , ChiuA . The efficacy of levofloxacin or ciprofloxacin in management of chronic non‐bacterial prostatitis. Urology2012;80(3):S154. ">Cheng 2010</a>; <a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. ">Choe 2014</a>; <a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>; <a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. ">Ye 2008</a>; <a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. ">Zhou 2008</a>). </p> </li> <li> <p>Anti‐inflammatories: <a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. ">Bates 2007</a>; <a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. ">Goldmeier 2005</a>; <a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. ">Jiang 2009</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>; <a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. ">Yang 2009</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>. </p> </li> <li> <p>Phytotherapy: (<a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. ">Apolikhin 2010</a>; <a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>; <a href="./references#CD012552-bbs2-0006" title="CaiT , WagenlehnerFM , LucianiLG , TiscioneD , MalossiniG , VerzeP , et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine2014;8(4):1032‐8. ">Cai 2014</a>; <a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. ">Cai 2017</a>; <a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. ">Cha 2009</a>; <a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a><a href="./references#CD012552-bbs2-0022" title="GiammussoB , DiMauroR , BernardiniR . The efficacy of an association of palmitoylethanolamide and alpha‐lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Archivio Italiano di Urologia e Andrologia2017;89(1):17‐21. ">Giammusso 2017</a>; <a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. ">Iwamura 2015</a>; <a href="./references#CD012552-bbs2-0032" title="KaplanSA , VolpeMA , TeAE . A prospective, 1‐year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(1):284‐8. ">Kaplan 2004</a>; <a href="./references#CD012552-bbs2-0041" title="LeeCB , HaUS , LeeSJ , KimSW , ChoYH . Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World Journal of Urology2006;24(1):55‐60. ">Lee 2006a</a>; <a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. ">Macchione 2017</a>; <a href="./references#CD012552-bbs2-0049" title="MauriziA , DeLucaF , ZanghiA , ManziE , LeonardoC , GuidottiM , et al. The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica2019;90(4):260‐4. [PUBMED: 30655636] ">Maurizi 2019</a>; <a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. ">Morgia 2010</a>; <a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. ">Morgia 2017</a>; <a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. ">Okada 1985</a>; <a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. ">Park 2005</a>; <a href="./references#CD012552-bbs2-0069" title="ReissiglA , DjavanB , PointnerJ . Prospective placebo‐controlled multicenter trial on safety and efficacy of phytotherapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(61):Abstract 233. [MEDLINE: 14665844] ">Reissigl 2004</a>; <a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. ">Shoskes 1999</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>; <a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. ">Xu 2000</a>; <a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. ">Ye 2006</a>). </p> </li> <li> <p>Botulinum toxin A (<a href="./references#CD012552-bbs2-0019" title="ElshawafH . Chemodenervation of the rhabdosphincter (EUS) alone versus combined injection of both EUS &amp; prostate in patients with prostatitis and chronic pelvic pain syndrome type III. Prospective randomized controlled trial. (Abstract number 394). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. ">Elshawaf 2009</a>; <a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>; <a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a>). </p> </li> <li> <p>Allopurinol (<a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. ">Persson 1996</a>; <a href="./references#CD012552-bbs2-0099" title="ZiaeeAM , AkhavizadeganH , KarbakhshM . Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. International Brazilian Journal of Urology2006;32(2):181‐6. ">Ziaee 2006</a>). </p> </li> <li> <p>Traditional Chinese medicine (<a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. ">Chen 2009</a>; <a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. ">Hu 2015</a>; <a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. ">Li 2003</a>; <a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. ">Li 2007</a>; <a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. ">Li 2012</a>; <a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. ">Peng 2003</a>; <a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. ">Shi 1994</a>; <a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. ">Sun 2008</a>; <a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. ">Tan 2009</a>; <a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. ">Wang 2004</a>; <a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. ">Xia 2014</a>; <a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. ">Zhang 2007</a>). </p> </li> <li> <p>Other pharmacological agents</p> </li> </ul> <ul class="plain" id="CD012552-list-0028"> <li> <ul id="CD012552-list-0029"> <li> <p>Anticholinergics agents (<a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. ">Kim 2008</a>; <a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. ">Kim 2011b</a>) </p> </li> <li> <p>Antidepressant (<a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. ">Giannantoni 2014</a>; <a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. ">Lee 2005</a>; <a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. ">Turkington 2002</a>; <a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. ">Zhang 2017</a>) </p> </li> <li> <p>Mepartricin (<a href="./references#CD012552-bbs2-0008" title="CavalliniG . Mepartricin in the treatment of male pelvic pain syndrome secondary to chronic nonbacterial prostatitis/prostatodynia. Minerva Urologica e Nefrologica [Italian Journal of Urology and Nephrology]2001;53(1):13‐7. ">Cavallini 2001</a>; <a href="./references#CD012552-bbs2-0016" title="DeRoseAF , GalloF , GiglioM , CarmignaniG . Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo‐controlled trial. Urology2004;63(1):13‐6. DeRoseAF , TraversoP , MontanaroT , CarmignaniG . The role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS): A randomized prospective placebo‐controlled trial. Journal of Urology2010;183(4):e311. ">De Rose 2004</a>) </p> </li> <li> <p>OM‐89 (<a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. ">Wagenlehner 2014</a>) </p> </li> <li> <p>Pentosan (<a href="./references#CD012552-bbs2-0058" title="NickelJC , ForrestJB , TomeraK , Hernandez‐GraulauJ , MoonTD , SchaefferAJ , et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. Journal of Urology2005;173(4):1252‐5. ">Nickel 2005</a>; <a href="./references#CD012552-bbs2-0084" title="WedrenH . Effects of sodium pentosanpolysulphate on symptoms related to chronic non‐bacterial prostatitis. A double‐blind randomized study. Scandinavian Jpurnal of Urology and Nephrology1987;21(2):81‐8. ">Wedren 1987</a>) </p> </li> <li> <p>Phosphodiesterase inhibitors (<a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. ">Abdalla 2018</a>; <a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. ">Kong 2014</a>; <a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. ">Lin 2007</a>; <a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. ">Park 2012</a>; <a href="./references#CD012552-bbs2-0065" title="ParkHJ , ParkNC , MoonDG , KimTN , NamJK , ParkSW . Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction. European Urology Supplements2017;16(3):e453. ">Park 2017</a>; <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>) </p> </li> <li> <p>Pregabalin (<a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>) </p> </li> <li> <p>Tanezumab (<a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. ">Nickel 2016</a>) </p> </li> </ul> </li> </ul> </p> </section> <section id="CD012552-sec-0089"> <h5 class="title">Outcomes</h5> <p>Almost all studies reported the effects of the interventions on prostatitis symptoms. All but three studies used the NIH‐CPSI score: two studies (<a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. ">Lee 2005</a>; <a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. ">Leskinen 1999</a>) used a 100‐point validated scale (Prostatitis Symptom Severity Index (PSSI)) and <a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. ">Lacquaniti 1999</a> used another validated scale (0 to 12, from <a href="./references#CD012552-bbs2-0228" title="NealDEJr , MoonTD . Use of terazosin in prostatodynia and validation of a symptom score questionnaire. Urology1994;43(4):460‐5. [PUBMED: 7512296] ">Neal 1994</a>). </p> <p>Other secondary outcomes relevant to this review were reported inconsistently. Ten studies did not report prostatitis symptoms: three studies reported global improvement as a composite outcome of symptoms and laboratory findings (<a href="./references#CD012552-bbs2-0008" title="CavalliniG . Mepartricin in the treatment of male pelvic pain syndrome secondary to chronic nonbacterial prostatitis/prostatodynia. Minerva Urologica e Nefrologica [Italian Journal of Urology and Nephrology]2001;53(1):13‐7. ">Cavallini 2001</a>; <a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. ">Peng 2003</a>; <a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. ">Shi 1994</a>) and seven studies reported clinical improvement using locally‐developed scales (<a href="./references#CD012552-bbs2-0015" title="ChurakovAA , KolesnikovAI , BliumbergBI , PopkovVM . Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction. Urologiia2012;5:64‐6, 68. ">Churakov 2012</a>; <a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a>; <a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a>; <a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. ">Persson 1996</a>; <a href="./references#CD012552-bbs2-0084" title="WedrenH . Effects of sodium pentosanpolysulphate on symptoms related to chronic non‐bacterial prostatitis. A double‐blind randomized study. Scandinavian Jpurnal of Urology and Nephrology1987;21(2):81‐8. ">Wedren 1987</a>; <a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. ">Xu 2000</a>; <a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. ">Okada 1985</a>). Some of these studies provided information about adverse events. </p> <p>We found mostly short‐term outcomes for the included comparisons. Median follow‐up was eight weeks (interquartile range 6 to 12 weeks; range 4 to 72 weeks). </p> </section> <section id="CD012552-sec-0090"> <h5 class="title">Funding sources</h5> <p>Most studies (54 studies, 55%) did not specify their funding sources. Seven studies were financed by their local government (<a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. ">Bates 2007</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>; <a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. ">Li 2007</a>; <a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. ">Li 2012</a>; <a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. ">Peng 2003</a>; <a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. ">Zhang 2007</a>; <a href="./references#CD012552-bbs2-0097" title="ChiCTR1800019441 . A clinical observation of dapoxetine combined with tamsulosin in treatment of type III prostatitis with premature ejaculation. http://www.chictr.org.cn/showproj.aspx?proj=28436 (Date of Registration: 2018‐11‐11). ZhaoL , TianR , LiangC , ZhangL , SongW , ZhaoJ , et al. Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation. Andrologia2019;51(8):e13319. [PUBMED: 31131928] ">Zhao 2019</a>), one study by a non‐governmental organisation (<a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. ">Lee 2005</a>), three studies by universities (<a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. ">Kim 2008</a>; <a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. ">Kong 2014</a>; <a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. ">Ryu 2007</a>), six studies received mixed financing from government and pharmaceutical companies (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>; <a href="./references#CD012552-bbs2-0056" title="NickelJC , DowneyJ , PontariMA , ShoskesD A , ZeitlinSI . A randomized placebo‐controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU International2004;93(7):991‐5. ">Nickel 2004a</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>) and 15 studies were funded by pharmaceutical companies (<a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. ">Cheah 2003</a>; <a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a>; <a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a>; <a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. ">Goldmeier 2005</a>; <a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. ">Jung 2006</a>; <a href="./references#CD012552-bbs2-0049" title="MauriziA , DeLucaF , ZanghiA , ManziE , LeonardoC , GuidottiM , et al. The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica2019;90(4):260‐4. [PUBMED: 30655636] ">Maurizi 2019</a>; <a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. ">Nickel 2003b</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0058" title="NickelJC , ForrestJB , TomeraK , Hernandez‐GraulauJ , MoonTD , SchaefferAJ , et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. Journal of Urology2005;173(4):1252‐5. ">Nickel 2005</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>; <a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. ">Nickel 2016</a>; <a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. ">Turkington 2002</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>; <a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. ">Wagenlehner 2014</a>; <a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. ">Ye 2008</a>). Thirteen studies specified that they had no funding (<a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. ">Abdalla 2018</a>; <a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. ">Apolikhin 2010</a>; <a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>; <a href="./references#CD012552-bbs2-0015" title="ChurakovAA , KolesnikovAI , BliumbergBI , PopkovVM . Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction. Urologiia2012;5:64‐6, 68. ">Churakov 2012</a>; <a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. ">Leskinen 1999</a>; <a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. ">Morgia 2017</a>; <a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. ">Macchione 2017</a>; <a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. ">Sivkov 2005</a>; <a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. ">Park 2012</a>; <a href="./references#CD012552-bbs2-0069" title="ReissiglA , DjavanB , PointnerJ . Prospective placebo‐controlled multicenter trial on safety and efficacy of phytotherapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(61):Abstract 233. [MEDLINE: 14665844] ">Reissigl 2004</a>; <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. ">Zhang 2017</a>). </p> </section> </section> <section id="CD012552-sec-0091"> <h4 class="title">Excluded studies</h4> <p>We excluded 54 studies for the following reasons (see <a href="./references#CD012552-sec-0280" title="">Characteristics of excluded studies</a>). </p> <p>Twelve studies evaluated an ineligible participant population: eight studies included participants with bacterial prostatitis, but with no disaggregated data for CP/CPPS (<a href="./references#CD012552-bbs2-0103" title="BarbaliasGA , NikiforidisG , LiatsikosEN . Alpha‐blockers for the treatment of chronic prostatitis in combination with antibiotics. Journal of Urology1998;159(3):883‐7. ">Barbalias 1998</a>; <a href="./references#CD012552-bbs2-0105" title="ChenCQ , YiQT , ChenCH , GongM . Effect of Interventions for Premature Ejaculation in the Treatment of Chronic Prostatitis with Secondary Premature Ejaculation. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae2016;38(4):393‐8. [PUBMED: 27594150] ">Chen 2016</a>; <a href="./references#CD012552-bbs2-0110" title="FengH , HuC , LiL . Influence of whole‐range systematic nursing intervention of therapeutic effect and compliance of patients with chronic prostatitis. Chinese Nursing Research2011;25(5A):1146‐8. ">Feng 2011</a>; <a href="./references#CD012552-bbs2-0111" title="GaleoneG , SpadavecchiaR , BalducciMT , PagliaruloV . The role of Proxelan in the treatment of chronic prostatitis. Results of a randomized trial. Minerva Urologia e Nefrologia2012;64(2):135‐41. ">Galeone 2012</a>; <a href="./references#CD012552-bbs2-0112" title="GlybochkoPV , Alyaev YuG , ChalyjME , VoskanyanGA . Primary assessment of electrode pharmaphoresis efficacy in treatment of chronic bacterial prostatitis. European Urology Supplements2014;13(1):e571. ">Glybochko 2014</a>; <a href="./references#CD012552-bbs2-0113" title="GolubchikovVA , SitnikovNV , KochetovAG , PerekhodovSN , SidorovOV , RoiukRV , et al. Optimal treatment of benign prostatic hyperplasia (BPH) with comorbid chronic prostatitis (category IIIA). Urologiia2005;4:9‐12. ">Golubchikov 2005</a>; <a href="./references#CD012552-bbs2-0123" title="LokshinKL , AlyaevYG , VinarovAZ , SpivakLG . Randomized open label comparative study of efficacy and safety of combination (ciprofloxacin+doxazosin) vs. monotherapy (ciprofloxacin) in patients with category II or category IIIA prostatitis. European Urology Supplements2010;9(2):140. ">Lokshin 2010</a>; <a href="./references#CD012552-bbs2-0143" title="Pushkar'DI , ZaitsevAV , SegalAS . Longidase in the treatment of chronic prostatitis. Urologiia2006;6:26‐8. ">Pushkar' 2006</a>; <a href="./references#CD012552-bbs2-0145" title="SimmonsPD , ThinRN . Minocycline in chronic abacterial prostatitis: a double‐blind prospective trial. British Journal of Urology1985;57(1):43‐5. ">Simmons 1985</a>) and three studies did not use the NIH criteria for CP/CPPS (<a href="./references#CD012552-bbs2-0128" title="MinjieZ , MingyueY , LeiC , ChaoY , WeiZ , JunJ , et al. The effectiveness of long‐needle acupuncture at acupoints BL30 and BL35 for CP/CPPS: a randomized controlled pilot study. BMC Complementary &amp; Alternative Medicine2017;17:1‐6. ">Minjie 2017</a>; <a href="./references#CD012552-bbs2-0139" title="NickelJC , RoehrbornC , MontorsiF , WilsonTH , RittmasterRS . Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. Journal of Urology2011;186(4):1313‐8. ">Nickel 2011b</a>; <a href="./references#CD012552-bbs2-0153" title="ZhangMJ , WengJF , ShiYL , ChengWJ , RuanXJ , ZhangQY . Effect of Aike Mixture on the inflammatory infiltration in patients with chronic prostatitis type III A. Chinese Journal of Integrated Medicine2011;17(1):26‐30. ">Zhang 2011</a>) </p> <p>We found 31 studies to have an ineligible study design: 27 studies specified that they did not use randomisation or used a non‐random sequence for the allocation of participants (<a href="./references#CD012552-bbs2-0100" title="Abdel‐MeguidTA , MosliHA , FarsiH , AlsayyadA , TayibA , SaitM , et al. Treatment of refractory category III nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinumtoxinA: a prospective controlled study. The Canadian journal of urology2018;25(2):9273‐80. [PUBMED: 29680006] ">Abdel‐Meguid 2018</a>; <a href="./references#CD012552-bbs2-0101" title="AliaevIuG , VinarovAZ , LokshinKL , SpivakLG . Efficiency and safety of prostamol‐Uno in patients with chronic abacterial prostatitis. Urologiia2006;1:47‐50. ">Aliaev 2006</a>; <a href="./references#CD012552-bbs2-0102" title="AllenS , AghajanyanIG . Effect of thermobalancing therapy on chronic prostatitis and chronic pelvic pain syndrome. Journal of Clinical Urology2017;10(4):347‐54. AllenS , AghajanyanIG . New independent thermobalancing treatment with therapeutic device for chronic prostatitis/chronic pelvic pain syndrome. Nephro‐Urology Monthly2017;9(2):1‐6. ">Allen 2017</a>; <a href="./references#CD012552-bbs2-0106" title="ColleenS , MårdhPA . Effect of metacycline treatment on non‐acute prostatitis. Scandinavian Journal of Urology and Nephrology1975;9(3):198‐204. ">Colleen 1975</a>; <a href="./references#CD012552-bbs2-0107" title="DRKS00009352 . Effect of the physiotherapeutic device and thermobalancing therapy compared with no therapy on pain, urinary symptoms, quality of life and prostate volume in men with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS). www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00009352 (first received 11 november 2015). ">DRKS00009352</a>; <a href="./references#CD012552-bbs2-0109" title="EvliyaoğluY , BurgutR . Lower urinary tract symptoms, pain and quality of life assessment in chronic non‐bacterial prostatitis patients treated with alpha‐blocking agent doxazosin; versus placebo. International Urology and Nephrology2002;34(3):351‐6. ">Evliyaoğlu 2002</a>; <a href="./references#CD012552-bbs2-0114" title="HongJY , ZhangYY . Observation on therapeutic effect of abdominal cluster‐needling on chronic non‐bacterial prostatitis. Zhongguo Zhen Jiu2008;28(1):24‐6. ">Hong 2008</a>; <a href="./references#CD012552-bbs2-0115" title="IkeuchiT . Clinical studies on chronic prostatitis and prostatitis‐like syndrome (4). The kampo treatment for intractable prostatitis. Hinyokika Kiyo1990;36(7):801‐6. ">Ikeuchi 1990</a>; <a href="./references#CD012552-bbs2-0116" title="ISRCTN43221600 . Pilot study for the evaluation of a combined psycho‐ and physiotherapeutic treatment program for patients with chronic pelvic pain syndrome (CPPS). www.isrctn.com/ISRCTN43221600 (first received 14 March 2016). ">ISRCTN43221600</a>; <a href="./references#CD012552-bbs2-0117" title="KalininaSN , Koren'kovDG , FesenkoVN , DemidovDA , TiktinskijNO . Pathogenetic treatment of chronic nonbacterial prostatis complicated by sperm disorders. Urologiia2015;4(4):64‐6, 68. ">Kalinina 2015</a>; <a href="./references#CD012552-bbs2-0118" title="KamalovAA , EfremovEA , DorofeevSD , PaniushkinSM . Use of oral vitaprost in the treatment of chronic abacterial prostatitis. Urologiia2006;5:45‐50. ">Kamalov 2006</a>; <a href="./references#CD012552-bbs2-0119" title="KoganMI , ShangichevAV , BelousovII . Efficacy of magnetolaser therapy of patients with an inflammatory form of chronic abacterial prostatitis. Urologiia2010;2:42‐4. ">Kogan 2010</a>; <a href="./references#CD012552-bbs2-0121" title="LeeHN , KimJS , ShimBS . The recurrence of chronic pelvic pain syndrome and the role of Uro‐Vaxom‐. Korean Journal of Urology2006;47(1):42‐6. ">Lee 2006b</a>; <a href="./references#CD012552-bbs2-0122" title="LengJ , LvJ , DaiS , ChenB , WangY . The cocktail treatment of chronic nonbacterial prostatits. Chinese Journal of Andrology2007;21(1):26‐8. ">Leng 2007</a>; <a href="./references#CD012552-bbs2-0124" title="LopatkinNA , KamalovAA , MazoEB , DorofeevSD , EfremovEA , KozdobaAS , et al. Administration of oral vitaprost for prevention of exacerbations of chronic abacterial prostatitis. Urologiia2009;1:29‐35. ">Lopatkin 2009</a>; <a href="./references#CD012552-bbs2-0125" title="LoranOB , Pushkar'DI , TedeevVV , NosovitskiiPB . Gentos in the treatment of chronic abacterial prostatitis. Urologiia2003;6:30‐2. ">Loran 2003</a>; <a href="./references#CD012552-bbs2-0126" title="MaY , LiX , LiF , YuW , WangZ . Clinical research of chronic pelvic cavity pain syndrome treated with acupoint catgut embedding therapy. Zhongguo Zhen Jiu2015;35(6):561‐6. MaY , WangZL , SunZX , MenB , ShenBQ . Efficacy observation on chronic pelvic pain syndrome of damp‐heat stagnation pattern treated with acupoint catgut embedding therapy. Zhongguo Zhen Jiu2014;34(4):351‐4. ">Ma 2015</a>; <a href="./references#CD012552-bbs2-0140" title="NishinoY , MiwaK , MoriyamaY , FujihiroS , MasueT , KikuchiM , et al. Tadalafil ameliorates symptoms of patients with benign prostatic hyperplasia complicated by chronic pelvic pain syndrome. Hinyokika kiyo. Acta urologica Japonica2017;63(3):101‐5. ">Nishino 2017</a>; <a href="./references#CD012552-bbs2-0141" title="OsbornDE , GeorgeNJ , RaoPN . Prostatodynia ‐ physiological characteristics and rational management with muscle relaxants. BJU International1981;53(6):621‐3. ">Osborn 1981</a>; <a href="./references#CD012552-bbs2-0142" title="PavoneC , AbbadessaD , TarantinoML , OxeniusI , LaganaA , LupoA , et al. Associating Serenoa repens, Urtica dioica and Pinus pinaster. Safety and efficacy in the treatment of lower urinary tract symptoms. Prospective study on 320 patients. Urologia2010;77(1):43‐51. ">Pavone 2010</a>; <a href="./references#CD012552-bbs2-0144" title="RazumovSV , EgorovAA . Validity of using physical therapy in combined treatment of chronic prostatitis. Urologiia2005;2:42‐6. ">Razumov 2005</a>; <a href="./references#CD012552-bbs2-0146" title="StamatiouKN , MoschourisH . A prospective interventional study in chronic prostatitis with emphasis to clinical features. Urology Journal2014;11(4):1829‐33. ">Stamatiou 2014</a>; <a href="./references#CD012552-bbs2-0147" title="TakahashiK , OzakiY , YoshidaT , FujimotoN , MatsumotoT , NakashimaM , et al. Clinical evaluation of treatment using mainly levofloxacin and cernitin pollen extract for chronic non‐bacterial prostatitis as judged by the National Institutes of Health Chronic Prostatitis Symptom Index. Nishinihon Journal of Urology2005;67(11):637‐48. ">Takahashi 2005</a>; <a href="./references#CD012552-bbs2-0148" title="ThinRN , SimmonsPD . Review of results of four regimens for treatment of chronic non‐bacterial prostatitis. British Journal of Urology1983;55(5):519‐21. ">Thin 1983</a>; <a href="./references#CD012552-bbs2-0149" title="TkachukVN , Al'‐ShukriSK , Lotsan‐MedvedevAK . Vitaprost efficacy in patients with chronic abacterial prostatitis. Urologiia2006;2:71‐2, 74. ">Tkachuk 2006</a>; <a href="./references#CD012552-bbs2-0150" title="TkachukV N , Al'‐ShukriS K h , TkacukI N , KornienkoV I . [Correction of erectile dysfunction in patients with chronic abacterial prostatitis]. Urologiia2011;‐(6):29‐31. ">Tkachuk 2011</a>; <a href="./references#CD012552-bbs2-0152" title="XuS , QiG , TangP , LiY . Combined therapy for the chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(6):429‐30, 433. ">Xu 2004</a>); two studies reported the follow‐up of a single arm of a randomised controlled trial (<a href="./references#CD012552-bbs2-0120" title="KotarinosR , FortmanC , NevilleC , BadilloS , O'DoughertyB , FraserL , et al. Physical findings in patients with urologic chronic pelvic pain syndromes (UCPPS). Neurourology and Urodynamics2009;28(7):911‐2. ">Kotarinos 2009</a>; <a href="./references#CD012552-bbs2-0127" title="MarxS , CimniakU , RutzM , ReschKL . Long‐term effects of osteopathic treatment of chronic prostatitis with chronic pelvic pain syndrome: a 5‐year follow‐up of a randomized controlled trial and considerations on the pathophysiological context. Urologe A2013;52(3):384‐90. ">Marx 2013</a>); one study was a non‐controlled study of different routes of administration of an intervention (<a href="./references#CD012552-bbs2-0108" title="El‐enenMA , Abou‐FarhaM , El‐AbdA , El‐TatawyH , TawfikA , El‐AbdS , et al. Intraprostatic injection of botulinum toxin‐A in patients with refractory chronic pelvic pain syndrome: The transurethral vs transrectal approach. Arab Journal of Urology2015;13(2):94‐9. ">El‐enen 2015</a>), and one study was a phase II dose‐finding study with an adaptive design (<a href="./references#CD012552-bbs2-0151" title="WagenlehnerFM , VanTillJW , HoubiersJG , MartinaRV , CerneusDP , MelisJH , et al. Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis/chronic pelvic pain syndrome: an adaptive double‐blind, randomized controlled trial. Urology2017;103:191‐7. [PUBMED: 28254462] ">Wagenlehner 2017</a>). </p> <p>Additionally, 11 studies were terminated and no outcome data were available, due to problems in their conduct (<a href="./references#CD012552-bbs2-0104" title="BschleipferT , WagenlehnerFM , WeidnerW . Intraprostatic botulinum toxin A injection in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). Urologe A2007;46(9):1030‐2. EUCTR2007‐001602‐24‐DE . Intraprostatic injection of Botulinumtoxin type A in patients with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) ‐ CP(BTX)PS. www.clinicaltrialsregister.eu/ctr‐search/trial/2007‐001602‐24/DE (first received 02 June 2009). ">Bschleipfer 2007</a>; <a href="./references#CD012552-bbs2-0137" title="NCT02042651 . A sham controlled study of the effects of ultrasonic shockwaves as a treatment for chronic pelvic pain. clinicaltrials.gov/ct2/show/NCT02042651 (first received 23 January 2014). ">NCT02042651</a>; <a href="./references#CD012552-bbs2-0129" title="NCT00194597 . Trial of viagra in men with chronic pelvic pain syndrome Type III. clinicaltrials.gov/ct2/show/NCT00194597 (first received 19 September 2005). ">NCT00194597</a>; <a href="./references#CD012552-bbs2-0130" title="NCT00194623 . Botox as a treatment for chronic male pelvic pain syndrome. clinicaltrials.gov/ct2/show/NCT00194623 (first received 19 September 2005). ">NCT00194623</a>; <a href="./references#CD012552-bbs2-0138" title="NCT03500159 . Efficacy and safety of AQX‐1125 in subjects with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). clinicaltrials.gov/ct2/show/NCT03500159 (first received 17 April 2018). ">NCT03500159</a>; <a href="./references#CD012552-bbs2-0131" title="NCT00194636 . Effectiveness of sympathetic plexus block on male pelvic pain (prostatitis, prostatodynia). clinicaltrials.gov/ct2/show/NCT00194636 (first received 19 September 2005). ">NCT00194636</a>; <a href="./references#CD012552-bbs2-0132" title="NCT00301405 . Open‐label study of thalidomide for chronic prostatitis/chronic pelvic pain. clinicaltrials.gov/ct2/show/NCT00301405 (first received 10 March 2006). ">NCT00301405</a>; <a href="./references#CD012552-bbs2-0133" title="NCT00464373 . Botulinum toxin type A for the treatment of male chronic pelvic pain syndrome. clinicaltrials.gov/ct2/show/NCT00464373 (first received 23 April 2007). ">NCT00464373</a>; <a href="./references#CD012552-bbs2-0134" title="NCT00529386 . Botox for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). clinicaltrials.gov/ct2/show/NCT00529386 (first received 14 September 2007). ">NCT00529386</a>; <a href="./references#CD012552-bbs2-0135" title="NCT01678911 . Efficacy of Gralise® for chronic pelvic pain. clinicaltrials.gov/ct2/show/NCT01678911 (First received 29 June 2015). ">NCT01678911</a>; <a href="./references#CD012552-bbs2-0136" title="NCT01830829 . JALYN for benign prostatic hyperplasia (BPH) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). clinicaltrials.gov/ct2/show/NCT01830829 (First received 12 April 2013). ">NCT01830829</a>). </p> </section> </section> <section id="CD012552-sec-0092"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD012552-fig-0002">Figure 2</a> for a summary of 'Risk of bias' assessments. See <a href="#CD012552-fig-0003">Figure 3</a> for the individual assessments of the included studies. Detailed descriptions of the supporting judgements can be found in the <a href="./references#CD012552-sec-0279" title="">Characteristics of included studies</a>. Considering a global assessment of risk of bias for the main outcomes of this review, only three studies had low risk of bias (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>), 23 studies had unclear risk of bias (<a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>; <a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. ">Cha 2009</a>; <a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0013" title="ChengC‐H , LaiY‐W , HsuehT‐Y , ChiuY‐C , ChenS‐S , LuS‐H , et al. The efficacy of levofloxacin or ciprofloxacin in the management of chronic non‐bacterial prostatitis. International Journal of Urology2010;17:A335. LaiY , ChengC , HsuehT , ChiuY , ChenS , ChiuA . The efficacy of levofloxacin or ciprofloxacin in management of chronic non‐bacterial prostatitis. Urology2012;80(3):S154. ">Cheng 2010</a>; <a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a>; <a href="./references#CD012552-bbs2-0019" title="ElshawafH . Chemodenervation of the rhabdosphincter (EUS) alone versus combined injection of both EUS &amp; prostate in patients with prostatitis and chronic pelvic pain syndrome type III. Prospective randomized controlled trial. (Abstract number 394). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. ">Elshawaf 2009</a>; <a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. ">Abdalla 2018</a>; <a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>; <a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. ">Jung 2006</a>; <a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. ">Kim 2008</a>; <a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. ">Lacquaniti 1999</a>; <a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. ">Li 2003</a>; <a href="./references#CD012552-bbs2-0051" title="MoKI , LeeKS , KimDG . Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2006;47(5):536‐40. ">Mo 2006</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>; <a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. ">Park 2012</a>; <a href="./references#CD012552-bbs2-0069" title="ReissiglA , DjavanB , PointnerJ . Prospective placebo‐controlled multicenter trial on safety and efficacy of phytotherapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(61):Abstract 233. [MEDLINE: 14665844] ">Reissigl 2004</a>; <a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. ">Ryu 2007</a>; <a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. ">Yang 2009</a>; <a href="./references#CD012552-bbs2-0089" title="MinggenY , ZhoudaZ , ZhimingZ , HailiL , ZhenqiangX , ChaoxianZ , et al. Tamsulosin therapy for chronic nonbacterial prostatitis: A randomized double‐blind placebo controlled clinical trial. Chinese Journal of Andrology2010;24(12):32‐5. ">Yang 2010</a>; <a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. ">Ye 2006</a>; <a href="./references#CD012552-bbs2-0092" title="YounCW , SonK‐C , ChoiH‐S , KwonDD , ParkK , RyuSB . Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha‐blocker combination therapy for patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome. Korean Journal of Urology2008;49(1):72‐6. ">Youn 2008</a>; <a href="./references#CD012552-bbs2-0099" title="ZiaeeAM , AkhavizadeganH , KarbakhshM . Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. International Brazilian Journal of Urology2006;32(2):181‐6. ">Ziaee 2006</a>) and the remaining 70 studies had at least one domain with high risk of bias. </p> <div class="figure" id="CD012552-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012552-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012552-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012552-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012552-sec-0093"> <h4 class="title">Allocation</h4> <section id="CD012552-sec-0094"> <h5 class="title">Random sequence generation</h5> <p>Thirty‐one studies specified an adequate method of random sequence allocation (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>; <a href="./references#CD012552-bbs2-0006" title="CaiT , WagenlehnerFM , LucianiLG , TiscioneD , MalossiniG , VerzeP , et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine2014;8(4):1032‐8. ">Cai 2014</a>; <a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. ">Cai 2017</a>; <a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. ">Cheah 2003</a>; <a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. ">Choe 2014</a>; <a href="./references#CD012552-bbs2-0016" title="DeRoseAF , GalloF , GiglioM , CarmignaniG . Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo‐controlled trial. Urology2004;63(1):13‐6. DeRoseAF , TraversoP , MontanaroT , CarmignaniG . The role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS): A randomized prospective placebo‐controlled trial. Journal of Urology2010;183(4):e311. ">De Rose 2004</a>; <a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a>; <a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a>; <a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. ">Goldmeier 2005</a>; <a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a>; <a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. ">Hu 2015</a>; <a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. ">Lacquaniti 1999</a>; <a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>; <a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. ">Morgia 2010</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>; <a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. ">Nickel 2003b</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. ">Nickel 2016</a>; <a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. ">Persson 1996</a>; <a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>; <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>; <a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. ">Tan 2009</a>; <a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. ">Turkington 2002</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>; <a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. ">Wagenlehner 2014</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>). The remaining studies were at unclear risk of bias for random sequence generation. </p> </section> <section id="CD012552-sec-0095"> <h5 class="title">Allocation concealment</h5> <p>Twenty‐two studies specified an adequate method of allocation concealment (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. ">Bates 2007</a>; <a href="./references#CD012552-bbs2-0016" title="DeRoseAF , GalloF , GiglioM , CarmignaniG . Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo‐controlled trial. Urology2004;63(1):13‐6. DeRoseAF , TraversoP , MontanaroT , CarmignaniG . The role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS): A randomized prospective placebo‐controlled trial. Journal of Urology2010;183(4):e311. ">De Rose 2004</a>; <a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a>; <a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>; <a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. ">Goldmeier 2005</a>; <a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a>; <a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. ">Iwamura 2015</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>; <a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. ">Morgia 2010</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>; <a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. ">Nickel 2003b</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>; <a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. ">Nickel 2016</a>; <a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. ">Okada 1985</a>; <a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. ">Persson 1996</a>; <a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>; <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>; <a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. ">Wagenlehner 2014</a>). One study specified that they did not conceal the allocation of participants and was deemed at high risk of bias for this domain (<a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. ">Choe 2014</a>). The remaining studies were at unclear risk of bias in allocation concealment. </p> </section> </section> <section id="CD012552-sec-0096"> <h4 class="title">Blinding</h4> <section id="CD012552-sec-0097"> <h5 class="title">Blinding of participants and personnel</h5> <p>Nineteen studies specified an adequate method for the blinding of participants and personnel (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. ">Bates 2007</a>; <a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a>; <a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>; <a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. ">Goldmeier 2005</a>; <a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. ">Iwamura 2015</a>; <a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. ">Lacquaniti 1999</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>; <a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. ">Nickel 2003b</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>; <a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. ">Nickel 2016</a>; <a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. ">Okada 1985</a>; <a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>; <a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. ">Sivkov 2005</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>; <a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. ">Wagenlehner 2014</a>). Forty‐four studies did not adequately blind participants or personnel and were deemed at high risk of bias, considering that all outcomes were subjective (<a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. ">Apolikhin 2010</a>; <a href="./references#CD012552-bbs2-0006" title="CaiT , WagenlehnerFM , LucianiLG , TiscioneD , MalossiniG , VerzeP , et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine2014;8(4):1032‐8. ">Cai 2014</a>; <a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. ">Cai 2017</a>; <a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. ">Chen 2009</a>; <a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. ">Choe 2014</a>; <a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. ">Erdemir 2010</a>; <a href="./references#CD012552-bbs2-0022" title="GiammussoB , DiMauroR , BernardiniR . The efficacy of an association of palmitoylethanolamide and alpha‐lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Archivio Italiano di Urologia e Andrologia2017;89(1):17‐21. ">Giammusso 2017</a>; <a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. ">Giannantoni 2014</a>; <a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a>; <a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. ">Hu 2015</a>; <a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. ">Jeong 2008</a>; <a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. ">Jiang 2009</a>; <a href="./references#CD012552-bbs2-0032" title="KaplanSA , VolpeMA , TeAE . A prospective, 1‐year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(1):284‐8. ">Kaplan 2004</a>; <a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>; <a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. ">Kim 2011b</a>; <a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. ">Kong 2014</a>; <a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. ">Kulovac 2007</a>; <a href="./references#CD012552-bbs2-0041" title="LeeCB , HaUS , LeeSJ , KimSW , ChoYH . Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World Journal of Urology2006;24(1):55‐60. ">Lee 2006a</a>; <a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. ">Li 2007</a>; <a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. ">Li 2012</a>; <a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. ">Lin 2007</a>; <a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>; <a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. ">Macchione 2017</a>; <a href="./references#CD012552-bbs2-0049" title="MauriziA , DeLucaF , ZanghiA , ManziE , LeonardoC , GuidottiM , et al. The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica2019;90(4):260‐4. [PUBMED: 30655636] ">Maurizi 2019</a>; <a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. ">Morgia 2017</a>; <a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. ">Park 2005</a>; <a href="./references#CD012552-bbs2-0065" title="ParkHJ , ParkNC , MoonDG , KimTN , NamJK , ParkSW . Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction. European Urology Supplements2017;16(3):e453. ">Park 2017</a>; <a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. ">Peng 2003</a>; <a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. ">Shi 1994</a>; <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>; <a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. ">Sun 2008</a>; <a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. ">Tan 2009</a>; <a href="./references#CD012552-bbs2-0077" title="TucuV , TasciAI , FazlioluA , OdunctemurA , OzbekE , CekM . Comparison of the efficiency of mono and triple theraphy in chronic pelvic pain syndrome. Turk Urol. Derg.2006;32(3):393‐7. ">Tugcu 2006</a>; <a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>; <a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. ">Wang 2004</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. ">Xia 2014</a>; <a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. ">Xu 2000</a>; <a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. ">Ye 2008</a>; <a href="./references#CD012552-bbs2-0093" title="ZengX , YeZ , YangW , LiuJ , ZhangX , ZhouX , et al. Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis. Zhonghua Nan Ke Xue2004;10(4):278‐81. ">Zeng 2004</a>; <a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. ">Zhang 2007</a>; <a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. ">Zhang 2017</a>; <a href="./references#CD012552-bbs2-0097" title="ChiCTR1800019441 . A clinical observation of dapoxetine combined with tamsulosin in treatment of type III prostatitis with premature ejaculation. http://www.chictr.org.cn/showproj.aspx?proj=28436 (Date of Registration: 2018‐11‐11). ZhaoL , TianR , LiangC , ZhangL , SongW , ZhaoJ , et al. Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation. Andrologia2019;51(8):e13319. [PUBMED: 31131928] ">Zhao 2019</a>; <a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. ">Zhou 2008</a>). The remaining studies were at unclear risk of bias of blinding of participants and personnel. </p> </section> <section id="CD012552-sec-0098"> <h5 class="title">Blinding of outcome assessment</h5> <p>All the outcomes for this review were participant‐reported outcomes. Thirty‐five studies reported blinding of participants (outcome assessors) (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. ">Bates 2007</a>; <a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>; <a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. ">Cheah 2003</a>; <a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0016" title="DeRoseAF , GalloF , GiglioM , CarmignaniG . Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo‐controlled trial. Urology2004;63(1):13‐6. DeRoseAF , TraversoP , MontanaroT , CarmignaniG . The role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS): A randomized prospective placebo‐controlled trial. Journal of Urology2010;183(4):e311. ">De Rose 2004</a>; <a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a>; <a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>; <a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. ">Goldmeier 2005</a>; <a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. ">Iwamura 2015</a>; <a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. ">Lacquaniti 1999</a>; <a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. ">Lee 2005</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>; <a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. ">Morgia 2017</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>; <a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. ">Nickel 2003b</a>; <a href="./references#CD012552-bbs2-0056" title="NickelJC , DowneyJ , PontariMA , ShoskesD A , ZeitlinSI . A randomized placebo‐controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU International2004;93(7):991‐5. ">Nickel 2004a</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0058" title="NickelJC , ForrestJB , TomeraK , Hernandez‐GraulauJ , MoonTD , SchaefferAJ , et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. Journal of Urology2005;173(4):1252‐5. ">Nickel 2005</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>; <a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. ">Nickel 2016</a>; <a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. ">Okada 1985</a>; <a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. ">Persson 1996</a>; <a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>; <a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. ">Shoskes 1999</a>; <a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. ">Sivkov 2005</a>; <a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. ">Turkington 2002</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>; <a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. ">Wagenlehner 2014</a>; <a href="./references#CD012552-bbs2-0084" title="WedrenH . Effects of sodium pentosanpolysulphate on symptoms related to chronic non‐bacterial prostatitis. A double‐blind randomized study. Scandinavian Jpurnal of Urology and Nephrology1987;21(2):81‐8. ">Wedren 1987</a>; <a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. ">Yang 2009</a>; <a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. ">Ye 2006</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>; <a href="./references#CD012552-bbs2-0099" title="ZiaeeAM , AkhavizadeganH , KarbakhshM . Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. International Brazilian Journal of Urology2006;32(2):181‐6. ">Ziaee 2006</a>). Thirty‐nine studies did not adequately blind participants (<a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. ">Apolikhin 2010</a>; <a href="./references#CD012552-bbs2-0006" title="CaiT , WagenlehnerFM , LucianiLG , TiscioneD , MalossiniG , VerzeP , et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine2014;8(4):1032‐8. ">Cai 2014</a>; <a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. ">Cai 2017</a>; <a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. ">Chen 2009</a>; <a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. ">Choe 2014</a>; <a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. ">Erdemir 2010</a>; <a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. ">Giannantoni 2014</a>; <a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a>; <a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. ">Hu 2015</a>; <a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. ">Jeong 2008</a>; <a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. ">Jiang 2009</a>; <a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>; <a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. ">Kim 2011b</a>; <a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. ">Kulovac 2007</a>; <a href="./references#CD012552-bbs2-0041" title="LeeCB , HaUS , LeeSJ , KimSW , ChoYH . Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World Journal of Urology2006;24(1):55‐60. ">Lee 2006a</a>; <a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. ">Li 2007</a>; <a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. ">Li 2012</a>; <a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. ">Lin 2007</a>; <a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>; <a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. ">Macchione 2017</a>; <a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. ">Park 2005</a>; <a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. ">Peng 2003</a>; <a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. ">Shi 1994</a>; <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>; <a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. ">Sun 2008</a>; <a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. ">Tan 2009</a>; <a href="./references#CD012552-bbs2-0077" title="TucuV , TasciAI , FazlioluA , OdunctemurA , OzbekE , CekM . Comparison of the efficiency of mono and triple theraphy in chronic pelvic pain syndrome. Turk Urol. Derg.2006;32(3):393‐7. ">Tugcu 2006</a>; <a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>; <a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. ">Wang 2004</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. ">Xia 2014</a>; <a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. ">Xu 2000</a>; <a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. ">Ye 2008</a>; <a href="./references#CD012552-bbs2-0093" title="ZengX , YeZ , YangW , LiuJ , ZhangX , ZhouX , et al. Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis. Zhonghua Nan Ke Xue2004;10(4):278‐81. ">Zeng 2004</a>; <a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. ">Zhang 2007</a>; <a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. ">Zhang 2017</a>; <a href="./references#CD012552-bbs2-0097" title="ChiCTR1800019441 . A clinical observation of dapoxetine combined with tamsulosin in treatment of type III prostatitis with premature ejaculation. http://www.chictr.org.cn/showproj.aspx?proj=28436 (Date of Registration: 2018‐11‐11). ZhaoL , TianR , LiangC , ZhangL , SongW , ZhaoJ , et al. Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation. Andrologia2019;51(8):e13319. [PUBMED: 31131928] ">Zhao 2019</a>; <a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. ">Zhou 2008</a>). The remaining studies were at unclear risk of bias of outcome assessment. </p> </section> </section> <section id="CD012552-sec-0099"> <h4 class="title">Incomplete outcome data</h4> <p>Forty‐three studies specified that outcome data for all outcomes were available in all or nearly all participants (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. ">Apolikhin 2010</a>; <a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>; <a href="./references#CD012552-bbs2-0006" title="CaiT , WagenlehnerFM , LucianiLG , TiscioneD , MalossiniG , VerzeP , et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine2014;8(4):1032‐8. ">Cai 2014</a>; <a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. ">Chen 2009</a>; <a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a>; <a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. ">Erdemir 2010</a>; <a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>; <a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a>; <a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. ">Hu 2015</a>; <a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. ">Jeong 2008</a>; <a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. ">Jiang 2009</a>; <a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. ">Jung 2006</a>; <a href="./references#CD012552-bbs2-0032" title="KaplanSA , VolpeMA , TeAE . A prospective, 1‐year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(1):284‐8. ">Kaplan 2004</a>; <a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. ">Kim 2008</a>; <a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. ">Kong 2014</a>; <a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. ">Li 2003</a>; <a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. ">Li 2007</a>; <a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. ">Lin 2007</a>; <a href="./references#CD012552-bbs2-0049" title="MauriziA , DeLucaF , ZanghiA , ManziE , LeonardoC , GuidottiM , et al. The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica2019;90(4):260‐4. [PUBMED: 30655636] ">Maurizi 2019</a>; <a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. ">Morgia 2010</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. ">Park 2005</a>; <a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. ">Peng 2003</a>; <a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>; <a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. ">Shi 1994</a>; <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>; <a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. ">Sun 2008</a>; <a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. ">Tan 2009</a>; <a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. ">Wang 2004</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. ">Xia 2014</a>; <a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. ">Yang 2009</a>; <a href="./references#CD012552-bbs2-0089" title="MinggenY , ZhoudaZ , ZhimingZ , HailiL , ZhenqiangX , ChaoxianZ , et al. Tamsulosin therapy for chronic nonbacterial prostatitis: A randomized double‐blind placebo controlled clinical trial. Chinese Journal of Andrology2010;24(12):32‐5. ">Yang 2010</a>; <a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. ">Ye 2006</a>; <a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. ">Ye 2008</a>; <a href="./references#CD012552-bbs2-0093" title="ZengX , YeZ , YangW , LiuJ , ZhangX , ZhouX , et al. Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis. Zhonghua Nan Ke Xue2004;10(4):278‐81. ">Zeng 2004</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>; <a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. ">Zhou 2008</a>; <a href="./references#CD012552-bbs2-0099" title="ZiaeeAM , AkhavizadeganH , KarbakhshM . Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. International Brazilian Journal of Urology2006;32(2):181‐6. ">Ziaee 2006</a>). Thirty‐six had unbalanced or high attrition (or both) of outcome data at follow‐up and were deemed at high risk of bias (<a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. ">Bates 2007</a>; <a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. ">Cai 2017</a>; <a href="./references#CD012552-bbs2-0008" title="CavalliniG . Mepartricin in the treatment of male pelvic pain syndrome secondary to chronic nonbacterial prostatitis/prostatodynia. Minerva Urologica e Nefrologica [Italian Journal of Urology and Nephrology]2001;53(1):13‐7. ">Cavallini 2001</a>; <a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. ">Cheah 2003</a>; <a href="./references#CD012552-bbs2-0016" title="DeRoseAF , GalloF , GiglioM , CarmignaniG . Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo‐controlled trial. Urology2004;63(1):13‐6. DeRoseAF , TraversoP , MontanaroT , CarmignaniG . The role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS): A randomized prospective placebo‐controlled trial. Journal of Urology2010;183(4):e311. ">De Rose 2004</a>; <a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a>; <a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. ">Goldmeier 2005</a>; <a href="./references#CD012552-bbs2-0026" title="GülO , ErogluM , OzokU . Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. International Urology and Nephrology2001;32(3):433‐6. ">Gül 2001</a>; <a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. ">Iwamura 2015</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>; <a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. ">Kim 2011b</a>; <a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. ">Lee 2005</a>; <a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. ">Leskinen 1999</a>; <a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. ">Li 2012</a>; <a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>; <a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. ">Morgia 2017</a>; <a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. ">Nickel 2003b</a>; <a href="./references#CD012552-bbs2-0056" title="NickelJC , DowneyJ , PontariMA , ShoskesD A , ZeitlinSI . A randomized placebo‐controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU International2004;93(7):991‐5. ">Nickel 2004a</a>; <a href="./references#CD012552-bbs2-0058" title="NickelJC , ForrestJB , TomeraK , Hernandez‐GraulauJ , MoonTD , SchaefferAJ , et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. Journal of Urology2005;173(4):1252‐5. ">Nickel 2005</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. ">Nickel 2016</a>; <a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. ">Okada 1985</a>; <a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. ">Persson 1996</a>; <a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. ">Shoskes 1999</a>; <a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. ">Sivkov 2005</a>; <a href="./references#CD012552-bbs2-0077" title="TucuV , TasciAI , FazlioluA , OdunctemurA , OzbekE , CekM . Comparison of the efficiency of mono and triple theraphy in chronic pelvic pain syndrome. Turk Urol. Derg.2006;32(3):393‐7. ">Tugcu 2006</a>; <a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. ">Turkington 2002</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>; <a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. ">Wagenlehner 2014</a>; <a href="./references#CD012552-bbs2-0084" title="WedrenH . Effects of sodium pentosanpolysulphate on symptoms related to chronic non‐bacterial prostatitis. A double‐blind randomized study. Scandinavian Jpurnal of Urology and Nephrology1987;21(2):81‐8. ">Wedren 1987</a>; <a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. ">Xu 2000</a>; <a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. ">Zhang 2007</a>; <a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. ">Zhang 2017</a>; <a href="./references#CD012552-bbs2-0097" title="ChiCTR1800019441 . A clinical observation of dapoxetine combined with tamsulosin in treatment of type III prostatitis with premature ejaculation. http://www.chictr.org.cn/showproj.aspx?proj=28436 (Date of Registration: 2018‐11‐11). ZhaoL , TianR , LiangC , ZhangL , SongW , ZhaoJ , et al. Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation. Andrologia2019;51(8):e13319. [PUBMED: 31131928] ">Zhao 2019</a>). The remaining studies were at unclear risk of bias in this domain. </p> </section> <section id="CD012552-sec-0100"> <h4 class="title">Selective reporting</h4> <p>Ten studies had low risk of reporting bias when comparing their outcomes to their protocols or trial registrations (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>; <a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. ">Iwamura 2015</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>; <a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>; <a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. ">Wagenlehner 2014</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>). Twenty studies reported some of their outcomes graphically or with missing data and were deemed at high risk of bias (<a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. ">Apolikhin 2010</a>; <a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. ">Bates 2007</a>; <a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. ">Choe 2014</a>; <a href="./references#CD012552-bbs2-0015" title="ChurakovAA , KolesnikovAI , BliumbergBI , PopkovVM . Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction. Urologiia2012;5:64‐6, 68. ">Churakov 2012</a>; <a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. ">Erdemir 2010</a>; <a href="./references#CD012552-bbs2-0022" title="GiammussoB , DiMauroR , BernardiniR . The efficacy of an association of palmitoylethanolamide and alpha‐lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Archivio Italiano di Urologia e Andrologia2017;89(1):17‐21. ">Giammusso 2017</a>; <a href="./references#CD012552-bbs2-0032" title="KaplanSA , VolpeMA , TeAE . A prospective, 1‐year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(1):284‐8. ">Kaplan 2004</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. ">Kulovac 2007</a>; <a href="./references#CD012552-bbs2-0041" title="LeeCB , HaUS , LeeSJ , KimSW , ChoYH . Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World Journal of Urology2006;24(1):55‐60. ">Lee 2006a</a>; <a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. ">Leskinen 1999</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>; <a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. ">Morgia 2010</a>; <a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. ">Nickel 2003b</a>; <a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. ">Nickel 2016</a>; <a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. ">Persson 1996</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>; <a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. ">Wang 2004</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>; <a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. ">Zhou 2008</a>). The remaining studies were at unclear risk of reporting bias. </p> </section> <section id="CD012552-sec-0101"> <h4 class="title">Other potential sources of bias</h4> <p>Four studies were at high risk of bias for this domain: in two studies (<a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. ">Nickel 2016</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>), the pharmaceutical company participated in the conduct and publication of the study: in one study there were large baseline difference between groups (<a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. ">Park 2005</a>), and in another study an active run‐in phase was implemented (<a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. ">Ye 2008</a>). Nineteen studies were at unclear risk of bias for this domain: eight studies had insufficient data to make a judgement, since they were available as abstract only (<a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. ">Abdalla 2018</a>; <a href="./references#CD012552-bbs2-0013" title="ChengC‐H , LaiY‐W , HsuehT‐Y , ChiuY‐C , ChenS‐S , LuS‐H , et al. The efficacy of levofloxacin or ciprofloxacin in the management of chronic non‐bacterial prostatitis. International Journal of Urology2010;17:A335. LaiY , ChengC , HsuehT , ChiuY , ChenS , ChiuA . The efficacy of levofloxacin or ciprofloxacin in management of chronic non‐bacterial prostatitis. Urology2012;80(3):S154. ">Cheng 2010</a>; <a href="./references#CD012552-bbs2-0019" title="ElshawafH . Chemodenervation of the rhabdosphincter (EUS) alone versus combined injection of both EUS &amp; prostate in patients with prostatitis and chronic pelvic pain syndrome type III. Prospective randomized controlled trial. (Abstract number 394). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. ">Elshawaf 2009</a>; <a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. ">Macchione 2017</a>; <a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. ">Park 2012</a>; <a href="./references#CD012552-bbs2-0065" title="ParkHJ , ParkNC , MoonDG , KimTN , NamJK , ParkSW . Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction. European Urology Supplements2017;16(3):e453. ">Park 2017</a>; <a href="./references#CD012552-bbs2-0069" title="ReissiglA , DjavanB , PointnerJ . Prospective placebo‐controlled multicenter trial on safety and efficacy of phytotherapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(61):Abstract 233. [MEDLINE: 14665844] ">Reissigl 2004</a>; <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>), nine studies reported baseline characteristics poorly or they were not available (<a href="./references#CD012552-bbs2-0022" title="GiammussoB , DiMauroR , BernardiniR . The efficacy of an association of palmitoylethanolamide and alpha‐lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Archivio Italiano di Urologia e Andrologia2017;89(1):17‐21. ">Giammusso 2017</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>; <a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. ">Kim 2011b</a>; <a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. ">Kulovac 2007</a>; <a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. ">Sivkov 2005</a>; <a href="./references#CD012552-bbs2-0077" title="TucuV , TasciAI , FazlioluA , OdunctemurA , OzbekE , CekM . Comparison of the efficiency of mono and triple theraphy in chronic pelvic pain syndrome. Turk Urol. Derg.2006;32(3):393‐7. ">Tugcu 2006</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>; <a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. ">Zhou 2008</a>), one sturdy reported small differences in baseline characteristics (<a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. ">Kong 2014</a>), and two studies provided no information about how many participants were in each group (<a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. ">Lacquaniti 1999</a>; <a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. ">Morgia 2010</a>). The remaining studies were at low risk of other bias. </p> </section> </section> <section id="CD012552-sec-0102"> <h3 class="title" id="CD012552-sec-0102">Effects of interventions</h3> <p>See: <a href="./full#CD012552-tbl-0001"><b>Summary of findings for the main comparison</b> Alpha blockers compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</a>; <a href="./full#CD012552-tbl-0002"><b>Summary of findings 2</b> 5‐alpha reductase inhibitors compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</a>; <a href="./full#CD012552-tbl-0003"><b>Summary of findings 3</b> Antibiotic therapy compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</a>; <a href="./full#CD012552-tbl-0004"><b>Summary of findings 4</b> Anti‐inflammatories compared to control for chronic prostatitis/chronic pelvic pain syndrome</a>; <a href="./full#CD012552-tbl-0005"><b>Summary of findings 5</b> Phytotherapy compared to placebo or other agents for chronic prostatitis/chronic pelvic pain syndrome</a>; <a href="./full#CD012552-tbl-0006"><b>Summary of findings 6</b> Botulinum toxin A compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</a>; <a href="./full#CD012552-tbl-0007"><b>Summary of findings 7</b> Allopurinol compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</a>; <a href="./full#CD012552-tbl-0008"><b>Summary of findings 8</b> Traditional Chinese Medicine compared to placebo or usual care for chronic prostatitis/chronic pelvic pain syndrome</a> </p> <p>Unless stated otherwise, mean differences in prostatitis symptoms refer to NIH‐CPSI scores and the responder rate refers to the number of participants who achieved a six‐point decrease or a 25% decrease in NIH‐CPSI scores (See <a href="#CD012552-sec-0052">Types of outcome measures</a>). Other outcome measurements may vary. The number of participants under each comparison represent the total number of randomized participants, whereas the number of participants for each outcome are those analysed. </p> <section id="CD012552-sec-0103"> <h4 class="title">1. Alpha blockers versus placebo</h4> <p>Twenty‐four studies with 2387 randomized participants compared the use of alpha blockers versus placebo or no additional treatment (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. ">Cha 2009</a>; <a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. ">Cheah 2003</a>; <a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a>; <a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. ">Erdemir 2010</a>; <a href="./references#CD012552-bbs2-0026" title="GülO , ErogluM , OzokU . Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. International Urology and Nephrology2001;32(3):433‐6. ">Gül 2001</a>; <a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. ">Jeong 2008</a>; <a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. ">Jung 2006</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. ">Kulovac 2007</a>; <a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>; <a href="./references#CD012552-bbs2-0051" title="MoKI , LeeKS , KimDG . Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2006;47(5):536‐40. ">Mo 2006</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>; <a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. ">Ryu 2007</a>; <a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. ">Sivkov 2005</a>; <a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0089" title="MinggenY , ZhoudaZ , ZhimingZ , HailiL , ZhenqiangX , ChaoxianZ , et al. Tamsulosin therapy for chronic nonbacterial prostatitis: A randomized double‐blind placebo controlled clinical trial. Chinese Journal of Andrology2010;24(12):32‐5. ">Yang 2010</a>; <a href="./references#CD012552-bbs2-0092" title="YounCW , SonK‐C , ChoiH‐S , KwonDD , ParkK , RyuSB . Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha‐blocker combination therapy for patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome. Korean Journal of Urology2008;49(1):72‐6. ">Youn 2008</a>). See <a href="#CD012552-tbl-0009">Table 1</a> and <a href="#CD012552-tbl-0010">Table 2</a> for further details of the participants and interventions. See <a href="./full#CD012552-tbl-0001">summary of findings Table for the main comparison</a>. Three studies were not included in this summary due to missing data and are described below (<a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. ">Cha 2009</a>; <a href="./references#CD012552-bbs2-0026" title="GülO , ErogluM , OzokU . Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. International Urology and Nephrology2001;32(3):433‐6. ">Gül 2001;</a><a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. ">Lacquaniti 1999</a>). We used data from <a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. ">Cha 2009</a> for the outcome of adverse events. </p> <section id="CD012552-sec-0104"> <h5 class="title">1.1.1. Prostatitis symptoms: short‐term</h5> <p>Based on 18 studies with 1524 participants with a six‐week to six‐month follow‐up (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. ">Cheah 2003</a>; <a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. ">Erdemir 2010</a>; <a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. ">Jung 2006</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. ">Kulovac 2007</a>; <a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>; <a href="./references#CD012552-bbs2-0051" title="MoKI , LeeKS , KimDG . Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2006;47(5):536‐40. ">Mo 2006</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>; <a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. ">Ryu 2007</a>; <a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. ">Yang 2009</a>; <a href="./references#CD012552-bbs2-0092" title="YounCW , SonK‐C , ChoiH‐S , KwonDD , ParkK , RyuSB . Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha‐blocker combination therapy for patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome. Korean Journal of Urology2008;49(1):72‐6. ">Youn 2008</a>), we are uncertain of the effects of alpha blockers on prostatitis symptoms compared to placebo or to no additional treatment (random‐effects meta‐analysis; MD −5.01, 95% CI −7.41 to −2.61; I<sup>2</sup> = 98%; <a href="./references#CD012552-fig-0006" title="">Analysis 1.1</a>). These lower scores were observed across all subscores of pain, urinary symptoms and QoL (<a href="./references#CD012552-fig-0007" title="">Analysis 1.2</a>; <a href="./references#CD012552-fig-0008" title="">Analysis 1.3</a>; <a href="./references#CD012552-fig-0009" title="">Analysis 1.4</a>). The quality of evidence was very low, due to study limitations, inconsistency (high statistical heterogeneity) and imprecision. We could not identify asymmetry in the funnel plot suggestive of publication bias (see <a href="#CD012552-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD012552-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Alpha‐blockers versus placebo, outcome: 1.1 Prostatitis symptoms: short term." data-id="CD012552-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Alpha‐blockers versus placebo, outcome: 1.1 Prostatitis symptoms: short term. </p> </div> </div> </div> <p>Based on seven studies with 721 participants reported (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. ">Jeong 2008</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>), we are uncertain of the effects of alpha blockers in the responders rate compared to placebo or to no additional treatment (random‐effects meta‐analysis; RR 1.23, 95% CI 0.94 to 1.61; I<sup>2</sup> = 66%; <a href="./references#CD012552-fig-0010" title="">Analysis 1.5</a>). The quality of evidence was very low, due to unclear or high risk of bias in most domains in most studies, inconsistency (high statistical heterogeneity) and imprecision (a confidence interval that crosses the minimal clinically important difference (MCID)). </p> <p>We found that four studies (<a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. ">Ryu 2007</a>; <a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0089" title="MinggenY , ZhoudaZ , ZhimingZ , HailiL , ZhenqiangX , ChaoxianZ , et al. Tamsulosin therapy for chronic nonbacterial prostatitis: A randomized double‐blind placebo controlled clinical trial. Chinese Journal of Andrology2010;24(12):32‐5. ">Yang 2010</a>) had standard deviation (SD) values close to one, which is unusual in a body of research in which this value is close to six. We contacted study authors to clarify if this was an error (e.g. if they were the standard error instead of standard deviation), but we received no response. </p> </section> <section id="CD012552-sec-0105"> <h5 class="title">1.1.2. Prostatitis symptoms: long‐term</h5> <p>Based on four studies with 235 participants with one‐year follow‐up (<a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. ">Erdemir 2010</a>; <a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. ">Mehik 2003</a>; <a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. ">Sivkov 2005</a>; <a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>), we are uncertain of the effects of alpha blockers on prostatitis symptoms compared to placebo or to no additional treatment, measured by NIH‐CPSI score (random‐effects meta‐analysis; MD −5.60, 95% CI −10.89 to −0.32; I<sup>2</sup> = 98%; <a href="./references#CD012552-fig-0011" title="">Analysis 1.6</a>). The quality of the evidence was very low due to unclear or high risk of bias in most domains in most studies, inconsistency (high statistical heterogeneity) and imprecision (the confidence interval crosses the threshold for the MCID). </p> <p>Based on one study with 92 participants (<a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>), alpha blockers may have result in a small increase in the responders rate compared to placebo or to no additional treatment (RR 1.57, 95% CI 1.06 to 2.32; <a href="./references#CD012552-fig-0012" title="">Analysis 1.7</a>). The quality of evidence was low, due to unclear risk of bias and imprecision (the confidence interval crosses the threshold for the MCID). </p> </section> <section id="CD012552-sec-0106"> <h5 class="title">1.2. Adverse events</h5> <p>Based on 19 studies with 1588 participants (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. ">Cha 2009</a>; <a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. ">Cheah 2003</a>; <a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a>; <a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. ">Erdemir 2010</a>; <a href="./references#CD012552-bbs2-0026" title="GülO , ErogluM , OzokU . Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. International Urology and Nephrology2001;32(3):433‐6. ">Gül 2001</a>; <a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. ">Jeong 2008</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0051" title="MoKI , LeeKS , KimDG . Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2006;47(5):536‐40. ">Mo 2006</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>; <a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. ">Ryu 2007</a>; <a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. ">Sivkov 2005</a>; <a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0089" title="MinggenY , ZhoudaZ , ZhimingZ , HailiL , ZhenqiangX , ChaoxianZ , et al. Tamsulosin therapy for chronic nonbacterial prostatitis: A randomized double‐blind placebo controlled clinical trial. Chinese Journal of Andrology2010;24(12):32‐5. ">Yang 2010</a>), we found that participants who received alpha blockers may experience more adverse events (RR 1.60, 95% CI 1.09 to 2.34; I<sup>2</sup> = 48%; <a href="./references#CD012552-fig-0013" title="">Analysis 1.8</a>) compared to those who received placebo or no additional intervention at six‐week to six‐month follow‐up. The quality of the evidence is low, due to unclear or high risk of bias in most domains in most studies, and imprecision (the confidence interval crosses the threshold for the MCID). We could not identify asymmetry in the funnel plot suggestive of publication bias (see <a href="#CD012552-fig-0005">Figure 5</a>). Common adverse events included: dizziness, hypotension, palpitations, retrograde ejaculation, headache, and heartburn. </p> <div class="figure" id="CD012552-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Alpha‐blockers versus placebo, outcome: 1.8 Adverse events." data-id="CD012552-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Alpha‐blockers versus placebo, outcome: 1.8 Adverse events.</p> </div> </div> </div> </section> <section id="CD012552-sec-0107"> <h5 class="title">1.3. Sexual dysfunction</h5> <p>Based on four studies with 452 participants (<a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. ">Chen 2011</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. ">Ryu 2007</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>), alpha blockers probably result in little to no difference in sexual dysfunction, measured by IIEF scale at six‐ to 12‐week follow‐up (MD 0.26, 95% CI −1.13 to 1.65; I<sup>2</sup> = 0%, <a href="./references#CD012552-fig-0014" title="">Analysis 1.9</a>). The quality of the evidence was moderate, due to an unclear or high risk of bias in most domains in most studies. </p> </section> <section id="CD012552-sec-0108"> <h5 class="title">1.4. Quality of life</h5> <p>Based on three studies with 421 participants (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>; <a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. ">Nickel 2011a</a>), alpha blockers probably result in little to no difference in quality of life, measured by SF‐12 Health Status Questionnaire at six‐ to 12‐week follow‐up (mental domain MD 0.15, 95% CI −2.63 to 2.92; I<sup>2</sup> = 51%; <a href="./references#CD012552-fig-0015" title="">Analysis 1.10</a>; physical domain MD 1.17, 95% CI −0.97 to 3.30; I<sup>2</sup> = 47%, <a href="./references#CD012552-fig-0016" title="">Analysis 1.11</a>). The quality of the evidence was moderate, due to unclear or high risk of bias in some of the included studies. </p> </section> <section id="CD012552-sec-0109"> <h5 class="title">1.5. Anxiety and depression</h5> <p>Based on one study with 232 participants (<a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. ">Nickel 2008</a>), alpha blockers probably result in little to no difference in anxiety and depression, measured by the Hospital Anxiety and Depression Scale at 12‐week follow‐up (MD −1.10, 95% CI −2.54 to 0.34; <a href="./references#CD012552-fig-0017" title="">Analysis 1.12</a>). The quality of evidence was low, due to high risk of attrition bias and imprecision (the confidence interval crosses the threshold for the MCID). </p> </section> <section id="CD012552-sec-0110"> <h5 class="title">1.6. Urinary symptoms</h5> <p>Based on two studies with 143 participants (<a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. ">Cheah 2003</a>; <a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. ">Ryu 2007</a>), we are uncertain of the effect of alpha blockers on urinary symptoms compared to placebo or to no additional treatment, measured by IPSS at 12‐ to 14‐week follow‐up (MD −2.68, 95% CI −5.90 to 0.54; I<sup>2</sup> = 88%; <a href="./references#CD012552-fig-0018" title="">Analysis 1.13</a>). The quality of evidence was very low, due to study limitations, inconsistency and imprecision. </p> <section id="CD012552-sec-0111"> <h6 class="title">Sensitivity analysis: risk of bias</h6> <section id="CD012552-sec-0112"> <p><b>Prostatitis symptoms</b></p> <p>Excluding all studies with unclear or high risk of bias, we included only two studies with 153 participants under this comparison (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>). One of these studies (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>) indicated that there was little to no difference in prostatitis symptoms between those who received tamsulosin or placebo, (MD −1.00, 95% CI −3.35 to 1.35, I<sup>2</sup> = 0%). When analysing the number of responders, only two studies with 155 participants were included under this comparison (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>). Tamsulosin made little to no difference in the responder rate (RR 1.16, 95% CI 0.73 to 1.82; I<sup>2</sup> = 0%; <a href="./references#CD012552-fig-0019" title="">Analysis 1.14</a>). </p> </section> <section id="CD012552-sec-0113"> <p><b>Adverse events</b></p> <p>Excluding all studies with unclear or high risk of bias, we included only two studies with 153 participants under this comparison (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. ">Nickel 2004b</a>). Tamsulosin made little to no difference in the incidence of adverse events (random‐effects meta‐analysis: RR 0.96, 95% CI 0.63 to 1.47, I<sup>2</sup> = 0%; <a href="./references#CD012552-fig-0020" title="">Analysis 1.15</a>). </p> </section> </section> <section id="CD012552-sec-0114"> <h6 class="title">Sensitivity analysis: diagnostic criteria</h6> <p>We performed a sensitivity analysis excluding <a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a>, which did not meet the Research Consensus definition for CP/CPPS (<a href="./references#CD012552-bbs2-0230" title="NickelJC , NybergLM , HennenfentM . Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology1999;54(2):229‐33. [PUBMED: 10443716] ">Nickel 1999</a>). </p> <section id="CD012552-sec-0115"> <p><b>Prostatitis symptoms</b></p> <p>The exclusion of <a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a> did not produce a significant alteration in the estimate for this outcome (MD −4.96, 95% CI −7.47 to −2.46; I<sup>2</sup> = 98%; 18 studies, 1484 participants). </p> </section> <section id="CD012552-sec-0116"> <p><b>Adverse events</b></p> <p>The exclusion of <a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. ">Dunzendorfer 1983</a> did not produce a significant alteration to the estimate for this outcome (RR 1.44, 95% CI 1.05 to 1.99; I<sup>2</sup> = 33%; 17 studies, 1548 participants). </p> </section> </section> <section id="CD012552-sec-0117"> <h6 class="title">Subgroup analysis: co‐interventions</h6> <section id="CD012552-sec-0118"> <p><b>Prostatitis symptoms</b></p> <p>a) Studies that did not add any co‐interventions to the alpha blocker versus placebo comparison: MD −3.56, 95% CI −5.26 to −1.86; I<sup>2</sup> = 67%; 7 studies, 688 participants. </p> <p>b) Studies that added co‐interventions (analgesics or antibiotics, or both) to the alpha blocker versus placebo comparison: MD −5.69, 95% CI −8.90 to −2.48; I<sup>2</sup> = 99%; 11 studies, 836 participants. </p> <p>Test for subgroup differences: Chi<sup>2</sup> = 1.33, df = 1 (P = 0.25), I<sup>2</sup> = 24.7% (<a href="./references#CD012552-fig-0021" title="">Analysis 1.16</a>). </p> </section> <section id="CD012552-sec-0119"> <p><b>Adverse events</b></p> <p>a) Studies that did not include any co‐interventions to the alpha blocker versus placebo comparison: RR 1.69, 95% CI 1.10 to 2.60; I<sup>2</sup> = 59%; 11 studies, 1089 participants. </p> <p>b) Studies that included co‐interventions (analgesics or antibiotics, or both) to the alpha blocker versus placebo comparison: RR 1.20, 95% CI 0.46 to 3.17; I<sup>2</sup> = 0%; 8 studies, 499 participants. </p> <p>Test for subgroup differences: Chi<sup>2</sup> = 0.39, df = 1 (P = 0.53), I<sup>2</sup> = 0% (<a href="./references#CD012552-fig-0022" title="">Analysis 1.17</a>). </p> <p>No other predefined sensitivity analysis was possible for this comparison.</p> </section> </section> </section> <section id="CD012552-sec-0120"> <h5 class="title">Studies not included in meta‐analysis or 'Summary of findings' table</h5> <p>Three studies were not included in meta‐analysis due to missing outcome data:</p> <p> <ul id="CD012552-list-0030"> <li> <p><a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. ">Cha 2009</a>, with 103 participants, compared levofloxacin, levofloxacin plus alfuzosin, and a levofloxazin plus terpene mixture. Participants who received levofloxacin plus alfuzosin had fewer prostatitis symptoms measured by NIH‐CPSI scores (mean score 13) compared to those who received levofloxacin alone (mean score 15.4) at eight‐week follow‐up. Two participants in the alfuzosin group suffered from dizziness. P values and standard deviations were not available. No other outcomes relevant for this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0026" title="GülO , ErogluM , OzokU . Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. International Urology and Nephrology2001;32(3):433‐6. ">Gül 2001</a>, with 91 participants, compared terazosin and placebo. Participants who received terazosin had fewer prostatitis symptoms measured by PSSI scores (0 to 12 score, benefit is indicated by lower scores: MD −2.56, 95% CI −3.64 to −1.48). The study reported that none of the participants suffered adverse events. No other outcomes relevant for this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. ">Lacquaniti 1999</a>, with 80 participants, compared terazosin, tamsulosin and placebo. Participants who received terazosin and tamsulosin had fewer prostatitis symptoms measured by PSSI scores (0 to 12 score, benefit is indicated by lower scores: mean score in the terazosin group 1.221 and mean score in the tamsulosin group 1.324) compared to the placebo group (mean score 4.211, P &lt; 0.05). Five participants in the terazosin group suffered from hypotension, six participants in the tamsulosin group suffered from retrograde ejaculation, and two participants in the placebo group suffered from epigastric pain and hypotension. No other outcomes relevant for this review were reported in this study. </p> </li> </ul> </p> </section> </section> <section id="CD012552-sec-0121"> <h4 class="title">2. 5‐alpha reductase inhibitors versus placebo</h4> <p>Two studies with 177 randomized participants (<a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. ">Leskinen 1999</a>; <a href="./references#CD012552-bbs2-0056" title="NickelJC , DowneyJ , PontariMA , ShoskesD A , ZeitlinSI . A randomized placebo‐controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU International2004;93(7):991‐5. ">Nickel 2004a</a>) compared the use of a 5‐alpha reductase inhibitor (finasteride) versus placebo. See <a href="#CD012552-tbl-0009">Table 1</a> and <a href="#CD012552-tbl-0010">Table 2</a> for further details of the participants and interventions. See <a href="./full#CD012552-tbl-0002">summary of findings Table 2</a>. One additional study was not included in this summary due to missing data and is described below (<a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. ">Leskinen 1999</a>). We found only short‐term outcomes under this comparison. </p> <section id="CD012552-sec-0122"> <h5 class="title">2.1 Prostatitis symptoms</h5> <p>Based on one study with 64 participants with six‐month follow‐up (<a href="./references#CD012552-bbs2-0056" title="NickelJC , DowneyJ , PontariMA , ShoskesD A , ZeitlinSI . A randomized placebo‐controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU International2004;93(7):991‐5. ">Nickel 2004a</a>), finasteride probably causes a small reduction in prostatitis symptoms compared to placebo (MD −4.60, 95% CI −5.43 to −3.77; <a href="./references#CD012552-fig-0023" title="">Analysis 2.1</a>). The quality of evidence was moderate, due to unclear or high risk of bias in most domains. This drug may have resulted in little to no difference in the responders rate compared to placebo or to no additional treatment, but we are very uncertain about these results (RR 2.13, 95% CI 0.82 to 5.53; I<sup>2</sup> = 0%; <a href="./references#CD012552-fig-0024" title="">Analysis 2.2</a>). The quality of evidence was low, due to unclear or high risk of bias in most domains and imprecision (the confidence interval includes appreciable benefits and harms). </p> </section> <section id="CD012552-sec-0123"> <h5 class="title">2.2. Adverse events</h5> <p>Based on the two included studies under this comparison, finasteride may make little to no difference in the incidence of adverse events (RR 0.87, 95% CI 0.33 to 2.30; I<sup>2</sup> = 0%; 2 studies, 105 participants; <a href="./references#CD012552-fig-0025" title="">Analysis 2.3</a>). Common adverse events included: decrease libido, fatigue, mood change and gastrointestinal discomfort. The quality of evidence is low, due to unclear or high risk of bias in most domains in most studies, and imprecision (the confidence interval includes appreciable benefits and harms). </p> </section> <section id="CD012552-sec-0124"> <h5 class="title">2.3. Sexual dysfunction</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0125"> <h5 class="title">2.4. Quality of life</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0126"> <h5 class="title">2.5. Anxiety and depression</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0127"> <h5 class="title">2.6. Urinary symptoms</h5> <p>None of the included studies reported this outcome (see below).</p> </section> <section id="CD012552-sec-0128"> <h5 class="title">Study not included in meta‐analysis or 'Summary of findings' table</h5> <p>One study was not included in meta‐analysis due to missing outcome data: a study with 41 participants (<a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. ">Leskinen 1999</a>) compared the use of finasteride to placebo. The authors reported that those participants who received finasteride had fewer prostatitis symptoms at 12‐month follow‐up measured by NIH‐CPSI scores (mean decrease in scores estimated from a graph in the finasteride group was 16 points, and 8 points in the placebo group, P value not available). Participants in the finasteride group had a similar decrease in urinary symptoms to those in the placebo group at 12‐month follow‐up, measured by IPSS scores (mean decrease in both groups estimated from graphs was 8 points). </p> </section> </section> <section id="CD012552-sec-0129"> <h4 class="title">3. Antibiotics versus placebo</h4> <p>Six studies with 693 randomized participants compared the use of antibiotics versus placebo (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>; <a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. ">Kulovac 2007</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. ">Ye 2008</a>). All studies used quinolones (levofloxacin and ciprofloxacin). See <a href="#CD012552-tbl-0009">Table 1</a> and <a href="#CD012552-tbl-0010">Table 2</a> for further details of the participants and interventions. See <a href="./full#CD012552-tbl-0003">summary of findings Table 3</a>. Three studies were not included in this summary, due to missing data, and are described below (<a href="./references#CD012552-bbs2-0013" title="ChengC‐H , LaiY‐W , HsuehT‐Y , ChiuY‐C , ChenS‐S , LuS‐H , et al. The efficacy of levofloxacin or ciprofloxacin in the management of chronic non‐bacterial prostatitis. International Journal of Urology2010;17:A335. LaiY , ChengC , HsuehT , ChiuY , ChenS , ChiuA . The efficacy of levofloxacin or ciprofloxacin in management of chronic non‐bacterial prostatitis. Urology2012;80(3):S154. ">Cheng 2010</a>; <a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. ">Choe 2014</a>; <a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. ">Zhou 2008</a>). We found only short‐term outcomes under this comparison. </p> <section id="CD012552-sec-0130"> <h5 class="title">3.1. Prostatitis symptoms</h5> <p>Five studies with 372 participants fully reported this outcome as total NIH‐CPSI scores at six‐week to three‐month follow‐up (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>; <a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. ">Kulovac 2007</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>), and one study (<a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. ">Ye 2008</a>) with 105 participants only reported subscores. Antibiotics may result in a small reduction in prostatitis symptoms (random‐effects meta‐analysis, MD −2.43, 95% CI −4.72 to −0.15; I<sup>2</sup> = 75%; <a href="./references#CD012552-fig-0026" title="">Analysis 3.1</a>). This effect was evident in the pain subscore (<a href="./references#CD012552-fig-0027" title="">Analysis 3.2</a>) but not in the urinary symptoms or the quality of life subscores (<a href="./references#CD012552-fig-0028" title="">Analysis 3.3</a>; <a href="./references#CD012552-fig-0029" title="">Analysis 3.4</a>). The quality of evidence was low, due to high risk of bias (unclear or high risk of bias in most domains in the main study of this comparison) and inconsistency (statistical heterogeneity). </p> <p>Based on two studies with 178 participants with six‐month follow‐up (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>), antibiotics may have resulted in little to no difference in responder rate compared to placebo (random‐effects meta‐analysis, RR 1.12, 95% CI 0.73 to 1.74; I<sup>2</sup> = 0%; <a href="./references#CD012552-fig-0030" title="">Analysis 3.5</a>). The quality of evidence was low, due to unclear or high risk of bias in most domains in the main study of this comparison, and imprecision (few events, resulting in a confidence interval that includes appreciable benefits and harms). </p> </section> <section id="CD012552-sec-0131"> <h5 class="title">3.2. Adverse events</h5> <p>Based on four studies with 336 participants (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>; <a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. ">Ye 2008</a>), antibiotics probably result in little to no difference in adverse events (RR 1.01, 95% CI 0.66 to 1.55; I<sup>2</sup> = 0%; <a href="./references#CD012552-fig-0031" title="">Analysis 3.6</a>). Common adverse events included: dyspepsia, diarrhoea, sleep disorders, joint and articular pain, and upper respiratory complaints. The quality of evidence was moderate, due to imprecision (the confidence interval crosses the threshold for the MCID). </p> </section> <section id="CD012552-sec-0132"> <h5 class="title">3.3. Sexual dysfunction</h5> <p>Based on one study with 77 participants (<a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>), antibiotics probably result in little to no effect on sexual dysfunction at six‐week follow‐up (MD in IIEF scale 0.40, 95% CI −1.59 to 2.39; <a href="./references#CD012552-fig-0032" title="">Analysis 3.7</a>). The quality of evidence was moderate, due to high or unclear risk of bias in most domains. </p> </section> <section id="CD012552-sec-0133"> <h5 class="title">3.4. Quality of life</h5> <p>Based on one study with 87 participants (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>), antibiotics probably result in little to no effect on quality of life at six‐week follow‐up (MD in SF‐12 scale −3.90, 95% CI −7.94 to 0.14 (<a href="./references#CD012552-fig-0033" title="">Analysis 3.8</a>) for the mental domain, and MD 1.00, 95% CI −2.07 to 4.07 for the physical domain; <a href="./references#CD012552-fig-0034" title="">Analysis 3.9</a>). The quality of evidence was moderate, due to imprecision (the confidence interval crosses the threshold for the MCID). </p> </section> <section id="CD012552-sec-0134"> <h5 class="title">3.5. Anxiety and depression</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0135"> <h5 class="title">3.6. Urinary symptoms</h5> <p>Based on one study with 68 participants (<a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>), antibiotics probably result in little to no effect in urinary symptoms at three‐month follow‐up (MD −1.10, 95% CI −2.88 to 0.68; <a href="./references#CD012552-fig-0035" title="">Analysis 3.10</a>). The quality of evidence was moderate, due to high or unclear risk of bias in most domains. </p> <section id="CD012552-sec-0136"> <h6 class="title">Sensitivity analysis: risk of bias</h6> <section id="CD012552-sec-0137"> <p><b>Prostatitis symptoms</b></p> <p>Excluding all studies with unclear or high risk of bias, we included only one study with 196 participants under this comparison (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>). This study indicated that there was a small reduction in prostatitis symptoms in those participants who received antibiotics compared to placebo (NIH‐CPSI scores, MD −2.80, 95% CI −5.45 to −0.15). When analysing the number of responders, antibiotics made little to no difference in the responder rate (RR 1.00, 95% CI 0.48 to 2.09). </p> </section> <section id="CD012552-sec-0138"> <p><b>Adverse events</b></p> <p>Excluding all studies with unclear or high risk of bias, we included only one study with 196 participants under this comparison (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>). This study indicated that antibiotics made little to no difference in the incidence of adverse events (RR 0.97, 95% CI 0.60 to 1.57). </p> <p>No other predefined sensitivity analysis was possible for this comparison.</p> </section> </section> <section id="CD012552-sec-0139"> <h6 class="title">Subgroup analysis: age &gt; 50 years versus age &lt; 50 years</h6> <section id="CD012552-sec-0140"> <p><b>Prostatitis symptoms</b></p> <p>a) Studies that included participants with a mean age above 50 years: one study (<a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>) MD 0.60, 95% CI −3.79 to 4.99; 1 study, 80 participants. </p> <p>b) Studies that included participants with a mean age less than 50 years: four studies (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>; <a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. ">Kulovac 2007</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>) MD −2.92, 95% CI −5.37 to −0.46; I<sup>2</sup> = 78%; 4 studies, 292 participants. </p> <p>The test for subgroup differences was not significant: Chi<sup>2</sup> = 1.88, df = 1 (P = 0.17), I<sup>2</sup> = 46.8% (<a href="./references#CD012552-fig-0036" title="">Analysis 3.11</a>). </p> </section> <section id="CD012552-sec-0141"> <p><b>Adverse events</b></p> <p>a) Studies that included participants with a mean age above 50 years: one study (<a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. ">Nickel 2003a</a>) RR 1.17, 95% CI 0.46 to 2.97; 1 study, 80 participants. </p> <p>b) Studies that included participants with a mean age less than 50 years: three studies (<a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] ">Alexander 2004</a>; <a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. ">Ye 2006</a>; <a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. ">Wang 2016</a>) RR 0.97, 95% CI 0.60 to 1.57; I<sup>2</sup> = 0%; 3 studies, 256 participants. </p> <p>The test for subgroup differences was not significant: Chi<sup>2</sup> = 0.12, df = 1 (P = 0.73), I<sup>2</sup> = 0% (<a href="./references#CD012552-fig-0037" title="">Analysis 3.12</a>). </p> </section> </section> <section id="CD012552-sec-0142"> <h6 class="title">Subgroup analysis: co‐interventions</h6> <section id="CD012552-sec-0143"> <p><b>Prostatitis symptoms</b></p> <p>a) Studies that did not add any co‐interventions to the antibiotic versus placebo comparison: MD −1.57, 95% CI −4.77 to 1.63; I<sup>2</sup> = 41%; 2 studies, 167 participants. </p> <p>b) Studies that added co‐interventions (alpha blockers) with the antibiotics versus placebo comparison: MD −2.96, 95% CI −6.28 to 0.37; I<sup>2</sup> = 85%; 3 studies, 205 participants. </p> <p>Test for subgroup differences: Chi<sup>2</sup> = 0.35, df = 1 (P = 0.56), I<sup>2</sup> = 0% (<a href="./references#CD012552-fig-0038" title="">Analysis 3.13</a>). </p> </section> <section id="CD012552-sec-0144"> <p><b>Adverse events</b></p> <p>a) Studies that did not add any co‐interventions to the antibiotics versus placebo comparison: RR 1.01, 95% CI 0.66 to 1.55; I<sup>2</sup> = 0%; 2 studies, 175 participants. </p> <p>b) Studies that added co‐interventions (alpha blockers) to the antibiotics versus placebo comparison: not estimable (no adverse events in the included studies). </p> <p>Test for subgroup differences: Not applicable (<a href="./references#CD012552-fig-0039" title="">Analysis 3.14</a>). </p> <p>No other predefined subgroup analysis was possible for this comparison.</p> </section> </section> </section> <section id="CD012552-sec-0145"> <h5 class="title">Studies not included in meta‐analysis or 'Summary of findings' table</h5> <p>Three studies were not included in meta‐analysis due to missing outcome data:</p> <p> <ul id="CD012552-list-0031"> <li> <p><a href="./references#CD012552-bbs2-0013" title="ChengC‐H , LaiY‐W , HsuehT‐Y , ChiuY‐C , ChenS‐S , LuS‐H , et al. The efficacy of levofloxacin or ciprofloxacin in the management of chronic non‐bacterial prostatitis. International Journal of Urology2010;17:A335. LaiY , ChengC , HsuehT , ChiuY , ChenS , ChiuA . The efficacy of levofloxacin or ciprofloxacin in management of chronic non‐bacterial prostatitis. Urology2012;80(3):S154. ">Cheng 2010</a>, with 215 participants, compared levofloxacin 500 mg, ciprofloxacin 500 mg, levofloxacin 1 g and no antibiotics. Participants who received levofloxacin had fewer prostatitis symptoms compared to those who received ciprofloxacin or no antibiotics (P &lt; 0.05; study available as abstract only) at six‐week follow‐up. No other outcomes relevant for this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. ">Choe 2014</a>, with 75 participants, compared roxithromycin, ciprofloxacin and aceclofenac. Prostatitis symptoms: participants had a mean NIH‐CPSI score at 12‐week follow‐up of 9.8 in the roxithromycin group, 10 in the ciprofloxacin group and 14.3 in the aceclofenac group, but the authors reported that analysis of variance (ANOVA) yielded P values &gt; 0.05. This study also reported the number of responders (six‐point decrease of NIH‐CPSI scores) at 12‐week follow‐up: 15/25 in the roxithromycin group, 13/25 in the ciprofloxacin group and 18/25 in the aceclofenac group (Chi<sup>2</sup> and P &gt; 0.05). At 12‐week follow‐up, the three groups had similar urinary symptoms measured by IPSS scores (ANOVA P &gt; 0.05). "Three cases of mild dyspepsia, one case of diarrhoea, and one case of mild skin rash were reported", but the authors did not specify which treatment the participants had received. No other outcomes relevant for this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. ">Zhou 2008</a>, with 48 participants, compared tetracycline and placebo. The focus of this study was microbiological results. The study reported that participants who received tetracycline at three‐month follow‐up had a decrease in prostatitis measured by NIH‐CPSI scores (from 35.6 to 17.1), and "in the control group, however, no significant change was found in the [NIH]‐CPSI scores after placebo treatment". No other information was provided for the comparison between groups (mean differences, P values). No other outcomes relevant for this review were reported in this study. </p> </li> </ul> </p> </section> </section> <section id="CD012552-sec-0146"> <h4 class="title">4. Anti‐inflammatories versus placebo</h4> <p>Nine studies with 763 randomized participants were included under this comparison using different anti‐inflammatory agents: corticosteroids (<a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. ">Bates 2007</a>; <a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. ">Yang 2009</a>), antileukotrienes (<a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. ">Goldmeier 2005</a>), nonsteroidal antiinflammatory drugs (NSAID) (<a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. ">Jiang 2009</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>), and tiocolchicoside (<a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>). See <a href="#CD012552-tbl-0009">Table 1</a> and <a href="#CD012552-tbl-0010">Table 2</a> for further details of the participants and interventions. See <a href="./full#CD012552-tbl-0004">summary of findings Table 4</a>. Three additional studies were not included in this summary due to missing data, and are described below (<a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. ">Nickel 2003b</a>; <a href="./references#CD012552-bbs2-0077" title="TucuV , TasciAI , FazlioluA , OdunctemurA , OzbekE , CekM . Comparison of the efficiency of mono and triple theraphy in chronic pelvic pain syndrome. Turk Urol. Derg.2006;32(3):393‐7. ">Tugcu 2006</a>; <a href="./references#CD012552-bbs2-0093" title="ZengX , YeZ , YangW , LiuJ , ZhangX , ZhouX , et al. Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis. Zhonghua Nan Ke Xue2004;10(4):278‐81. ">Zeng 2004</a>). </p> <section id="CD012552-sec-0147"> <h5 class="title">4.1. Prostatitis symptoms</h5> <p>Based on seven studies with 585 participants (<a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. ">Jiang 2009</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>; <a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. ">Yang 2009</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>), anti‐inflammatories may cause a small reduction in prostatitis symptoms when compared to placebo at six‐week to six‐month follow‐up (random‐effects meta‐analysis, MD −2.50, 95% CI −3.74 to −1.26; I<sup>2</sup> = 88%; <a href="./references#CD012552-fig-0040" title="">Analysis 4.1</a>). This effect was only evident in the analysis of subscores of pain, but not in urinary symptoms and quality of life (<a href="./references#CD012552-fig-0041" title="">Analysis 4.2</a>; <a href="./references#CD012552-fig-0042" title="">Analysis 4.3</a>; <a href="./references#CD012552-fig-0043" title="">Analysis 4.4</a>). The quality of the evidence is low, due to high or unclear risk of bias in most studies, and inconsistency (high statistical heterogeneity). </p> <p>Based on two studies with 82 participants (<a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. ">Bates 2007</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>), anti‐inflammatories may have resulted in little to no difference in responder rate compared to placebo (random‐effects meta‐analysis, RR 1.44, 95% CI 0.68 to 3.03; I<sup>2</sup> = 0%; <a href="./references#CD012552-fig-0044" title="">Analysis 4.5</a>). The quality of the evidence is low, due to high or unclear risk of bias in most studies, and imprecision (few events, resulting in a confidence interval that includes appreciable benefits and harms). </p> <p><a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>, with 90 participants, reported long‐term results. For the comparison of tiocolchicoside, ibuprofen and terazosin versus terazosin alone, participants in the combined therapy group probably have fewer prostatitis symptoms (MD −10.50, 95% CI −11.12 to −9.88; <a href="./references#CD012552-fig-0045" title="">Analysis 4.6</a>). The quality of the evidence is moderate, due to high risk of bias. </p> </section> <section id="CD012552-sec-0148"> <h5 class="title">4.2. Adverse events</h5> <p>Based on seven studies with 540 participants with four‐week to six‐month follow‐up (<a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. ">Goldmeier 2005</a>; <a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. ">Jiang 2009</a>; <a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. ">Kim 2003</a>; <a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. ">Tuğcu 2007</a>; <a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. ">Wu 2008</a>; <a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. ">Yang 2009</a>; <a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. ">Zhao 2009</a>), anti‐inflammatories may result in little to no difference in adverse events (random‐effects meta‐analysis, RR 1.27, 95% CI 0.81 to 2.00; I<sup>2</sup> = 9%; <a href="./references#CD012552-fig-0046" title="">Analysis 4.7</a>). The quality of the evidence is low, due to high or unclear risk of bias in most studies, and imprecision (few events, resulting in a confidence interval that includes appreciable benefits and harms). Common adverse events included: nausea and gastrointestinal discomfort, heartburn, skin rash and hypersensitivity. </p> </section> <section id="CD012552-sec-0149"> <h5 class="title">4.3. Sexual dysfunction</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0150"> <h5 class="title">4.4. Quality of life</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0151"> <h5 class="title">4.5. Anxiety and depression</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0152"> <h5 class="title">4.6. Urinary symptoms</h5> <p>Based on one study with 72 participants (<a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. ">Kim 2011a</a>) with three‐month follow‐up, anti‐inflammatories probably result in little to no difference in urinary symptoms (MD −1.30, 95% CI −2.97 to 0.37; <a href="./references#CD012552-fig-0047" title="">Analysis 4.8</a>). The quality of evidence is moderate, due to high risk of bias. </p> <section id="CD012552-sec-0153"> <h6 class="title">Subgroup analysis: co‐interventions</h6> <section id="CD012552-sec-0154"> <p><b>Prostatitis symptoms</b></p> <p>a) Studies that did not add any co‐interventions to the anti‐inflammatories versus placebo comparison: MD −3.62, 95% CI −4.85 to −2.39; 1 study, 64 participants. </p> <p>b) Studies that added co‐interventions (alpha blockers or antibiotics) to the anti‐inflammatories versus placebo comparison: MD −2.29, 95% CI −3.67 to −0.90; I<sup>2</sup> = 89%; 6 studies, 521 participants. </p> <p>Test for subgroup differences: Chi<sup>2</sup> = 1.99, df = 1 (P = 0.16), I<sup>2</sup> = 49.8%; (<a href="./references#CD012552-fig-0048" title="">Analysis 4.9</a>). </p> </section> <section id="CD012552-sec-0155"> <p><b>Adverse events</b></p> <p>a) Studies that did not add any co‐interventions to the anti‐inflammatories versus placebo comparison: RR 2.00, 95% CI 0.19 to 20.97; 1 study, 64 participants. </p> <p>b) Studies that added co‐interventions (alpha blockers or antibiotics) to the anti‐inflammatories versus placebo comparison: RR 1.25, 95% CI 0.73 to 2.15; ; I<sup>2</sup> = 25%; 6 studies, 476 participants. </p> <p>Test for subgroup differences: Chi<sup>2</sup> = 0.14, df = 1 (P = 0.70), I<sup>2</sup> = 0%; (<a href="./references#CD012552-fig-0049" title="">Analysis 4.10</a>). </p> <p>No other predefined subgroup analysis was possible for this comparison.</p> </section> </section> </section> <section id="CD012552-sec-0156"> <h5 class="title">Studies not included in meta‐analysis or 'Summary of findings' table</h5> <p>Three studies were not included in meta‐analysis due to missing outcome data:</p> <p> <ul id="CD012552-list-0032"> <li> <p><a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. ">Nickel 2003b</a>, with 161 participants, compared rofecoxib in 50 mg and 25 mg doses to placebo. At six‐week follow‐up, participants had a similar decrease in prostatitis symptoms: mean change from baseline NIH‐CPSI was −4.2 in the placebo group, −4.9 in the rofecoxib 25 mg (P = 0.68 compared to placebo) and −6.2 in the rofecoxib 50 mg group (P = 0.68 compared to placebo). There was a greater number of responders (defined as a six‐point decrease in NIH‐CPSI scores) at six‐week follow‐up in the rofecoxib 50 mg group (62.5%) compared to the placebo group (39.7%; P = 0.031); however, there were no differences between the rofecoxib 25 mg group (46.2%) and the placebo group. Adverse events: two participants in the placebo group suffered from chest pain and atrial flutter, and two in the rofecoxib 50 mg group suffered from chest pain. No other outcomes relevant for this review were reported in this study. <b>Note</b>: this drug was withdrawn from the market in 2004 due to a increased risk of heart attack (<a href="./references#CD012552-bbs2-0250" title="SibbaldB . Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ : Canadian Medical Association Journal2004; Vol. 171, issue 9:1027‐8. [PUBMED: 15505253] ">Sibbald 2004</a>). </p> </li> <li> <p><a href="./references#CD012552-bbs2-0093" title="ZengX , YeZ , YangW , LiuJ , ZhangX , ZhouX , et al. Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis. Zhonghua Nan Ke Xue2004;10(4):278‐81. ">Zeng 2004</a>, with 60 participants, compared celecoxib 200 mg once daily or twice daily. At six‐week follow‐up, participants in the celecoxib twice‐daily group had fewer prostatitis symptoms compared to those in the celecoxib once‐daily group (MD −5.20, 95% CI −5.88 to −4.52). One participant in the celecoxib twice‐daily group suffered from headache and one participant in the celecoxib once‐daily group suffered from mild diarrhoea. No other outcomes relevant for this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0077" title="TucuV , TasciAI , FazlioluA , OdunctemurA , OzbekE , CekM . Comparison of the efficiency of mono and triple theraphy in chronic pelvic pain syndrome. Turk Urol. Derg.2006;32(3):393‐7. ">Tugcu 2006</a>, with 45 participants, compared the use of tiocolchicoside, ibuprofen and terazosin versus terazosin alone. Participants in both groups had similar prostatitis symptoms at six‐ and 12‐month follow‐up (only subscores were available, P &gt; 0.05). No other outcomes relevant for this review were reported in this study. </p> </li> </ul> </p> </section> </section> <section id="CD012552-sec-0157"> <h4 class="title">5. Phytotherapy versus placebo</h4> <p>Seven studies with 551 randomized participants were included under this comparison, using different phytotherapeutic agents: Prolit super septo® (combined agents) (<a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>); calendula‐curcuma (<a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. ">Morgia 2017</a>); cranberry (<a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. ">Park 2005</a>); quercetin (<a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. ">Shoskes 1999</a>); pollen extract (<a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>; <a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. ">Ye 2006</a>). See <a href="#CD012552-tbl-0009">Table 1</a> and <a href="#CD012552-tbl-0010">Table 2</a> for further details of the participants and interventions. See <a href="./full#CD012552-tbl-0005">summary of findings Table 5</a>. Fourteen studies were not included in this meta‐analysis due to missing data or because they do not compare phytotherapy to placebo (head‐to‐head comparisons) and are described below (<a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. ">Apolikhin 2010</a>; <a href="./references#CD012552-bbs2-0006" title="CaiT , WagenlehnerFM , LucianiLG , TiscioneD , MalossiniG , VerzeP , et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine2014;8(4):1032‐8. ">Cai 2014</a>; <a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. ">Cai 2017</a>; <a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. ">Cha 2009</a>; <a href="./references#CD012552-bbs2-0022" title="GiammussoB , DiMauroR , BernardiniR . The efficacy of an association of palmitoylethanolamide and alpha‐lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Archivio Italiano di Urologia e Andrologia2017;89(1):17‐21. ">Giammusso 2017</a>; <a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. ">Iwamura 2015</a>; <a href="./references#CD012552-bbs2-0032" title="KaplanSA , VolpeMA , TeAE . A prospective, 1‐year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(1):284‐8. ">Kaplan 2004</a>; <a href="./references#CD012552-bbs2-0041" title="LeeCB , HaUS , LeeSJ , KimSW , ChoYH . Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World Journal of Urology2006;24(1):55‐60. ">Lee 2006a</a>; <a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. ">Macchione 2017</a>; <a href="./references#CD012552-bbs2-0049" title="MauriziA , DeLucaF , ZanghiA , ManziE , LeonardoC , GuidottiM , et al. The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica2019;90(4):260‐4. [PUBMED: 30655636] ">Maurizi 2019</a>; <a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. ">Morgia 2010</a>; <a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. ">Okada 1985</a>; <a href="./references#CD012552-bbs2-0069" title="ReissiglA , DjavanB , PointnerJ . Prospective placebo‐controlled multicenter trial on safety and efficacy of phytotherapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(61):Abstract 233. [MEDLINE: 14665844] ">Reissigl 2004</a>; <a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. ">Xu 2000</a>). One study assessing the effects of cytoflavin did not report outcomes relevant to this review (<a href="./references#CD012552-bbs2-0015" title="ChurakovAA , KolesnikovAI , BliumbergBI , PopkovVM . Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction. Urologiia2012;5:64‐6, 68. ">Churakov 2012</a>). </p> <section id="CD012552-sec-0158"> <h5 class="title">5.1. Prostatitis symptoms</h5> <p>Based on five studies with 320 participants with one‐ to three‐month follow‐up (<a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>; <a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. ">Morgia 2017</a>; <a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. ">Park 2005</a>; <a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. ">Shoskes 1999</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>), phytotherapy may reduce prostatitis symptoms compared to placebo (random‐effects meta‐analysis, MD −5.02, 95% CI −6.81 to −3.23; I<sup>2</sup> = 60%; <a href="./references#CD012552-fig-0050" title="">Analysis 5.1</a>). These lower scores were observed across all subscores of pain, urinary symptoms and QoL (<a href="./references#CD012552-fig-0051" title="">Analysis 5.2</a>; <a href="./references#CD012552-fig-0052" title="">Analysis 5.3</a>; <a href="./references#CD012552-fig-0053" title="">Analysis 5.4</a>). The quality of evidence was low, due to unclear or high risk of bias in most domains in most studies, and imprecision (the confidence interval crosses the threshold for the MICD). </p> <p>Based on three studies with 224 participants with one‐ to three‐month follow‐up (<a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>; <a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. ">Shoskes 1999</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>), phytotherapy probably increases the responder rate compared to placebo (random‐effects meta‐analysis, RR 1.78, 95% CI 1.25 to 2.52; I<sup>2</sup> = 27%; <a href="./references#CD012552-fig-0054" title="">Analysis 5.5</a>). The quality of evidence was moderate, due to unclear or high risk of bias in most domains in the main study of this comparison. </p> </section> <section id="CD012552-sec-0159"> <h5 class="title">5.2. Adverse events</h5> <p>Based on seven studies with 540 participants with one‐ to three‐month follow‐up (<a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. ">Breusov 2014</a>; <a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. ">Elist 2006</a>; <a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. ">Morgia 2017</a>; <a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. ">Park 2005</a>; <a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. ">Shoskes 1999</a>; <a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>; <a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. ">Ye 2006</a>), phytotherapy may result in little to no difference in adverse events (random‐effects meta‐analysis, RR 1.13, 95% CI 0.54 to 2.36; I<sup>2</sup> = 0%; <a href="./references#CD012552-fig-0055" title="">Analysis 5.6</a>). The quality of the evidence is low, due to high or unclear risk of bias in most studies, and imprecision (few events, resulting in a confidence interval that includes appreciable benefits and harms). Common adverse events included: gastrointestinal discomfort including nausea, dyspepsia and diarrhoea, headache, and skin rash. </p> </section> <section id="CD012552-sec-0160"> <h5 class="title">5.3. Sexual dysfunction</h5> <p>Based on one study with 48 participants (<a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. ">Morgia 2017</a>), phytotherapy (in this case, calendula‐curcuma) may have improved sexual dysfunction at three‐month follow‐up (MD in IIEF score 3.50, 95% CI 2.67 to 4.33; <a href="./references#CD012552-fig-0056" title="">Analysis 5.7</a>). The quality of the evidence was low, due to high risk of bias and imprecision (the confidence interval crosses the threshold for the MCID). </p> </section> <section id="CD012552-sec-0161"> <h5 class="title">5.4. Quality of life</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0162"> <h5 class="title">5.5. Anxiety and depression</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0163"> <h5 class="title">5.6. Urinary symptoms</h5> <p>Based on one study with 139 participants (<a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. ">Wagenlehner 2009</a>), phytotherapy (in this case pollen extract) probably resulted in little to no difference in urinary symptoms at 12‐week follow‐up (IPSS score MD −1.14, 95% CI −2.36 to 0.08; <a href="./references#CD012552-fig-0057" title="">Analysis 5.8</a>). The quality of evidence was moderate, due to high risk of bias. </p> <section id="CD012552-sec-0164"> <h6 class="title">Sensitivity analysis: diagnostic criteria</h6> <p>We performed a sensitivity analysis excluding <a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. ">Shoskes 1999</a>, which did not meet the Research Consensus definition for CP/CPPS (<a href="./references#CD012552-bbs2-0230" title="NickelJC , NybergLM , HennenfentM . Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology1999;54(2):229‐33. [PUBMED: 10443716] ">Nickel 1999</a>). </p> <section id="CD012552-sec-0165"> <p><b>Prostatitis symptoms</b></p> <p>The exclusion of <a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. ">Shoskes 1999</a> did not produce a significant alteration to the estimate for this outcome (MD −4.95, 95% CI −6.99 to −2.91; I<sup>2</sup> = 70%; 4 studies, 292 participants). </p> </section> <section id="CD012552-sec-0166"> <p><b>Adverse events</b></p> <p>The exclusion of <a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. ">Shoskes 1999</a> did not produce a significant alteration to the estimate for this outcome (RR 1.07, 95% CI 0.49 to 2.34; I<sup>2</sup> = 0%; 6 studies, 512 participants = 512). </p> <p>No other predefined sensitivity analysis was possible for this comparison.</p> </section> </section> <section id="CD012552-sec-0167"> <h6 class="title">Subgroup analysis: co‐interventions</h6> <section id="CD012552-sec-0168"> <p><b>Prostatitis symptoms</b></p> <p>a) Studies that did not add any co‐interventions to the phytotherapy versus placebo comparison: MD −6.06, 95% CI −7.28 to −4.84; I<sup>2</sup> = 0%; 3 studies, 133 participants. </p> <p>b) Studies that added co‐interventions (alpha blockers or antibiotics, or both) to the phytotherapy versus placebo comparison: MD −3.92, 95% CI −6.76 to −1.08; I<sup>2</sup> = 75%; 2 studies, 187 participants. </p> <p>Test for subgroup differences: Chi<sup>2</sup> = 1.84, df = 1 (P = 0.17), I<sup>2</sup> = 45.7% (<a href="./references#CD012552-fig-0058" title="">Analysis 5.9</a>). </p> </section> <section id="CD012552-sec-0169"> <p><b>Adverse events</b></p> <p>a) Studies that did not add any co‐interventions to the phytotherapy versus placebo comparison: RR 2.09, 95% CI 0.33 to 13.30; I<sup>2</sup> = 0%; 4 studies, 191 participants. </p> <p>b) Studies that added co‐interventions (alpha blockers or antibiotics, or both) to the phytotherapy versus placebo comparison: RR 1.14, 95% CI 0.34 to 3.79; I<sup>2</sup> = 17%; 3 studies, 349 participants. </p> <p>Test for subgroup differences: Chi<sup>2</sup> = 0.29, df = 1 (P = 0.59), I<sup>2</sup> = 0% (<a href="./references#CD012552-fig-0059" title="">Analysis 5.10</a>). </p> <p>No other predefined sensitivity analysis was possible for this comparison.</p> </section> </section> </section> <section id="CD012552-sec-0170"> <h5 class="title">Studies not included in meta‐analysis or 'Summary of findings' table</h5> <p>Fourteen studies were not included in this summary due to missing data or because they do not compare phytotherapy to placebo (head‐to‐head comparisons) and are described below. </p> <section id="CD012552-sec-0171"> <h6 class="title">Pollen extract</h6> <p> <ul id="CD012552-list-0033"> <li> <p><a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. ">Apolikhin 2010</a>, with 78 participants, compared the use of a pollen extract pill (Cernilton®) three times a day for three months at a single dose or a double dose (two pills in each dose). Participants who received a higher dose may have had fewer prostatitis symptoms at six‐month follow‐up compared to those with a single dose (MD in NIH‐CPSI scores −2.40, 95% CI −4.28 to −0.52). No other outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0006" title="CaiT , WagenlehnerFM , LucianiLG , TiscioneD , MalossiniG , VerzeP , et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine2014;8(4):1032‐8. ">Cai 2014</a>, with 87 participants, compared the use of a pollen extract pill (Deprox®) and ibuprofen. Participants who received pollen extract had fewer prostatitis symptoms than those who received ibuprofen at 30‐day follow‐up (MD in NIH‐CPSI scores −6.70, 95% CI −7.65 to −5.75). Participants who received pollen extract and ibuprofen had similar urinary symptoms (MD in IPSS score MD −0.40, 95% CI −1.42 to 0.62). Participants in the pollen extract group had higher quality‐of‐life measurements compared to the ibuprofen group (Quality of Well‑Being scale, range 0 to 1, MD 0.10, 95% CI 0.03 to 0.17). One participant in the pollen extract group suffered from nausea and seven participants in the ibuprofen group suffered from nausea and epigastric pain. No other outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. ">Cai 2017</a>, with 70 participants, compared the use of a pollen extract pill (Deprox®) and bromelain. Participants who received pollen extract had fewer prostatitis symptoms than those who received bromelain at three‐month follow‐up (MD in NIH‐CPSI scores −10.80, 95% CI −12.51 to −9.09). Participants in the pollen extract group had higher quality‐of‐life measurements compared to the bromelain group (SF‐36 scale MD 3.70, 95% CI 2.45 to 4.95). One participant in the pollen extract group and two participants in the bromelain group suffered from nausea. No other outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. ">Iwamura 2015</a>, with 100 participants, compared the use of a pollen extract pill and Eviprostat® (a herbal supplement). At eight‐week follow‐up, prostatitis symptoms were similar in both groups (P = 0.76), with a similar incidence of responders (25% decrease in NIH‐CPSI scores: RR 0.80, 95% CI 0.71 to 1.08). There were two non‐severe adverse events in the pollen extract group and one in the Eviprostat® group. No other outcomes relevant to this review were reported in this study. This study included participants with a mean age above 50 years, and it was therefore not possible to conduct subgroup analysis, since no other study was included under this comparison. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. ">Macchione 2017</a>, with 63 participants, compared the use of pollen extract pill (Deprox®) and Serenoa repens. At six‐week follow‐up participants in the pollen extract group had fewer prostatitis symptoms measured by NIH‐CPSI scores compared to the Serenoa repens group (MD −3.70, 95% CI −5.67 to −1.73). Participants in the pollen extract group had fewer urinary symptoms measured by IPSS scores compared to the Serenoa repens group (MD −4.90, 95% CI −7.12 to −2.68). No other outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0049" title="MauriziA , DeLucaF , ZanghiA , ManziE , LeonardoC , GuidottiM , et al. The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica2019;90(4):260‐4. [PUBMED: 30655636] ">Maurizi 2019</a>, with 54 participants, compared the use of pollen extract pill (Deprox®) and quercetin. At four‐week follow‐up participants in the pollen extract group had fewer prostatitis symptoms measured by NIH‐CPSI scores compared to quercetin ( MD −2.63, 95% CI −3.61 to −1.65). Participants in the pollen extract group had similar urinary symptoms measured by IPSS scores compared to the quercetin group (MD −0.37, 95% CI −1.12 to 0.38). No participant suffered adverse in each group. No other outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. ">Okada 1985</a>, with 76 participants, compared the use of pollen extract to an amino acid compound ("PPC"), and <a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. ">Xu 2000</a>, with 60 participants, compared the use of pollen extract to a sequence of antibiotics. No outcomes relevant to this review were reported in these studies. </p> </li> </ul> </p> </section> <section id="CD012552-sec-0172"> <h6 class="title">Serenoa repens</h6> <p> <ul id="CD012552-list-0034"> <li> <p><a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. ">Morgia 2010</a>, with 102 participants, compared the use of Serenoa repens with other herbal extracts (Profluss®) and Serenoa repens alone. Participants in the Profluss® group had fewer prostatitis symptoms at 16‐week follow‐up (mean NIH‐CPSI score 13.27) compared to the Serenoa repens group (mean NIH‐CPSI score 20.52, P &lt; 0.001). Participants in the Profluss® group had a greater risk of achieving a response in prostatitis symptoms (&gt; 50% reduction in NIH‐CPSI scores) compared to those in the Serenoa repens group (RR 2.00, 95% CI 1.16 to 3.44). Participants in the Profluss® group had fewer urinary symptoms (mean IPSS score 7.6) compared to the Serenoa repens group (mean IPSS score 170.1, P &lt; 0.001). Four participants in the Profluss® group and three in the Serenoa repens groups suffered gastrointestinal adverse events. One participant in the Profluss® group and one in the Serenoa repens group suffered cephalea as an adverse event. No other outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0032" title="KaplanSA , VolpeMA , TeAE . A prospective, 1‐year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(1):284‐8. ">Kaplan 2004</a>, with 64 participants, compared the use of Serenoa repens to finasteride. The participants had similar prostatitis symptoms in both groups at three‐month follow‐up (results were available only in graph form). At 12‐month follow‐up, prostatitis symptoms measured by the mean NIH‐CPSI score was 24.6 in the Serenoa repens group and 18.1 in the finasteride group (P &lt; 0.02). At 12‐month follow‐up, urinary symptoms measured by the American Urological Association scale (AUA) were similar in both groups (mean score 10.4 in the Serenoa repens group and 11.9 in the finasteride group). Three participants suffered adverse events in the Serenoa repens group (headache) and two participants suffered adverse events in the finasteride group (decreased libido). No other outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0069" title="ReissiglA , DjavanB , PointnerJ . Prospective placebo‐controlled multicenter trial on safety and efficacy of phytotherapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(61):Abstract 233. [MEDLINE: 14665844] ">Reissigl 2004</a>, with 142 participants, compared the use of Serenoa repens to placebo. Participants in the Serenoa repens group had a greater risk of achieving a response in prostatitis symptoms (30% to 50% decrease in NIH‐CPSI scores) compared with the placebo group (RR 3.89, 95% CI 2.33 to 6.48). Participants in the Serenoa repens group had a greater risk of achieving a response in urinary symptoms (50% decrease in IPSS scores) compared to the placebo group (RR 4.33, 95% CI 2.46 to 7.62). No other outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0022" title="GiammussoB , DiMauroR , BernardiniR . The efficacy of an association of palmitoylethanolamide and alpha‐lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Archivio Italiano di Urologia e Andrologia2017;89(1):17‐21. ">Giammusso 2017</a>, with 44 participants, compared the administration of palmitoylethanolamide to Serenoa repens extract. The authors reported that those who received palmitoylethanolamide had a reduction in prostatitis symptoms (measured by NIH‐CPSI scores) and urinary scores (measured by IPSS scores), but they did not have an improvement in sexual dysfunction (measured by IIEF scores). These outcomes were reported in a narrative fashion and graphically. None of the participants suffered adverse events. No other outcomes relevant to this review were reported in this study. </p> </li> </ul> </p> </section> <section id="CD012552-sec-0173"> <h6 class="title">Terpene mixture</h6> <p> <ul id="CD012552-list-0035"> <li> <p><a href="./references#CD012552-bbs2-0041" title="LeeCB , HaUS , LeeSJ , KimSW , ChoYH . Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World Journal of Urology2006;24(1):55‐60. ">Lee 2006a</a>, with 50 participants, compared the use of a terpene mixture and ibuprofen. At six‐week follow‐up, participants who received the terpene mixture had similar prostatitis symptoms (mean NIH‐CPSI score 16.8) compared to those in the ibuprofen group (mean NIH‐CPSI score 15.3, P = 0.06). The study reported that three participants in the terpene mixture group suffered from heartburn. No other outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. ">Cha 2009</a>, with 103 participants, compared levofloxacin, levofloxacin plus alfuzosin and levofloxazin plus terpene mixture. Participants who received levofloxacin plus terpene mixture had fewer prostatitis symptoms measured by NIH‐CPSI scores (mean score 12.4) compared to those who received levofloxacin alone (mean score 15.4) at eight‐week follow‐up. One participant in the terpene mixture group suffered from nausea. P values and standard deviations were not available. No other outcomes relevant to this review were reported in this study. </p> </li> </ul> </p> </section> </section> </section> <section id="CD012552-sec-0174"> <h4 class="title">6. Botulinum toxin A versus placebo</h4> <p>Two studies compared the use of botulinum toxin A (BTA) to a sham procedure: one study with 60 participants (<a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>) applied the toxin to the prostate, and another study with 29 participants (<a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a>) applied the toxin to pelvic floor muscles. We report the outcomes of these studies separately due to this clinical heterogeneity in the interventions and participants (<a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a> included participants aged over 50 years, and <a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a> included participants with more severe baseline prostatitis symptoms). See <a href="#CD012552-tbl-0009">Table 1</a> and <a href="#CD012552-tbl-0010">Table 2</a> for further details of the participants and interventions. See <a href="./full#CD012552-tbl-0006">summary of findings Table 6</a>. One study that explored two different BTA injection protocols (<a href="./references#CD012552-bbs2-0019" title="ElshawafH . Chemodenervation of the rhabdosphincter (EUS) alone versus combined injection of both EUS &amp; prostate in patients with prostatitis and chronic pelvic pain syndrome type III. Prospective randomized controlled trial. (Abstract number 394). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. ">Elshawaf 2009</a>) is not included in the 'Summary of findings' table (see below). </p> <section id="CD012552-sec-0175"> <h5 class="title">6.1. Prostatitis symptoms</h5> <section id="CD012552-sec-0176"> <h6 class="title">6.1.1. Prostatitis symptoms: subgroup intraprostatic injection, participants &lt; 50 years old with basal NIH‐CPSI scores &gt; 30 </h6> <p>Based on one study with 60 participants (<a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>), intraprostatic BTA injection may have decreased prostatitis symptoms at six‐month follow‐up (MD −25.80, 95% CI −30.15 to −21.45; <a href="./references#CD012552-fig-0060" title="">Analysis 6.1</a>). These results were consistent across all subscores of pain, urinary symptoms and quality of life (<a href="./references#CD012552-fig-0061" title="">Analysis 6.2</a>; <a href="./references#CD012552-fig-0062" title="">Analysis 6.3</a>; <a href="./references#CD012552-fig-0063" title="">Analysis 6.4</a>). The quality of the evidence is low, due to unclear risk of selection bias and imprecision issues (small sample size resulting in a wide confidence interval). </p> </section> <section id="CD012552-sec-0177"> <h6 class="title">6.1.2. Prostatitis symptoms: subgroup pelvic floor muscles injection, participants &gt; 50 years old with basal NIH‐CPSI scores &lt; 30 </h6> <p>Based on one study with 29 participants (<a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a>), pelvic floor muscle BTA injection may have caused little to no effect in prostatitis symptoms at one‐month follow‐up (MD −2.60, 95% CI −5.59 to 0.39; <a href="./references#CD012552-fig-0060" title="">Analysis 6.1</a>). These results were consistent across subscores of urinary symptoms and quality of life, however pain scores in the BTA group were lower than the control group (<a href="./references#CD012552-fig-0061" title="">Analysis 6.2</a>; <a href="./references#CD012552-fig-0062" title="">Analysis 6.3</a>; <a href="./references#CD012552-fig-0063" title="">Analysis 6.4</a>). The quality of evidence is low, due to high risks of performance and detection bias, and imprecision issues (small sample size resulting in a wide confidence interval). </p> </section> </section> <section id="CD012552-sec-0178"> <h5 class="title">6.2. Adverse events</h5> <p>The study on intraprostatic BTA injection (<a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>) reported that two participants in the active treatment group suffered from haematuria (RR 5.00, 95% CI 0.25 to 99.95; 60 participants; <a href="./references#CD012552-fig-0064" title="">Analysis 6.5</a>). No participants in the study on pelvic floor muscle BTA injection (<a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. ">Gottsch 2011</a>) suffered adverse events. The quality of the evidence is low, due to unclear or high risks of bias and imprecision (few events). </p> </section> <section id="CD012552-sec-0179"> <h5 class="title">6.3. Sexual dysfunction</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0180"> <h5 class="title">6.4. Quality of life</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0181"> <h5 class="title">6.5. Anxiety and depression</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0182"> <h5 class="title">6.6. Urinary symptoms</h5> <p>The study on intraprostatic BTA injection reported this outcome (<a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. ">Falahatkar 2015</a>). Intraprostatic BTA injection may have decreased urinary symptoms (IPSS scores, MD −9.67, 95% CI −13.97 to −5.37; 60 participants; <a href="./references#CD012552-fig-0065" title="">Analysis 6.6</a>). The quality of the evidence is low, due to unclear risk of selection bias, and imprecision issues (small sample size resulting in a wide confidence interval). </p> </section> <section id="CD012552-sec-0183"> <h5 class="title">Studies not included in meta‐analysis or 'Summary of findings' table</h5> <p>One study was not included in meta‐analysis due to missing outcome data. <a href="./references#CD012552-bbs2-0019" title="ElshawafH . Chemodenervation of the rhabdosphincter (EUS) alone versus combined injection of both EUS &amp; prostate in patients with prostatitis and chronic pelvic pain syndrome type III. Prospective randomized controlled trial. (Abstract number 394). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. ">Elshawaf 2009</a>, with 52 participants, compared botulinum toxin A injection in the external urethral sphincter versus a combined injection in the prostate and external urethral sphincter. At six‐month follow‐up, the group with the combined injection had fewer prostatitis symptoms measured by NIH‐CPSI scores (P &lt; 0.05). None of the participants suffered adverse events. No other outcomes relevant for this review were reported in this study. </p> </section> </section> <section id="CD012552-sec-0184"> <h4 class="title">7. Allopurinol versus placebo</h4> <p>Two studies with 110 participants were included under this comparison (<a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. ">Persson 1996</a>; <a href="./references#CD012552-bbs2-0099" title="ZiaeeAM , AkhavizadeganH , KarbakhshM . Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. International Brazilian Journal of Urology2006;32(2):181‐6. ">Ziaee 2006</a>). See <a href="#CD012552-tbl-0009">Table 1</a> and <a href="#CD012552-tbl-0010">Table 2</a> for further details of the participants and interventions. See <a href="./full#CD012552-tbl-0007">summary of findings Table 7</a>. One of these studies (<a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. ">Persson 1996</a>) reported the incidence of adverse events (see below), but no outcomes relevant for this review were reported in this study, since the authors used a 12‐point scale that was not validated for this condition. </p> <section id="CD012552-sec-0185"> <h5 class="title">7.1. Prostatitis symptoms</h5> <p>Based on one study with 56 participants with three‐month follow‐up (<a href="./references#CD012552-bbs2-0099" title="ZiaeeAM , AkhavizadeganH , KarbakhshM . Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. International Brazilian Journal of Urology2006;32(2):181‐6. ">Ziaee 2006</a>), allopurinol may cause little to no different in prostatitis symptoms compared to placebo (MD −0.21, 95% CI −4.48 to 4.06; <a href="./references#CD012552-fig-0066" title="">Analysis 7.1</a>). This was also evident in pain and urinary subscores (<a href="./references#CD012552-fig-0067" title="">Analysis 7.2</a>; <a href="./references#CD012552-fig-0068" title="">Analysis 7.3</a>). The quality of evidence was low, due to unclear or high risks of bias in most domains and imprecision (the confidence interval includes appreciable benefits and harms). </p> </section> <section id="CD012552-sec-0186"> <h5 class="title">7.2. Adverse events</h5> <p>Based on the included studies with 110 participants, no adverse events were observed at three‐month follow‐up. The quality of the evidence is low, due to high or unclear risks of bias in both studies, and imprecision (zero events). </p> </section> <section id="CD012552-sec-0187"> <h5 class="title">7.3. Sexual dysfunction</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0188"> <h5 class="title">7.4. Quality of life</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0189"> <h5 class="title">7.5. Anxiety and depression</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0190"> <h5 class="title">7.6. Urinary symptoms</h5> <p>None of the included studies reported this outcome.</p> </section> </section> <section id="CD012552-sec-0191"> <h4 class="title">8. Traditional Chinese medicine (TCM) versus placebo</h4> <p>Seven studies with 970 randomized participants were included under this comparison (<a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. ">Hu 2015</a>; <a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. ">Li 2003</a>; <a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. ">Li 2012</a>; <a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. ">Sun 2008</a>; <a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. ">Tan 2009</a>; <a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. ">Xia 2014</a>; <a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. ">Zhang 2007</a>). See <a href="#CD012552-tbl-0009">Table 1</a> and <a href="#CD012552-tbl-0010">Table 2</a> for further details of the participants and interventions. See <a href="./full#CD012552-tbl-0008">summary of findings Table 8</a>. Five studies were not included in the 'Summary of findings' table and are described below (<a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. ">Chen 2009</a>; <a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. ">Li 2007</a>; <a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. ">Peng 2003</a>; <a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. ">Shi 1994</a>; <a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. ">Wang 2004</a>). </p> <section id="CD012552-sec-0192"> <h5 class="title">8.1. Prostatitis symptoms</h5> <p>Based on seven studies with 835 participants with two‐week to two‐month follow‐up (<a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. ">Hu 2015</a>; <a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. ">Li 2003</a>; <a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. ">Li 2012</a>; <a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. ">Sun 2008</a>; <a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. ">Tan 2009</a>; <a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. ">Xia 2014</a>; <a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. ">Zhang 2007</a>), TCM may reduce prostatitis symptoms compared to placebo (MD ‐3.13, 95% CI ‐4.99 to ‐1.28; I<sup>2</sup> = 82%, <a href="./references#CD012552-fig-0069" title="">Analysis 8.1</a>). These results were consistent in the pain and urinary subscores but not quality of life subscore (<a href="./references#CD012552-fig-0070" title="">Analysis 8.2</a>; <a href="./references#CD012552-fig-0071" title="">Analysis 8.3</a>; <a href="./references#CD012552-fig-0072" title="">Analysis 8.4</a>). The quality of evidence was low, due to high risk of bias (unclear or high risk of bias in most domains in most studies) and inconsistency (I<sup>2</sup> &gt; 80%), although some of this inconsistency might be explained by the differences between the interventions in this comparison (possible indirectness). </p> </section> <section id="CD012552-sec-0193"> <h5 class="title">8.2. Adverse events</h5> <p>Based on four studies with 584 participants at four‐ to eight‐week follow‐up (<a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. ">Li 2003</a>; <a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. ">Li 2012</a>; <a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. ">Tan 2009</a>; <a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. ">Zhang 2007</a>), TCM may cause little to no difference in adverse events compared to placebo (RR 1.34, 95% CI 0.22 to 8.02; I<sup>2</sup> = 45%; <a href="./references#CD012552-fig-0073" title="">Analysis 8.5</a>). The quality of evidence was low, due to high risk of bias (unclear or high risk of bias in most domains in most studies) and imprecision (few events, resulting in a confidence interval that includes appreciable benefits and harms). Common adverse events included gastrointestinal discomfort, nausea, vomiting and diarrhoea, and anal bleeding (for those TCM interventions that used suppositories). </p> </section> <section id="CD012552-sec-0194"> <h5 class="title">8.3. Sexual dysfunction</h5> <p>One study with 88 participants (<a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. ">Xia 2014</a>) reported this outcome at two‐week follow‐up. TCM probably resulted in little to no difference in sexual discomfort when compared to placebo (IIEF scores, MD 0.27, 95% CI −1.17 to 1.71; <a href="./references#CD012552-fig-0074" title="">Analysis 8.6</a>). The quality of evidence is moderate, due to high risk of or unclear risk of bias in most domains of the study. </p> </section> <section id="CD012552-sec-0195"> <h5 class="title">8.4. Quality of life</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0196"> <h5 class="title">8.5. Anxiety and depression</h5> <p>One study with 88 participants (<a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. ">Xia 2014</a>) reported this outcome at two‐week follow‐up. TCM may have resulted in a decrease in symptoms of anxiety and depression when compared to placebo (Hamilton Anxiety Rating Scale, MD −9.50, 95% CI −11.70 to −7.30; <a href="./references#CD012552-fig-0075" title="">Analysis 8.7</a>; Hamilton Depression Rating Scale, MD −7.84, 95% CI −10.71 to −4.97; <a href="./references#CD012552-fig-0076" title="">Analysis 8.8</a>). The quality of evidence is low, due to high risk of bias (unclear or high risk of bias in most domains in most studies) and imprecision (small sample size resulting in a wide confidence interval that crosses the threshold for the MCID). </p> </section> <section id="CD012552-sec-0197"> <h5 class="title">8.6. Urinary symptoms</h5> <p>None of the included studies reported this outcome</p> </section> <section id="CD012552-sec-0198"> <h5 class="title">Studies not included in meta‐analysis or 'Summary of findings' table</h5> <p>Five studies were not included in meta‐analysis due to missing outcome data or because they involve head‐to‐head comparisons: </p> <p> <ul id="CD012552-list-0036"> <li> <p><a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. ">Chen 2009</a>, with 70 participants, compared QianTongDing Decoction with indomethacin. Participants who received QianTongDing Decoction may have had fewer prostatitis symptoms at one‐month follow‐up (MD in NIH‐CPSI scores −6.80, 95% CI −7.94 to −5.66). The quality of evidence is low, due to high risk of bias and imprecision issues. Two participants in the indomethacin group suffered from epigastralgia. No participants in the QianTongDing group suffered adverse events. No other outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. ">Li 2007</a>, with 108 participants, compared a Tiaoshen Tonglin infusion with terazosin. Participants who received Tiaoshen Tonglin infusion may have had fewer prostatitis symptoms at two‐month follow‐up (MD in NIH‐CPSI scores −3.80, 95% CI −4.82 to −2.78). The incidence of adverse events was 2/56 in the Tiaoshen Tonglin and 12/52 in the terazosin group (dizziness and palpitations). The quality of evidence is low, due to high risk of bias and imprecision issues. No other outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. ">Peng 2003</a>, with 160 participants, compared an "antiphlogistic" agent in different regimens and with various co‐interventions. No outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. ">Shi 1994</a>, with 60 participants, compared QianLieAnWan capsules and QianLieKang (a type of pollen extract capsule). No outcomes relevant to this review were reported in this study. </p> </li> <li> <p><a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. ">Wang 2004</a>, with 38 participants, compared an intraprostatic injection of Chuanshentong to a placebo injection. At six‐week follow‐up there were more participants who had an appreciable reduction in prostatitis symptoms (six or more points decrease in NIH‐CPSI scores) in the active treatment group compared to the placebo group (RR 2.49, 95% CI 1.24 to 4.97). The study stated that there were no adverse events in the active treatment group. No outcomes relevant to this review were reported in this study. </p> </li> </ul> </p> </section> </section> <section id="CD012552-sec-0199"> <h4 class="title">9. Other pharmacological agents</h4> <p>In the following sections we provide a description of the studies that included other pharmacological agents (in alphabetical order). See <a href="#CD012552-tbl-0009">Table 1</a> and <a href="#CD012552-tbl-0010">Table 2</a> for further details of the participants and interventions. </p> <section id="CD012552-sec-0200"> <h5 class="title">9.1. Anticholinergics</h5> <p>Three studies with 202 randomized participants were included under this comparison (<a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. ">Kim 2008</a>; <a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. ">Kim 2011b;</a><a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>). </p> <section id="CD012552-sec-0201"> <h6 class="title">9.1.1. Prostatitis symptoms</h6> <p>Based on the three studies (<a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. ">Kim 2008</a>; <a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. ">Kim 2011b</a>; <a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>) with four‐ to eight‐week follow‐up, anticholinergics probably resulted in little to no difference in prostatitis symptoms compared to control (random‐effects meta‐analysis, MD −1.20, 95% CI −3.49 to 1.09; I<sup>2</sup> = 47%; 3 studies, 173 participants). The quality of evidence was moderate, due to high or unclear risks of bias in most domains. </p> </section> <section id="CD012552-sec-0202"> <h6 class="title">9.1.2. Adverse events</h6> <p>Two studies with 106 participants reported adverse events (<a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. ">Kim 2008</a>; <a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. ">Lu 2004</a>). These studies reported that there were globally no adverse events. The quality of evidence is low, due to high or unclear risks of bias in most domains, and imprecision (zero events in both groups). </p> </section> <section id="CD012552-sec-0203"> <h6 class="title">9.1.3. Sexual dysfunction</h6> <p>One study (<a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. ">Kim 2011b</a>) with 96 participants reported sexual dysfunction. Participants who received anticholinergics had similar sexual dysfunction measured by IIEF scores (MD 1.00, 95% CI −1.46 to 3.46). The quality of evidence was moderate, due to high or unclear risks of bias in most domains. </p> </section> <section id="CD012552-sec-0204"> <h6 class="title">9.1.4. Quality of life</h6> <p>None of the studies reported this outcome.</p> </section> <section id="CD012552-sec-0205"> <h6 class="title">9.1.5. Depression and anxiety</h6> <p>None of the studies reported this outcome.</p> </section> <section id="CD012552-sec-0206"> <h6 class="title">9.1.6. Urinary symptoms</h6> <p>Two studies with 133 participants reported urinary symptoms (<a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. ">Kim 2008</a>; <a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. ">Kim 2011b</a>). Participants who received anticholinergics may have a slight reduction in urinary symptoms (MD −2.32, 95% CI −4.24 to −0.40; I<sup>2</sup> = 0%). The quality of evidence was moderate, due to high or unclear risk of bias in most domains. </p> </section> </section> <section id="CD012552-sec-0207"> <h5 class="title">9.2. Antidepressants</h5> <p>Five studies with 495 randomized participants evaluated these agents: three studies with 94 participants compared antidepressants to placebo (<a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. ">Giannantoni 2014</a>; <a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. ">Lee 2005</a>; <a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. ">Turkington 2002</a>) and another study with 150 randomized participants compared duloxetine and doxazosin, sertraline and doxazosin, and doxazosin alone (doxazosin acted as a co‐intervention) (<a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. ">Zhang 2017</a>). One additional study with 251 randomized participants compared the use of dapoxetin as add‐on therapy to medical therapy versus medical therapy alone in patients with comorbid premature ejaculation (<a href="./references#CD012552-bbs2-0097" title="ChiCTR1800019441 . A clinical observation of dapoxetine combined with tamsulosin in treatment of type III prostatitis with premature ejaculation. http://www.chictr.org.cn/showproj.aspx?proj=28436 (Date of Registration: 2018‐11‐11). ZhaoL , TianR , LiangC , ZhangL , SongW , ZhaoJ , et al. Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation. Andrologia2019;51(8):e13319. [PUBMED: 31131928] ">Zhao 2019</a>) is described separately below. </p> <section id="CD012552-sec-0208"> <h6 class="title">Antidepressants versus placebo</h6> </section> <section id="CD012552-sec-0209"> <h6 class="title">9.2.1 Prostatitis symptoms</h6> <p><a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. ">Giannantoni 2014</a>, with 38 participants, reported that those who received duloxetine had fewer prostatitis symptoms compared to those who received placebo (MD −5.97, 95% CI −7.89 to −4.05) at 16‐week follow‐up. <a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. ">Lee 2005</a>, with 14 participants, reported this outcome using the Prostatitis Symptom Severity scale (0 to 100 score, benefit is indicated by lower scores). Participants who received sertraline had statistically non‐significantly lower mean scores (mean score 17.3) compared to those on placebo (mean score 26, P = 0.34) at 13‐week follow‐up. The quality of evidence was very low, due to high risk of bias, inconsistency and imprecision (few events). <a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. ">Zhang 2017</a>, with 150 participants, reported that those in the duloxetine group had fewer prostatitis symptoms at six‐month follow‐up (mean decrease 12.64 points) compared to those receiving sertraline (mean decrease 7.41 points, P &lt; 0.01) and to those receiving doxazosin alone (mean decrease 6.12 points, P &lt; 0.01). The responder rate was greater in the duloxetine group (88.6%) compared to the sertraline group (63.4%) and the doxazosin‐alone group (56.1%). </p> </section> <section id="CD012552-sec-0210"> <h6 class="title">9.2.2. Adverse events</h6> <p>Based on three studies with 94 participants (<a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. ">Giannantoni 2014</a>; <a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. ">Turkington 2002</a>; <a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. ">Lee 2005</a>) at 8‐ to 16‐week follow‐up, antidepressants may cause little to no difference in adverse events (random‐effects meta‐analysis, RR 1.65, 95% CI 0.54 to 5.04; I<sup>2</sup> = 14%). The quality of the evidence was low, due to high risk of bias and imprecision (few events). Common adverse events included gastrointestinal discomfort, decreased libido and ejaculatory disorders, sedation and dizziness. </p> <p><a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. ">Zhang 2017</a>, with 150 participants, reported narratively: three participants discontinued treatment due to adverse events in the duloxetine group, two in the sertraline group and two in the doxazosin group, and that "[the] occurrence rate of nausea and vomiting was 15.91% in duloxetine group, which was significantly higher than that in the other 2 groups, and some patients were unable to tolerate the adverse reactions". </p> </section> <section id="CD012552-sec-0211"> <h6 class="title">9.2.3. Sexual dysfunction</h6> <p><a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. ">Giannantoni 2014</a>, with 38 participants, reported this outcome using the IIEF score. Participants in both groups had similar scores at 16‐week follow‐up: mean score in the duloxetine group was 14.8, mean score in the placebo group was 15.3, P = "NS" (non‐significant). <a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. ">Lee 2005</a>, with 14 participants, reported this outcome using the Psychosexual Questionnaire. Participants in both groups had similar scores at 13‐week follow‐up: mean score in the sertraline group was 22.1, mean score in the placebo group was 23.1, P = 0.44. </p> <p>The quality of the evidence was low, due to high risk of bias and imprecision (few events). </p> </section> <section id="CD012552-sec-0212"> <h6 class="title">9.2.4. Quality of life</h6> <p><a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. ">Turkington 2002</a>, with 42 participants, reported that those who received fluvoxamine had improved quality of life at eight‐week follow‐up (measured by the General Health Questionnaire, mean score in the fluvoxamine group was 5.75 and mean score in the placebo group was 1.25, P &lt; 0.01). </p> <p>The quality of the evidence was low, due to high risk of bias and imprecision (small sample size, underpowered study). </p> </section> <section id="CD012552-sec-0213"> <h6 class="title">9.2.5. Depression and anxiety.</h6> <p><a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. ">Turkington 2002</a>, with 42 participants, reported that both groups had similar symptoms of anxiety and depression at eight‐week follow‐up (measured by Hamilton Depression Scale, P = 0.21 for the anxiety domain and 0.87 for the depression domain). </p> <p><a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. ">Giannantoni 2014</a>, with 38 participants, reported that those in the duloxetine group had fewer symptoms of anxiety (mean Hamilton Anxiety scale of 7.93, SD 6.54) compared to those who received placebo (mean score of 15.72, SD 10.11, P &lt; 0.01). The symptoms of depression (measured by Hamilton Depression scale) were fewer in the duloxetine group, but this difference was not statistically significant. Follow‐up was 16 weeks. </p> <p><a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. ">Lee 2005</a>, with 14 participants, reported that those who received sertraline had statistically non‐significantly lower mean symptoms of anxiety and depression as measured by the Hospital Anxiety and Depression scale (anxiety score was 6.7, depression score was 3.1 in the sertraline group, while anxiety score was 17.7, and depression score was 5.6 in the placebo group, P value = 0.4 and 0.3 respectively) at 13‐week follow‐up. </p> <p><a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. ">Zhang 2017</a>, with 150 participants, reported that those who received duloxetine had fewer symptoms of anxiety and depression at six‐month follow‐up measured by the Hospital Anxiety and Depression Scale (HADS) (mean decrease 9.43 points) compared to those who received sertraline (mean decrease 7.27 points, P &lt; 0.05) and those who received doxazosin alone (mean decrease 4.90 points, P &lt; 0.01). </p> <p>The quality of evidence was low, due to high risk of bias and imprecision (small sample size, underpowered studies). </p> </section> <section id="CD012552-sec-0214"> <h6 class="title">9.2.6. Urinary symptoms</h6> <p>None of the included studies reported this outcome.</p> </section> <section id="CD012552-sec-0215"> <h6 class="title">Antidepressants (dapoxetine) plus medical therapy versus medical therapy alone in men with premature ejaculation </h6> <p>A study with 251 randomized participants compared the use of dapoxetine as add‐on therapy to medical therapy versus medical therapy alone in patients suffering from CP/CPPS with comorbid premature ejaculation (<a href="./references#CD012552-bbs2-0097" title="ChiCTR1800019441 . A clinical observation of dapoxetine combined with tamsulosin in treatment of type III prostatitis with premature ejaculation. http://www.chictr.org.cn/showproj.aspx?proj=28436 (Date of Registration: 2018‐11‐11). ZhaoL , TianR , LiangC , ZhangL , SongW , ZhaoJ , et al. Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation. Andrologia2019;51(8):e13319. [PUBMED: 31131928] ">Zhao 2019</a>). </p> <p>In this study, based on available data from 114 participants, those who received dapoxetine may have had fewer prostatitis symptoms at 12 week follow‐up (NIH‐CPSI score, MD ‐4.37, 95% CI ‐6.88 to ‐1.86) and fewer sexual dysfunction (measured by the Premature Ejaculation Profile with a range from 0 to 16 and higher scores indicating improvement, MD 4.43, 95% CI 2.83 to 6.03) compared to those in the control group. Based on data from 251 participants, the incidence of adverse events was similar in both groups: 7.37% in the dapoxetine group and 4.91% in the control group (RR 1.50, 95% CI 0.45 to 5.04). No outcomes relevant to this review were reported in this study. The quality of the evidence was low due to imprecision and study limitations. </p> </section> </section> <section id="CD012552-sec-0216"> <h5 class="title">9.3. Mepartricin</h5> <p>Two studies analysed this intervention (<a href="./references#CD012552-bbs2-0008" title="CavalliniG . Mepartricin in the treatment of male pelvic pain syndrome secondary to chronic nonbacterial prostatitis/prostatodynia. Minerva Urologica e Nefrologica [Italian Journal of Urology and Nephrology]2001;53(1):13‐7. ">Cavallini 2001</a>; <a href="./references#CD012552-bbs2-0016" title="DeRoseAF , GalloF , GiglioM , CarmignaniG . Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo‐controlled trial. Urology2004;63(1):13‐6. DeRoseAF , TraversoP , MontanaroT , CarmignaniG . The role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS): A randomized prospective placebo‐controlled trial. Journal of Urology2010;183(4):e311. ">De Rose 2004</a>). </p> <p><a href="./references#CD012552-bbs2-0008" title="CavalliniG . Mepartricin in the treatment of male pelvic pain syndrome secondary to chronic nonbacterial prostatitis/prostatodynia. Minerva Urologica e Nefrologica [Italian Journal of Urology and Nephrology]2001;53(1):13‐7. ">Cavallini 2001</a>, with 42 participants, compared mepartricin versus vitamin C (as a placebo comparator). An adverse event was reported in 1/22 participants in the mepartricin group (epigastralgia), with none in the control group. No other outcomes relevant to this review were reported in this study. </p> <p><a href="./references#CD012552-bbs2-0016" title="DeRoseAF , GalloF , GiglioM , CarmignaniG . Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo‐controlled trial. Urology2004;63(1):13‐6. DeRoseAF , TraversoP , MontanaroT , CarmignaniG . The role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS): A randomized prospective placebo‐controlled trial. Journal of Urology2010;183(4):e311. ">De Rose 2004</a>, with 26 participants, compared mepartricin with placebo. At 60‐day follow‐up, participants who received mepartricin had fewer prostatitis symptoms measured by NIH‐CPSI scores (median 10, interquartile range 4 to 25), compared to those who received placebo (median 20, interquartile range 11 to 45, P = 0.0018). Two participants who received mepartricin suffered from epigastralgia. No other outcomes relevant to this review were reported in this study. </p> <p>The quality of the evidence for the reported outcomes was low, due to high risk of bias and imprecision (small sample size, underpowered studies). </p> <p><b>Note</b>: this drug has only limited availability worldwide (some European countries and Brazil). </p> </section> <section id="CD012552-sec-0217"> <h5 class="title">9.4. OM‐89 (<i>Escherichia coli</i> lysate) </h5> <p><a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. ">Wagenlehner 2014</a>, with 185 participants, compared the use of OM‐89 versus placebo. </p> <section id="CD012552-sec-0218"> <h6 class="title">9.4.1. Prostatitis symptoms</h6> <p>OM‐89 probably has little to no effect on prostatitis symptoms (MD −0.60, 95% CI −3.21 to 2.01) compared to those who received placebo at 12‐month follow‐up. The number of participants who achieved a 25% decrease in NIH‐CPSI scores was similar in both groups (RR 0.99, 95% CI 0.78 to 1.25). The quality of the evidence was moderate, due to high risk of bias. </p> </section> <section id="CD012552-sec-0219"> <h6 class="title">9.4.2. Adverse events</h6> <p>OM‐89 probably has little to no effect on adverse events (RR 0.99, 95% CI 0.78 to 1.25). The quality of the evidence for the reported outcomes was low, due to high risk of bias and imprecision (few events, resulting in a confidence interval that includes appreciable benefits and harms). </p> </section> <section id="CD012552-sec-0220"> <h6 class="title">9.4.3. Sexual dysfunction, quality of life, anxiety and depression, or urinary symptoms</h6> <p>No other outcomes relevant to this review were reported in this study.</p> </section> </section> <section id="CD012552-sec-0221"> <h5 class="title">9.5. Pentosan</h5> <p>Two studies with 130 participants (<a href="./references#CD012552-bbs2-0058" title="NickelJC , ForrestJB , TomeraK , Hernandez‐GraulauJ , MoonTD , SchaefferAJ , et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. Journal of Urology2005;173(4):1252‐5. ">Nickel 2005</a>; <a href="./references#CD012552-bbs2-0084" title="WedrenH . Effects of sodium pentosanpolysulphate on symptoms related to chronic non‐bacterial prostatitis. A double‐blind randomized study. Scandinavian Jpurnal of Urology and Nephrology1987;21(2):81‐8. ">Wedren 1987</a>) compared the use of pentosan with placebo. </p> <section id="CD012552-sec-0222"> <h6 class="title">9.5.1. Prostatitis symptoms</h6> <p>This outcome was reported by <a href="./references#CD012552-bbs2-0058" title="NickelJC , ForrestJB , TomeraK , Hernandez‐GraulauJ , MoonTD , SchaefferAJ , et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. Journal of Urology2005;173(4):1252‐5. ">Nickel 2005</a>, with 100 participants. Those in the pentosan group probably had similar prostatitis symptoms when compared to the placebo group at 16‐week follow‐up (NIH‐CPSI score MD −2.70, 95% CI −5.61 to 0.21). The quality of evidence is moderate, due to high risk of bias. </p> </section> <section id="CD012552-sec-0223"> <h6 class="title">9.5.2. Adverse events</h6> <p>In <a href="./references#CD012552-bbs2-0058" title="NickelJC , ForrestJB , TomeraK , Hernandez‐GraulauJ , MoonTD , SchaefferAJ , et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. Journal of Urology2005;173(4):1252‐5. ">Nickel 2005</a> adverse events were reported by 36/51 participants receiving pentosan and 34/49 receiving placebo. The most frequent adverse events were diarrhoea, nausea and headache. Six participants in the pentosan group had altered liver function tests, and one of them suffered from liver failure. In <a href="./references#CD012552-bbs2-0084" title="WedrenH . Effects of sodium pentosanpolysulphate on symptoms related to chronic non‐bacterial prostatitis. A double‐blind randomized study. Scandinavian Jpurnal of Urology and Nephrology1987;21(2):81‐8. ">Wedren 1987</a> two participants in the pentosan group suffered from diarrhoea while none in the placebo group reported any adverse event. The quality of evidence is low, due to high risk of bias and imprecision (few events). </p> </section> <section id="CD012552-sec-0224"> <h6 class="title">9.5.3. Sexual dysfunction, quality of life, anxiety and depression, or urinary symptoms</h6> <p>No other outcomes relevant to this review were reported in the included studies for this comparison. </p> </section> </section> <section id="CD012552-sec-0225"> <h5 class="title">9.6. Phosphodiesterase inhibitors</h5> <p>We included six studies with 536 randomized participants which compared the addition of phosphodiesterase inhibitors to medical therapy versus medical therapy alone (<a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. ">Abdalla 2018</a>; <a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. ">Kong 2014;</a><a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. ">Lin 2007;</a><a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. ">Park 2012</a>; <a href="./references#CD012552-bbs2-0065" title="ParkHJ , ParkNC , MoonDG , KimTN , NamJK , ParkSW . Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction. European Urology Supplements2017;16(3):e453. ">Park 2017</a>; <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>). </p> <section id="CD012552-sec-0226"> <h6 class="title">9.6.1.Prostatitis symptoms</h6> <p>Based on two studies with 226 participants (<a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. ">Kong 2014</a>; <a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. ">Lin 2007</a>), phosphodiesterase inhibitors may reduce prostatitis symptoms at six‐ to eight‐week follow‐up (random‐effect meta‐analysis, MD −4.37, 95% CI −5.24 to −3.50; I<sup>2</sup> = 82%). <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>, with 68 participants, reported that the mean decrease in NIH‐CPSI scores at six weeks was 18 in the tadalafil group and 8.4 in the control group (P &lt; 0.05). <a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. ">Park 2012</a>, with 78 participants, reported that the mean decrease in NIH‐CPSI scores at four weeks was 2.7 in the tadalafil group and 1.2 in the control group (P &lt; 0.05). <a href="./references#CD012552-bbs2-0065" title="ParkHJ , ParkNC , MoonDG , KimTN , NamJK , ParkSW . Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction. European Urology Supplements2017;16(3):e453. ">Park 2017</a>, with 86 participants, reported that the mean decrease in NIH‐CPSI scores at four weeks was 7.3 in the tadalafil group and 3.1 in the control group (P &lt; 0.05). <a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. ">Abdalla 2018</a>, with 108 participants, reported that NIH‐CPSI scores were lower at four‐week follow‐up (P &lt; 0.001) in those who received tadalafil and antibiotics compared to those who only received antibiotics. The quality of evidence is low, due to high or unclear risks of bias in most domains, and inconsistency. </p> </section> <section id="CD012552-sec-0227"> <h6 class="title">9.6.2. Adverse events</h6> <p><a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. ">Lin 2007</a>, with 138 participants, reported that there were no adverse events. Three studies (<a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. ">Kong 2014</a>; <a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. ">Park 2012</a>; <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>) reported that those in the phosphodiesterase inhibitors group suffered from frequent erections, dyspepsia, back pain, blurred vision and headache (no information on the control group). <a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. ">Abdalla 2018</a> reported that one participant in the tadalafil group suffered from flushing. The quality of evidence is low, due to high or unclear risks of bias in most domains, and imprecision (few events). </p> </section> <section id="CD012552-sec-0228"> <h6 class="title">9.6.3. Sexual dysfunction</h6> <p>Two studies with 226 participants provided sufficient information to pool the results in meta‐analysis (<a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. ">Kong 2014</a>; <a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. ">Lin 2007</a>). Participants who received phosphodiesterase inhibitors may have had less sexual dysfunction at six‐ to eight‐week follow‐up (measured by IIEF score, MD 6.80, 95% CI 5.05 to 8.55; I<sup>2</sup> = 76%). <a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. ">Park 2012</a>, with 78 participants, reported that those in the tadalafil group had less sexual dysfunction at four‐week follow‐up (mean increase in the IIEF score of 3.7) compared to those in the control group (mean increase in the IIEF score of 0.2, P &lt; 0.05). <a href="./references#CD012552-bbs2-0065" title="ParkHJ , ParkNC , MoonDG , KimTN , NamJK , ParkSW . Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction. European Urology Supplements2017;16(3):e453. ">Park 2017</a>, with 86 participants, reported that those in the tadalafil group had less sexual dysfunction at six‐week follow‐up (mean increase in the IIEF score of 3.8) compared to those in the control group (mean increase in the IIEF score of 0.2, P &lt; 0.05). <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>, with 68 participants, reported that those in the tadalafil group had less sexual dysfunction at six‐week follow‐up (mean increase in the IIEF score of 6.4) compared to those in the control group (mean decrease in the IIEF score of −0.7, P &lt; 0.05). <a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. ">Abdalla 2018</a>, with 108 participants, reported less sexual dysfunction (higher IIEF scores) at four‐week follow‐up (P &lt; 0.001) in those who received tadalafil and antibiotics compared to those who received antibiotics alone. The quality of evidence is low, due to high or unclear risks of bias in most domains, and imprecision (mean differences between scores crossed the MCID). </p> </section> <section id="CD012552-sec-0229"> <h6 class="title">9.6.4. Quality of life</h6> <p>None of the studies reported QoL.</p> </section> <section id="CD012552-sec-0230"> <h6 class="title">9.6.5. Depression and anxiety</h6> <p>None of the studies reported on depression and anxiety.</p> </section> <section id="CD012552-sec-0231"> <h6 class="title">9.6.6. Urinary symptoms</h6> <p>Four studies with 320 participants reported this outcome. <a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. ">Kong 2014</a>, with 88 participants, reported that those in the mirodenafil group had a greater decrease in urinary symptoms at six‐week follow‐up (measured by IPSS score, mean decrease of 4.3 points) compared to those in the control group (mean decrease of 1.1 points, P value &lt; 0.05). <a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. ">Park 2012</a>, with 78 participants, reported that those in the tadalafil group had a greater decrease in urinary symptoms at four‐week follow‐up (measured by IPSS score, mean decrease of 2.6 points) compared to those in the control group (mean decrease of 1 point, P value &lt; 0.05). <a href="./references#CD012552-bbs2-0065" title="ParkHJ , ParkNC , MoonDG , KimTN , NamJK , ParkSW . Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction. European Urology Supplements2017;16(3):e453. ">Park 2017</a>, with 86 participants, reported that those in the tadalafil group had a greater decrease in urinary symptoms at six‐week follow‐up (measured by IPSS score, mean decrease of 4.2 points) compared to those in the control group (mean decrease of 1.1 points, P value &lt; 0.05). <a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. ">Singh 2017</a>, with 68 participants, reported that those in the tadalafil group had a greater decrease in urinary symptoms at six‐week follow‐up (measured by IPSS score, mean decrease of 8.8 points) compared to those in the control group (mean decrease of 3.4 points, P value &lt; 0.05). The quality of evidence is low, due to high or unclear risk of bias in most domains, and imprecision (mean differences between scores crossed the MCID). </p> </section> </section> <section id="CD012552-sec-0232"> <h5 class="title">9.7. Pregabalin</h5> <p><a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>, with 324 participants, compared the use of pregabalin and placebo. </p> <section id="CD012552-sec-0233"> <h6 class="title">9.7.1. Prostatitis symptoms</h6> <p>Pregabalin causes little to no difference in prostatitis symptoms compared to placebo at six‐week follow‐up (measured by NIH‐CPSI score, MD −1.90, 95% CI −3.97 to 0.17). The number of participants who achieved a six‐point decrease in the score was similar in both groups (RR 1.32, 95% CI 0.99 to 1.76). The quality of evidence is high. </p> </section> <section id="CD012552-sec-0234"> <h6 class="title">9.7.2. Adverse events</h6> <p>There were 191 adverse events, and the authors state that there was no difference between groups (P = 0.40), but more participants suffered from neurological symptoms, including headache, in the pregabalin group than in the placebo group (RR 1.70, 95% CI 1.15 to 2.51). The quality of evidence is low, due to imprecision. </p> </section> <section id="CD012552-sec-0235"> <h6 class="title">9.7.3. Sexual dysfunction</h6> <p>Pregabalin causes little to no difference in sexual dysfunction compared to placebo (measured by the Sexual Health Inventory for Men, MD −0.80, 95% CI −2.69 to 1.09, P = 0.40). The quality of evidence is high. </p> </section> <section id="CD012552-sec-0236"> <h6 class="title">9.7.4. Quality of life</h6> <p>Pregabalin causes little to no difference in quality of life compared to placebo (measured by the SF‐12 questionnaire; P = 0.34 for physical domain and 0.22 for mental domain). The quality of evidence is high. </p> </section> <section id="CD012552-sec-0237"> <h6 class="title">9.7.5. Anxiety and depression</h6> <p>Pregabalin causes little to no difference in anxiety and depression compared to placebo (measured by the Hospital Anxiety and Depression Scale, P = 0.36). The quality of evidence is high. </p> </section> <section id="CD012552-sec-0238"> <h6 class="title">9.7.6. Urinary symptoms</h6> <p>The study did not report this outcome.</p> </section> </section> <section id="CD012552-sec-0239"> <h5 class="title">9.8. Tanezumab</h5> <p><a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. ">Nickel 2016</a>, with 62 participants, compared the monoclonal antibody tanezumab with placebo. </p> <section id="CD012552-sec-0240"> <h6 class="title">9.8.1. Prostatitis symptoms</h6> <p>Participants receiving tanezumab had similar prostatitis symptoms to those who received placebo at six‐week follow‐up (NIH‐CPSI score MD 1.43, 95% CI −6.71 to 3.85). The quality of the evidence is low, due to high risks of bias and imprecision (the confidence interval crosses the threshold for the MCID). </p> </section> <section id="CD012552-sec-0241"> <h6 class="title">9.8.2. Adverse events</h6> <p>Adverse events were reported in 19/30 participants receiving tanezumab and in 12/32 of those receiving placebo. The most frequent adverse events were paraesthesias, arthralgia, headache, pain in an extremity, and insomnia. The quality of evidence is low, due study limitations and imprecision. </p> </section> <section id="CD012552-sec-0242"> <h6 class="title">9.8.3. Sexual dysfunction, quality of life, anxiety and depression, or urinary symptoms</h6> <p>No other outcomes relevant to this review were reported in this study.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012552-sec-0243" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012552-sec-0243">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012552-sec-0333">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012552-sec-0243"></div> <section id="CD012552-sec-0244"> <h3 class="title" id="CD012552-sec-0244">Summary of main results</h3> <p>We included 99 unique studies with 9119 men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), with the assessment of 16 types of pharmacological interventions. Most of our comparisons included short‐term follow‐up information. The median age of the participants was 38 years. </p> <section id="CD012552-sec-0245"> <h4 class="title">Main comparisons</h4> <p>We found low‐ to very low‐quality evidence that alpha blockers may reduce prostatitis symptoms based on a reduction in NIH‐CPSI scores of more than two (but less than eight) with an increased incidence of minor adverse events such as dizziness and hypotension Moderate‐ to low‐quality evidence indicates that 5‐alpha reductase inhibitors, antibiotics, anti‐inflammatories, and phytotherapy probably cause a small decrease in prostatitis symptoms and may not be associated with a greater incidence of adverse events. Intraprostatic BTA injection may cause a large reduction in prostatitis symptoms with procedure‐related adverse events (haematuria), but pelvic floor muscle BTA injection may not have the same effects (low‐quality evidence). Allopurinol may also be ineffective for the reduction of prostatitis symptoms (low‐quality evidence). We assessed a wide range of interventions involving traditional Chinese medicine; low‐quality evidence showed they may reduce prostatitis symptoms without an increased incidence in adverse events. </p> </section> <section id="CD012552-sec-0246"> <h4 class="title">Other interventions</h4> <p>Moderate‐ to high‐quality evidence indicates that the following interventions may be ineffective for the reduction of prostatitis symptoms: anticholinergics, OM‐89, pentosan, and pregabalin. Low‐ to very low‐quality evidence indicates that antidepressants and tanezumab may be ineffective for the reduction of prostatitis symptoms. Low‐quality evidences indicates that mepartricin and phosphodiesterase inhibitors may reduce prostatitis symptoms, without an increased incidence in adverse events. </p> </section> </section> <section id="CD012552-sec-0247"> <h3 class="title" id="CD012552-sec-0247">Overall completeness and applicability of evidence</h3> <p>Our review focused on men with CP/CPPS. Almost all the included studies used the consistent inclusion criteria defined by the NIH (<a href="./references#CD012552-bbs2-0232" title="NybergLM , KriegerJN , NickelJC . National Institutes of Health classification of chronic prostatitis. In: NickelJC editor(s). Textbook of Prostatitis. London: CRC Press, 1999. ">Nyberg 1999</a>). These diagnostic criteria are related to clinical practice, since these participants are usually tested for urological diseases that could mimic CP/CPPS. However, some of the impact of the NIH consensus on the diagnosis of CP/CPPS might have changed the classification of participants across time (<a href="./references#CD012552-bbs2-0214" title="KriegerJN , RossSO , DeutschL , RileyDE . The NIH Consensus concept of chronic prostatitis/chronic pelvic pain syndrome compared with traditional concepts of nonbacterial prostatitis and prostatodynia. Current Urology Reports2002;3(4):301‐6. [PUBMED: 12149161] ">Krieger 2002</a>), so the results of older trials must be interpreted with caution with the current diagnostic criteria. We incorporated a sensitivity analysis based on this consideration. </p> <p>We maintained open inclusion criteria for the included interventions. This decision was based on the poorly understood pathophysiological determinants for CP/CPPS (see <a href="#CD012552-sec-0030">Background</a>). This led to the inclusion of a wide variety of pharmacological interventions, which could relate to clinical practice, considering that people with CP/CPPS usually try different treatment options before achieving some form of relief. There might be difficulties in the interpretation of some head‐to‐head comparisons, since we do not know the effectiveness of each separate intervention: for example, for the comparison of pollen extract (deprox®) versus bromelain we might not know if pollen extract and bromelain are superior to placebo in the first place in order to analyse their relative effectiveness. </p> <p>Our review focused on critical patient‐important outcomes; however, most studies did not report them consistently, especially the incidence of adverse events. This is a common problem in clinical trials (<a href="./references#CD012552-bbs2-0208" title="IoannidisJP , LauJ . Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA2001;285(4):437‐43. [PUBMED: 11242428] ">Ioannidis 2001</a>), and poses difficulties when estimating the net benefit of the interventions. Additionally, most of the included studies did not report the effects of their interventions on quality of life (QoL), sexual function and mental health, considering the important impact of CP/CPPS in these domains (<a href="./references#CD012552-bbs2-0215" title="KrsmanovicA , TrippDA , NickelJC , ShoskesDA , PontariM , LitwinMS , et al. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Journal de l'Association des Urologues du Canada [Canadian Urological Association Journal]2014;8(11‐12):403‐8. [PUBMED: 25553153] ">Krsmanovic 2014</a>). We acknowledge that the NIH‐CPSI score includes QoL and urinary symptom subscores that, alongside the pain subscore, contribute to a total score that has proved to be valid and reliable (<a href="./references#CD012552-bbs2-0221" title="LitwinMS , McNaughton‐CollinsM , FowlerFJ , NickelJC , CalhounEA , PontariMA , et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. Journal of Urology1999;162(2):369‐75. ">Litwin 1999</a>; McNaughton Collins 2001; <a href="./references#CD012552-bbs2-0237" title="PropertKJ , McNaughton‐CollinsM , LeibyBE , O'LearyMP , KusekJW , LitwinMS , et al. A prospective study of symptoms and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome: the National Institutes of Health chronic prostatitis cohort study. Journal of Urology2006;175(2):619‐23. ">Propert 2006</a>; <a href="./references#CD012552-bbs2-0257" title="TurnerJA , CiolMA , VonKorffM , BergerR . Validity and responsiveness of the national institutes of health chronic prostatitis symptom index. Journal of Urology2003;169(2):580‐3. ">Turner 2003</a>); however, these subscores have not been individually validated for these constructs. We acknowledge that the validated scores for QoL, urinary symptoms, sexual dysfunction, and anxiety and depression might not have been validated in the subpopulation of men with CP/CPPS, so their values should be interpreted cautiously, especially using the assessment of the minimal clinically important difference (MCID). </p> <p>Some pharmacological interventions may have different impacts on the main outcomes for this conditions. For example: phosphodiesterase inhibitors may have a greater impact on sexual dysfunction than on prostatitis symptoms; analgesics alone or in combinations may be used more when pain exacerbations occur. For this purpose, the UPOINTS approach allows the clinician to screen the person's characteristics and needs to guide the selection of pharmacological and non‐pharmacological interventions (<a href="./references#CD012552-bbs2-0223" title="MagriV , WagenlehnerF , PerlettiG , SchneiderS , MarrasE , NaberKG , et al. Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. Journal of Urology2010;184(6):2339‐45. [PUBMED: 20952019] ">Magri 2010</a>; <a href="./references#CD012552-bbs2-0249" title="ShoskesDA , NickelJC , RackleyRR , PontariMA . Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer and Prostatic Diseases2008;12(2):177‐83. ">Shoskes 2008b</a>). When considering adverse events, we have listed those most commonly reported in clinical trials. We acknowledge that there might be a wide range of possible adverse events that clinical trials might not have captured, and that observational studies could provide more information on this topic (<a href="./references#CD012552-bbs2-0251" title="SinghS , LokeYK . Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials2012; Vol. 13:138. [PUBMED: 22906139] ">Singh 2012</a>). Most adverse events were self‐limiting and with minor impact (e.g. gastrointestinal discomfort). In some cases the authors titrated the drugs to reduce the impact of early‐onset adverse events, such as postural hypotension for alpha blockers (<a href="./references#CD012552-bbs2-0219" title="LeporH . Alpha blockers for the treatment of benign prostatic hyperplasia. Reviews in Urology2007; Vol. 9, issue 4:181‐90. [PUBMED: 18231614] ">Lepor 2007</a>). Additionally, there might be other suggestions, as being cautious when standing up from bed, in order to avoid this adverse event (<a href="./references#CD012552-bbs2-0189" title="FigueroaJJ , BasfordJR , LowPA . Preventing and treating orthostatic hypotension: As easy as A, B, C. Cleveland Clinic Journal of Medicine2010; Vol. 77, issue 5:298‐306. [PUBMED: 20439562] ">Figueroa 2010</a>). Other adverse events that may not be transient (e.g. retrograde ejaculation) might be more challenging to treat, and a discussion with the patient may be warranted in order to elicit the importance of these outcomes, especially in relation to sexual activity and expectations (<a href="./references#CD012552-bbs2-0219" title="LeporH . Alpha blockers for the treatment of benign prostatic hyperplasia. Reviews in Urology2007; Vol. 9, issue 4:181‐90. [PUBMED: 18231614] ">Lepor 2007</a>). Unlike surgery‐induced retrograde ejaculation, this adverse event usually reverts to normal when alpha blockers are suspended. </p> <p>Furthermore, most studies reported results at four‐ to 12‐week follow‐up, which might be insufficient considering that men with CP/CPPS generally have a long, fluctuating history of symptoms, usually for years (<a href="./references#CD012552-bbs2-0180" title="ClemensJQ , ClauwDJ , KrederK , KriegerJN , KusekJW , LaiHH , et al. Comparison of baseline urological symptoms in men and women in the MAPP research cohort. Journal of Urology2015;193(5):1554‐8. [PUBMED: 25463989] ">Clemens 2015</a>). </p> <p>We had planned to explore the effect of the interventions in subgroups of men with different degrees of disease severity and in subgroups of men with common comorbidities (<a href="./references#CD012552-bbs2-0193" title="GasperiM , KriegerJN , ForsbergC , GoldbergJ , BuchwaldD , AfariN . Chronic prostatitis and comorbid non‐urological overlapping pain conditions: a co‐twin control study. Journal of Psychosomatic Research2017;102:29‐33. [PUBMED: 28992894] ">Gasperi 2017</a>), but the included studies provided insufficient data for this, so our analyses were limited. </p> <p>This review supplements another Cochrane Review in the same area: <i>Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome</i> (<a href="./references#CD012552-bbs2-0191" title="FrancoJV , TurkT , JungJH , XiaoYT , IakhnoS , GarroteV , et al. Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database of Systematic Reviews2018, Issue 5. [DOI: 10.1002/14651858.CD012551.pub3] ">Franco 2018</a>). In that review we highlighted that acupuncture and extracorporeal shockwave therapy are probably beneficial for this condition. While we found no evidence for psychological support for this condition, psychotherapy (e.g. cognitive behavioural therapy) has been effective in the management of somatoform disorders (<a href="./references#CD012552-bbs2-0258" title="VanDesselN , DenBoeftM , Van derWoudenJC , KleinstäuberM , LeoneSS , TerluinB , et al. Non‐pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD011142.pub2; CD011142] ">Van Dessel 2014</a>). </p> <p>Some of the included treatments for the main comparisons expressed in the 'Summary of findings' tables and in other sections of the review have not been part of routine care for CP/CPPS, especially: anticholinergics, mepartricin, OM‐89, phosphodiesterase inhibitors, pregabalin and tanezumab. In support of this, we used, as an example, the recommendations by the European Association of Urology (available at <a href="http://uroweb.org/guideline/chronic-pelvic-pain/" target="_blank">uroweb.org/guideline/chronic‐pelvic‐pain/</a> (last accessed July 2018)). As the guideline authors stated, careful consideration should be given when considering the applicability of these interventions in daily practice. For example, botulinum toxin A may not be easily accessible or acceptable for most men, since it involves an intraprostatic injection. As the GRADE Evidence to Decision Framework states, a careful evaluation of the patient's values and preferences, resource use and equity issues and the acceptability and feasibility of the interventions is warranted when drafting guidelines recommendations (<a href="./references#CD012552-bbs2-0165" title="Alonso‐CoelloP , SchünemannHJ , MobergJ , Brignardello‐PetersenR , AklEA , DavoliM , et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ (Clinical Research Ed.)2016;353:i2016. [PUBMED: 27353417] ">Alonso‐Coello 2016</a>); something that is beyond the scope of this review. </p> </section> <section id="CD012552-sec-0248"> <h3 class="title" id="CD012552-sec-0248">Quality of the evidence</h3> <p>The main limitations of the body of evidence were the following.</p> <p> <ul id="CD012552-list-0037"> <li> <p>Study limitations: most studies had problems when masking the interventions from study personnel and participants. This is particularly important for this review, considering that all the predefined outcomes were subjective and participant‐reported. Many studies had a considerable amount of missing outcome data and there was little explanation as to how this was handled (e.g. using methods such as 'last observation carried forward'). Additionally, most studies poorly reported random sequence generation and allocation concealment, and most had no published protocol or analysis plan to assess the risk of selective reporting. </p> </li> <li> <p>Inconsistency: we found considerable heterogeneity in some of the main comparisons; we were unable to explain this using our predefined sensitivity and subgroup analyses. We added a subgroup analysis based on one of our predefined conditions, but none of these analyses yielded significant results. </p> </li> <li> <p>Imprecision: we estimated an optimal information size of 74 for the primary outcome 'prostatitis symptoms', and almost 50% of the studies had a smaller sample size; most studies therefore suffered from imprecision. Nevertheless, in some cases meta‐analysis of some of the included studies increased the number of participants for each comparison, overcoming this limitation. This was more difficult to do for the outcome 'adverse events', in which the small number of events (in some cases there were none) resulted in considerable imprecision. </p> </li> <li> <p>Publication bias: we assessed the risk of publication bias using funnel plots in few outcomes, due to the paucity of trials, and we did not find evidence of any suggestive asymmetry. </p> </li> </ul> </p> </section> <section id="CD012552-sec-0249"> <h3 class="title" id="CD012552-sec-0249">Potential biases in the review process</h3> <p>We strictly followed our published protocol to reduce the risk of bias in the conduct of this review. </p> <p>We performed a comprehensive search in multiple databases, trial registries and other sources to reduce the risk of meta‐bias in our review. We did not restrict the searches or inclusion of studies on the basis of language of publication. Thirty‐eight studies were written in a language other than English. We incorporated three additional authors (JHJ, SI, YX) who helped in the process of developing and writing this review by reading and processing the articles in Korean, Russian and Chinese. However, the assessment of the individual studies was done by a single author and this could have introduced errors in the process of developing the judgements for risk of bias and data extraction. We tried to minimise these errors by using computer‐assisted translation and thorough discussion of the extracted data with our co‐authors. </p> <p>We were unable to retrieve some of the studies on traditional Chinese medicine (TCM) published in some Chinese journals (available at the China National Knowledge Infrastructure database) that were included in other reviews that searched Chinese databases (see <a href="#CD012552-sec-0250">Agreements and disagreements with other studies or reviews</a>). Should we find the reports of these studies, we will evaluate them for inclusion in updates of this review, since we have no clear information about their eligibility. We note, however, that the reported results of these studies in the corresponding reviews are consistent with our findings. </p> <p>We contacted study authors on multiple occasions with a variable rate of response. However, we acknowledge that many of the ratings of 'unclear' risk of bias were due to limitations in the report of the studies, rather than a true risk of bias in the conduct of these trials. We also contacted authors in order to obtain missing outcome data (e.g. standard deviation, number of participants, P values, etc.) with a poor response rate in most cases. We nevertheless report all available outcome data under "Studies not included in meta‐analysis or 'Summary of findings' table". </p> <p>We deleted the 'Clinical Phenotyping' item as an intervention in our review, as suggested by a peer reviewer. We acknowledge that this strategy might not constitute in itself an intervention. This change has not affected the results of this review, since we found no trials on this subject. We also modified the presentation of some of the methods in this review (assessment of outcomes and GRADE methods), but this did not affect the results of the review either (see <a href="#CD012552-sec-0271">Differences between protocol and review</a>). </p> <p>We intended to explain the reasons for statistical heterogeneity across studies for many comparisons, but were unable to do so using our predefined and post hoc subgroup analyses. This led to the downgrading of our confidence in the evidence due to inconsistency, according to the GRADE criteria. We acknowledge that there is wide variability in the underlying causes and clinical manifestations of men suffering from this condition across studies, so we believe that there might be other variables that could explain this inconsistency. Given that the underlying cause of CP/CPPS remains unknown and may encompass different pathogenic pathways (<a href="./references#CD012552-bbs2-0169" title="Appiya SantharamM , KhanFU , NaveedM , AliU , AhsanMZ , KhongorzulP , et al. Interventions to chronic prostatitis/Chronic pelvic pain syndrome treatment. Where are we standing and what's next?. European Journal of Pharmacology2019;857:172429. [PUBMED: 31170381] ">Appiya 2019</a>), unless there are clear distinctions of these pathways and different subtypes of CP/CPPS with common aetiologic and prognostic factors, we might expect that these inconsistencies across study populations of the different trials will persist. </p> </section> <section id="CD012552-sec-0250"> <h3 class="title" id="CD012552-sec-0250">Agreements and disagreements with other studies or reviews</h3> <p>We found several systematic reviews addressing interventions for CP/CPPS. These reviews had several methodological limitations: lack of a protocol stating the review methods, insufficiently comprehensive searches, inadequate language restrictions and no integration of the quality of the evidence with the results, for example, by using GRADE methods. </p> <section id="CD012552-sec-0251"> <h4 class="title">Cochrane Reviews</h4> <p>In a previous Cochrane Review on pregabalin for CP/CPPS (<a href="./references#CD012552-bbs2-0164" title="AboumarzoukOM , NelsonRL . Pregabalin for chronic prostatitis. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD009063.pub2] ">Aboumarzouk 2012</a>) the authors included the same trial (<a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. ">Pontari 2010</a>) as ours and reached similar conclusions, but we considered that the included study had low risk of bias, while the previous review considered it to be at high risk of bias. Our judgements are justified in the <a href="./references#CD012552-sec-0279" title="">Characteristics of included studies</a> section. Three systematic reviews (two of them Cochrane Reviews) included both pharmacological and non‐pharmacological interventions (<a href="./references#CD012552-bbs2-0224" title="McNaughton CollinsM , MacDonaldR , WiltTJ . Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. Annals of Internal Medicine2000;133(5):367‐81. ">McNaughton 2000</a>; <a href="./references#CD012552-bbs2-0265" title="McNaughton CollinsM , MacDonaldR , WiltTJ . Interventions for chronic abacterial prostatitis. Cochrane Database of Systematic Reviews1999, Issue 4. [DOI: 10.1002/14651858.CD002080] ">McNaughton Collins 1999</a>; <a href="./references#CD012552-bbs2-0225" title="McNaughtonC O , WiltT . Allopurinol for chronic prostatitis. Cochrane Database of Systematic Reviews2002, Issue 4. [DOI: 10.1002/14651858.CD001041] ">McNaughton 2002</a>). We included some of the trials covered in these reviews. The findings on the effectiveness and the limitations of the quality of evidence were similar, but most of the included studies were from before 1999, when the Research Consensus defined the latest criteria for this condition (<a href="./references#CD012552-bbs2-0232" title="NybergLM , KriegerJN , NickelJC . National Institutes of Health classification of chronic prostatitis. In: NickelJC editor(s). Textbook of Prostatitis. London: CRC Press, 1999. ">Nyberg 1999</a>). For this reason, we performed a sensitivity analysis analysing this effect, as suggested by a peer reviewer of our previous review (<a href="./references#CD012552-bbs2-0191" title="FrancoJV , TurkT , JungJH , XiaoYT , IakhnoS , GarroteV , et al. Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database of Systematic Reviews2018, Issue 5. [DOI: 10.1002/14651858.CD012551.pub3] ">Franco 2018</a>). </p> </section> <section id="CD012552-sec-0252"> <h4 class="title">Other reviews</h4> <p>In a comprehensive review, <a href="./references#CD012552-bbs2-0167" title="AnothaisintaweeT , AttiaJ , NickelJC , ThammakraisornS , NumthavajP , McEvoyM , et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta‐analysis. JAMA2011;305(1):78‐86. ">Anothaisintawee 2011</a> evaluated the effects of alpha blockers, antibiotics, anti‐inflammatories, finasteride, phytotherapy, pentosan, pregabalin and combined therapy and included the same trials as our review with similar results; however, this review stated that "the magnitude of apparent benefit with α‐blockers may be distorted by publication bias" which we did not find in our assessment. </p> <p><a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. ">Cai 2017</a> focused on the effects of pollen extract and included animal studies, non‐randomised studies and some of the clinical trials included in this review, with the same results. Two systematic reviews (<a href="./references#CD012552-bbs2-0181" title="CohenJM , FaginAP , HaritonE , NiskaJR , PierceMW , KuriyamaA , et al. Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta‐analysis. PLoS One2012;7(8):e41941. ">Cohen 2012</a>; <a href="./references#CD012552-bbs2-0262" title="YangM , ZhaoX , HouY . Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): A systematic review and meta‐analysis of randomized controlled trials (RCTs). Chinese Journal of Andrology2008;22(4):20‐6. ">Yang 2008</a>) included the trials in this review but were underpowered for some comparisons, such as those including antibiotics and anti‐inflammatories. <a href="./references#CD012552-bbs2-0262" title="YangM , ZhaoX , HouY . Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): A systematic review and meta‐analysis of randomized controlled trials (RCTs). Chinese Journal of Andrology2008;22(4):20‐6. ">Yang 2008</a> included some trials only available at the China National Knowledge Infrastructure (CNKI). </p> <p>A systematic review of TCM for chronic prostatitis (<a href="./references#CD012552-bbs2-0178" title="ChenJ , HuL . Traditional Chinese medicine for the treatment of chronic prostatitis in China: a systematic review and meta‐analysis. Journal of Alternative and Complementary Medicine2006;12(8):763‐9. ">Chen 2006</a>) included nine randomised trials from the CNKI database, none of which we included in this review. They found that there was low‐quality evidence that TCM was equivalent or superior to western therapies, but the meta‐analysis pooled randomised and non‐randomised studies. It is not clear if they included participants with bacterial prostatitis. </p> <p><a href="./references#CD012552-bbs2-0188" title="EricksonBA , SchaefferAJ , VanLeB . Chronic prostatitis. BMJ Clinical Evidence2008;2008:1802. ">Erickson 2008</a> (and its update <a href="./references#CD012552-bbs2-0216" title="LeB , SchaefferAJ . Chronic prostatitis. BMJ Clinical Evidence2011;2011:1802. ">Le 2011</a>) included some of the studies for pharmacological interventions for CP/CPPS. This review stated that 5‐alpha reductase inhibitors, allopurinol, alpha blockers, mepartricin, NSAIDs, pentosan, and quercetin may have little or no beneficial effect for this condition, but with great uncertainties because of the low quality of the body of evidence. While most findings in that review are similar to ours, the authors focused their analysis of alpha blockers on the largest study with low risk of bias. This agrees with our sensitivity analysis in which we found alpha blockers to be ineffective. Two other reviews (<a href="./references#CD012552-bbs2-0217" title="LeeSW , LiongML , YuenKH , LiongYV , KriegerJN . Chronic prostatitis/chronic pelvic pain syndrome: role of alpha blocker therapy. Urology International2007;78(2):97‐105. ">Lee 2007</a>; <a href="./references#CD012552-bbs2-0261" title="YangG , WeiQ , LiH , YangY , ZhangS , DongQ . The effect of alpha‐adrenergic antagonists in chronic prostatitis/chronic pelvic pain syndrome: a meta‐analysis of randomized controlled trials. Journal of Andrology2006;27(6):847‐52. ">Yang 2006</a>) assessed the effect of alpha blockers, but their assessments of study quality were limited. </p> <p>A systematic review with a network meta‐analysis (<a href="./references#CD012552-bbs2-0239" title="QinZ , WuJ , ZhouJ , LiuZ . Systematic review of acupuncture for chronic prostatitis/chronic pelvic pain syndrome. Medicine2016;95(11):e3095. [PUBMED: 26986148] ">Qin 2016</a>) assessed the effects of acupuncture, alpha blockers, antibiotics and combination therapy, including the same trials as this review with similar findings on effectiveness. The surface under the cumulative ranking (SUCRA) plot revealed interesting findings comparing non‐pharmacological therapies and pharmacological therapies, favouring acupuncture and electroacupuncture. Another review using network meta‐analysis (<a href="./references#CD012552-bbs2-0254" title="ThakkinstianA , AttiaJ , AnothaisintaweeT , NickelJC . Alpha‐blockers, antibiotics and anti‐inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU International2012;110(7):1014‐22. ">Thakkinstian 2012</a>) also had similar findings but the authors reflected that "results are discrepant between the analyses of symptom scores and treatment responsiveness". We believe that this relates to the fact that difference symptom scores require smaller sample sizes than measurements of treatment effects for dichotomous outcomes. This is why most analyses for 'responders' were downgraded due to imprecision. </p> <p><a href="./references#CD012552-bbs2-0222" title="MagistroG , WagenlehnerFM , GrabeM , WeidnerW , StiefCG , NickelJC . Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. European Urology2016;69(2):286‐97. ">Magistro 2016</a> included similar trials but with a narrower scope, and the authors stated "Our current understanding of the pathophysiology underlying CP/CPPS resulting in this highly variable syndrome does not speak in favour of a monotherapy for management". </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012552-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012552-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012552-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012552-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Alpha‐blockers versus placebo, outcome: 1.1 Prostatitis symptoms: short term." data-id="CD012552-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Alpha‐blockers versus placebo, outcome: 1.1 Prostatitis symptoms: short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Alpha‐blockers versus placebo, outcome: 1.8 Adverse events." data-id="CD012552-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Alpha‐blockers versus placebo, outcome: 1.8 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 1 Prostatitis symptoms: short term." data-id="CD012552-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 1 Prostatitis symptoms: short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 2 Prostatitis symptoms: pain." data-id="CD012552-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 2 Prostatitis symptoms: pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 3 Prostatitis symptoms: urinary." data-id="CD012552-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 3 Prostatitis symptoms: urinary.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 4 Prostatitis symptoms: quality of life." data-id="CD012552-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 4 Prostatitis symptoms: quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 5 Prostatitis symptoms: responders rate." data-id="CD012552-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 5 Prostatitis symptoms: responders rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 6 Prostatitis symptoms: long term." data-id="CD012552-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 6 Prostatitis symptoms: long term.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 7 Prostatitis symptoms: long term." data-id="CD012552-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 7 Prostatitis symptoms: long term.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-08.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 8 Adverse events." data-id="CD012552-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 8 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 9 Sexual dysfunction." data-id="CD012552-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 9 Sexual dysfunction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 10 Quality of life: mental." data-id="CD012552-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 10 Quality of life: mental.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 11 Quality of life: physical." data-id="CD012552-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 11 Quality of life: physical.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 12 Anxiety and depression." data-id="CD012552-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 12 Anxiety and depression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 13 Urinary symptoms." data-id="CD012552-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 13 Urinary symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 14 Prostatitis symptoms: responders rate (sensitivity analysis according to risk of bias)." data-id="CD012552-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 14 Prostatitis symptoms: responders rate (sensitivity analysis according to risk of bias). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 15 Adverse events (sensitivity analysis according to risk of bias)." data-id="CD012552-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 15 Adverse events (sensitivity analysis according to risk of bias). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 16 Prostatitis symptoms: short term (subgroup analysis by co‐interventions)." data-id="CD012552-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 16 Prostatitis symptoms: short term (subgroup analysis by co‐interventions). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alpha‐blockers versus placebo, Outcome 17 Adverse events (subgroup analysis by co‐interventions)." data-id="CD012552-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Alpha‐blockers versus placebo, Outcome 17 Adverse events (subgroup analysis by co‐interventions). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 5 alpha reductase inhibitors versus placebo, Outcome 1 Prostatitis symptoms." data-id="CD012552-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 5 alpha reductase inhibitors versus placebo, Outcome 1 Prostatitis symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 5 alpha reductase inhibitors versus placebo, Outcome 2 Prostatitis symptoms: responder rate." data-id="CD012552-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 5 alpha reductase inhibitors versus placebo, Outcome 2 Prostatitis symptoms: responder rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 5 alpha reductase inhibitors versus placebo, Outcome 3 Adverse events." data-id="CD012552-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 5 alpha reductase inhibitors versus placebo, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 1 Prostatitis symptoms." data-id="CD012552-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 1 Prostatitis symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 2 Prostatitis symptoms: pain." data-id="CD012552-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 2 Prostatitis symptoms: pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 3 Prostatitis symptoms: urinary." data-id="CD012552-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 3 Prostatitis symptoms: urinary.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 4 Prostatitis symptoms: quality of life." data-id="CD012552-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 4 Prostatitis symptoms: quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 5 Prostatitis symptoms: responder rate." data-id="CD012552-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 5 Prostatitis symptoms: responder rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 6 Adverse events." data-id="CD012552-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 7 Sexual dysfunction." data-id="CD012552-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 7 Sexual dysfunction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 8 Quality of life: mental." data-id="CD012552-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 8 Quality of life: mental.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 9 Quality of life: physical." data-id="CD012552-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 9 Quality of life: physical.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 10 Urinary symptoms." data-id="CD012552-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 10 Urinary symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 11 Prostatitis symptoms: subgroup analysis (age)." data-id="CD012552-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 11 Prostatitis symptoms: subgroup analysis (age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 12 Adverse events: subgroup analysis (age)." data-id="CD012552-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 12 Adverse events: subgroup analysis (age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 13 Prostatitis symptoms: subgroup analysis (co‐interventions)." data-id="CD012552-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 13 Prostatitis symptoms: subgroup analysis (co‐interventions). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antibiotic therapy versus placebo, Outcome 14 Adverse events: subgroup analysis (co‐interventions)." data-id="CD012552-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Antibiotic therapy versus placebo, Outcome 14 Adverse events: subgroup analysis (co‐interventions). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiinflammatories versus placebo, Outcome 1 Prostatitis symptoms." data-id="CD012552-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Antiinflammatories versus placebo, Outcome 1 Prostatitis symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiinflammatories versus placebo, Outcome 2 Prostatitis symptoms: pain." data-id="CD012552-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Antiinflammatories versus placebo, Outcome 2 Prostatitis symptoms: pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiinflammatories versus placebo, Outcome 3 Prostatitis symptoms: urinary." data-id="CD012552-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Antiinflammatories versus placebo, Outcome 3 Prostatitis symptoms: urinary.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiinflammatories versus placebo, Outcome 4 Prostatitis symptoms: quality of life." data-id="CD012552-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Antiinflammatories versus placebo, Outcome 4 Prostatitis symptoms: quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiinflammatories versus placebo, Outcome 5 Prostatitis symptoms: responder rate." data-id="CD012552-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Antiinflammatories versus placebo, Outcome 5 Prostatitis symptoms: responder rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiinflammatories versus placebo, Outcome 6 Prostatitis symptoms: long term." data-id="CD012552-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Antiinflammatories versus placebo, Outcome 6 Prostatitis symptoms: long term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiinflammatories versus placebo, Outcome 7 Adverse events." data-id="CD012552-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Antiinflammatories versus placebo, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiinflammatories versus placebo, Outcome 8 Urinary symptoms." data-id="CD012552-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Antiinflammatories versus placebo, Outcome 8 Urinary symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiinflammatories versus placebo, Outcome 9 Prostatitis symptoms: subgroup analysis (co‐interventions)." data-id="CD012552-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Antiinflammatories versus placebo, Outcome 9 Prostatitis symptoms: subgroup analysis (co‐interventions). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antiinflammatories versus placebo, Outcome 10 Adverse events." data-id="CD012552-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Antiinflammatories versus placebo, Outcome 10 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Phytotherapy versus placebo, Outcome 1 Prostatitis symptoms." data-id="CD012552-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Phytotherapy versus placebo, Outcome 1 Prostatitis symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Phytotherapy versus placebo, Outcome 2 Prostatitis symptoms: pain subscore." data-id="CD012552-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Phytotherapy versus placebo, Outcome 2 Prostatitis symptoms: pain subscore.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Phytotherapy versus placebo, Outcome 3 Prostatitis symptoms: urinary symptoms." data-id="CD012552-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Phytotherapy versus placebo, Outcome 3 Prostatitis symptoms: urinary symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Phytotherapy versus placebo, Outcome 4 Prostatitis symptoms: quality of life." data-id="CD012552-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Phytotherapy versus placebo, Outcome 4 Prostatitis symptoms: quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Phytotherapy versus placebo, Outcome 5 Prostatitis symptoms: responder rate." data-id="CD012552-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Phytotherapy versus placebo, Outcome 5 Prostatitis symptoms: responder rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Phytotherapy versus placebo, Outcome 6 Adverse events." data-id="CD012552-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Phytotherapy versus placebo, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Phytotherapy versus placebo, Outcome 7 Sexual dysfunction." data-id="CD012552-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Phytotherapy versus placebo, Outcome 7 Sexual dysfunction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Phytotherapy versus placebo, Outcome 8 Urinary symptoms." data-id="CD012552-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Phytotherapy versus placebo, Outcome 8 Urinary symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Phytotherapy versus placebo, Outcome 9 Prostatitis symptoms: subgroup analysis (co‐interventions)." data-id="CD012552-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Phytotherapy versus placebo, Outcome 9 Prostatitis symptoms: subgroup analysis (co‐interventions). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Phytotherapy versus placebo, Outcome 10 Adverse events: subgroup analysis (co‐interventions)." data-id="CD012552-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Phytotherapy versus placebo, Outcome 10 Adverse events: subgroup analysis (co‐interventions). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Botulinum toxin A versus placebo, Outcome 1 Prostatitis symptoms." data-id="CD012552-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Botulinum toxin A versus placebo, Outcome 1 Prostatitis symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Botulinum toxin A versus placebo, Outcome 2 Prostatitis symptoms: pain subscore." data-id="CD012552-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Botulinum toxin A versus placebo, Outcome 2 Prostatitis symptoms: pain subscore. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Botulinum toxin A versus placebo, Outcome 3 Prostatitis symptoms: urinary subscore." data-id="CD012552-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Botulinum toxin A versus placebo, Outcome 3 Prostatitis symptoms: urinary subscore. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Botulinum toxin A versus placebo, Outcome 4 Prostatitis symptoms: quality of life." data-id="CD012552-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Botulinum toxin A versus placebo, Outcome 4 Prostatitis symptoms: quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Botulinum toxin A versus placebo, Outcome 5 Adverse events." data-id="CD012552-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Botulinum toxin A versus placebo, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Botulinum toxin A versus placebo, Outcome 6 Urinary symptoms." data-id="CD012552-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Botulinum toxin A versus placebo, Outcome 6 Urinary symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Allopurinol versus placebo, Outcome 1 Prostatitis symptoms." data-id="CD012552-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Allopurinol versus placebo, Outcome 1 Prostatitis symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Allopurinol versus placebo, Outcome 2 Prostatitis symptoms: pain subscore." data-id="CD012552-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Allopurinol versus placebo, Outcome 2 Prostatitis symptoms: pain subscore.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Allopurinol versus placebo, Outcome 3 Prostatitis symptoms: urinary subscore." data-id="CD012552-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Allopurinol versus placebo, Outcome 3 Prostatitis symptoms: urinary subscore.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 1 Prostatitis symptoms." data-id="CD012552-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 1 Prostatitis symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 2 Prostatitis symptoms: pain subscore." data-id="CD012552-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 2 Prostatitis symptoms: pain subscore. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 3 Prostatitis symptoms: urinary subscore." data-id="CD012552-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 3 Prostatitis symptoms: urinary subscore. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 4 Prostatitis symptoms: quality of life." data-id="CD012552-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 4 Prostatitis symptoms: quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 5 Adverse events." data-id="CD012552-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 5 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 6 Sexual dysfunction." data-id="CD012552-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 6 Sexual dysfunction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 7 Anxiety and depression: anxiety." data-id="CD012552-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 7 Anxiety and depression: anxiety. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012552-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/urn:x-wiley:14651858:media:CD012552:CD012552-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_t/tCD012552-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 8 Anxiety and depression: depression." data-id="CD012552-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Traditional chinese medicine versus placebo or usual care, Outcome 8 Anxiety and depression: depression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/media/CDSR/CD012552/image_n/nCD012552-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012552-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Alpha blockers compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Alpha blockers compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre and multicentre studies in Bosnia and Herzegovina, Canada, China, USA, Finland, Germany, Malaysia, Russia, South Korea and Turkey<br/> <b>Intervention:</b> alpha blockers (terazosin, doxazosin, phenoxybenzamine, tamsulosin, alfuzosin, silodosin)<br/> <b>Comparison:</b> placebo or no intervention </p> <p>Some comparisons included alpha blockers as add‐on therapy to medical therapy (e.g. antibiotics) versus medical therapy alone. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with alpha‐blockers</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: range 6 weeks to 6 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1524<br/> (18 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ranged from 12.1 to 24.14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.01 lower<br/> (7.41 lower to 2.61 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>253</p> <p>(4 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The mean prostatitis symptoms ranged from 18.7 to 22.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 5.6 lower<br/> (10.89 lower to 0.82 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostatitis symptoms: 'responders'<br/> Number of participants with a 25% or 6‐point decrease in NIH‐CPSI scores<br/> Follow‐up: range 6 weeks to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>721<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.23<br/> (0.94 to 1.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 more per 1000<br/> (29 fewer to 291 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> <p>Any adverse event<br/> Follow‐up: range 6 weeks to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1588<br/> (19 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.60<br/> (1.09 to 2.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 more per 1000<br/> (8 more to 126 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction<br/> Assessed with: International Index of Erectile Function Scale. Benefit is indicated by higher scores<br/> Scale from: 5 to 25<br/> Follow‐up: range 6 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>452<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual dysfunction ranged from 16.1 to 18.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.26 higher<br/> (1.13 lower to 1.65 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> Assessed with: Short Form‐12 Health Status Questionnaire. Benefit is indicated by higher scores. The effect is reported for mental domain.<br/> Scale from: 0 to 100<br/> Follow‐up: range 6 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>421<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life ranged from 41 to 46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.15 higher<br/> (2.63 lower to 2.92 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression<br/> Assessed with: Hospital Anxiety and Depression Scale. Benefit is indicated by lower scores<br/> Scale from: 0 to 21<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety and depression was 12.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.1 lower<br/> (2.54 lower to 0.34 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval;<b>MD:</b> Mean difference; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to study limitations: unclear or high risk of bias in most domains in most studies.<br/> <sup>b</sup>Downgraded one level due to inconsistency: substantial or considerable heterogeneity.<br/> <sup>c</sup>Downgraded one level due to imprecision: confidence interval crosses the assumed threshold for the minimal clinically important difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Alpha blockers compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012552-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">5‐alpha reductase inhibitors compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>5‐alpha reductase inhibitors compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre studies in Finland and USA<br/> <b>Intervention:</b> finasteride<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with 5 alpha reductase inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: 6 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms was 21.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.6 lower<br/> (5.43 lower to 3.77 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostatitis symptoms: 'responders'<br/> Number of participants with a 25% decrease in NIH‐CPSI scores<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>64<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.13<br/> (0.82 to 5.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 more per 1000<br/> (27 fewer to 686 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>105<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/> (0.33 to 2.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 fewer per 1000<br/> (109 fewer to 212 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to high risk of bias: unclear or high risk of bias in most domains in the main study of this comparison.<br/> <sup>b</sup>Downgraded one level due to imprecision: confidence interval includes appreciable benefits and harms. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">5‐alpha reductase inhibitors compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012552-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antibiotic therapy compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Antibiotic therapy compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre and multicentre studies in USA, Canada, South Korea, Bosnia and Herzegovina and China<br/> <b>Intervention:</b> antibiotic therapy (ciprofloxacin or levofloxacin)<br/> <b>Comparison:</b> placebo </p> <p>Some comparisons included antibiotics as add‐on therapy to medical therapy (e.g. alpha blockers) versus medical therapy alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with antibiotic therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: range 6 weeks to 3 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>372<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ranged from 8.6 to 18.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.43 lower<br/> (4.72 lower to 0.15 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostatitis symptoms: 'responders'<br/> Number of participants with a 25% or 6‐point decrease in NIH‐CPSI scores<br/> Follo‐up: range 6 weeks to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>178<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/> (0.73 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 more per 1000<br/> (77 fewer to 211 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: range 3 weeks to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>336<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/> (0.66 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 more per 1000<br/> (72 fewer to 117 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction<br/> Assessed with: International Index of Erectile Function Scale. Benefit is indicated by higher scores<br/> Scale from: 5 to 25<br/> Follow‐up: 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual dysfunction was 16.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.4 higher<br/> (1.59 lower to 2.39 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> Assessed with: SF‐12 Health Status Questionnaire. Benefit is indicated by higher scores. The effect is reported for mental domain<br/> Scale from: 0 to 100<br/> Follow up: 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was 44.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.9 lower<br/> (7.94 lower to 0.14 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to inconsistency: statistical heterogeneity 75%.<br/> <sup>b</sup>Downgraded one level due to high risk of bias: unclear or high risk of bias in most domains in the main study of this comparison.<br/> <sup>c</sup>Downgraded one level due to imprecision: confidence interval crosses the threshold for the minimal clinically important difference.<br/> <sup>d</sup>We did not downgrade for risk of bias since the main study contributing to this estimate has low risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antibiotic therapy compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012552-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Anti‐inflammatories compared to control for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Anti‐inflammatories compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre and multicentre studies in UK, South Korea, Turkey, China<br/> <b>Intervention:</b> anti‐inflammatories (non‐steroidal anti‐inflammatories, corticosteroids, antileukotrienes, tiocolchicoside)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with anti‐inflammatories</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: range 6 weeks to 6 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>585<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ranged from 8.6 to 19.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.5 lower<br/> (3.74 lower to 1.26 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostatitis symptoms: 'responders'<br/> Number of participants with a 25% or 6‐point decrease in NIH‐CPSI scores<br/> Follow‐up: range 8 weeks to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>82<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.44<br/> (0.68 to 3.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 more per 1000<br/> (29 fewer to 185 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: range 4 weeks to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>540<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.27<br/> (0.81 to 2.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 more per 1000<br/> (19 fewer to 98 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to high risk of bias: unclear or high risk of bias in most domains in most studies.<br/> <sup>b</sup>Downgraded one level due to inconsistency: high statistical heterogeneity (&gt; 80%).<br/> <sup>c</sup>Downgraded one level due to imprecision: confidence interval crosses the threshold for the minimal clinically important difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Anti‐inflammatories compared to control for chronic prostatitis/chronic pelvic pain syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012552-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Phytotherapy compared to placebo or other agents for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Phytotherapy compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre and multicentre studies in Russia, USA, Italy, South Korea, Germany and China<br/> <b>Intervention:</b> phytotherapeutics agents (pollen extract, calendula‐curcuma, Prolit Super Septo®, flavonoids and cranberries)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or other agents</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with phytotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: range 1 month to 3 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ranged from 10.3 to 14.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.02 lower<br/> (6.81 lower to 3.23 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostatitis symptoms: 'responders'<br/> Number of participants with a 25% or 6‐point decrease in NIH‐CPSI scores<br/> Follow‐up: range 1 month to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>224<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.78<br/> (1.25 to 2.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>384 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299 more per 1000<br/> (96 more to 584 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: range 1 month to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>540<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.54 to 2.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 more per 1000<br/> (19 fewer to 56 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction<br/> Assessed with: International Index of Erectile Function Scale Benefit is indicated by higher scores<br/> Scale from: 5 to 25<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual dysfunction was 18.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.5 higher<br/> (2.67 higher to 4.33 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to high risk of bias: unclear or high risk of bias in most domains in most studies.<br/> <sup>b</sup>Downgraded one level due to imprecision: confidence interval crosses the threshold for the minimal clinically important difference.<br/> <sup>c</sup>Downgraded one level due to imprecision: few events, resulting in a confidence interval that includes appreciable benefits and harms. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Phytotherapy compared to placebo or other agents for chronic prostatitis/chronic pelvic pain syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012552-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Botulinum toxin A compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Botulinum toxin A compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient,outpatient, single‐centre studies in Iran and USA<br/> <b>Intervention:</b> botulinum toxin A injection (intraprostatic or pelvic floor muscles)<br/> <b>Comparison:</b> sham procedure (saline injection) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with botulinum toxin A</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms</p> <p><b>Subgroup</b>: Intraprostatic injection, participants age &gt; 50 years old, basal NIH‐CPSI score &gt; 30 </p> <p>Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: 6 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ‐ Intraprostatic injection was 36.37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 25.8 lower<br/> (30.15 lower to 21.45 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms</p> <p><b>Subgroup</b>: Pelvic floor muscles injection, participants age &lt; 50 years old, basal NIH‐CPSI score &lt; 30<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ‐ Pelvic floor muscles injection was 27.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.6 lower<br/> (5.59 lower to 0.39 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Assessed with: e.g.: haematuria<br/> Follow‐up: range 1 month to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>89<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.00<br/> (0.25 to 99.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 more per 1000<br/> (16 fewer to 2.151 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to unclear risk of bias (random sequence generation).<br/> <sup>b</sup>Downgraded one level due to imprecision: small sample size resulting in wide confidence interval.<br/> <sup>c</sup>Downgraded one level due to high risks of performance and detection bias,<br/> <sup>d</sup>Downgraded one level due to high risk of bias: unclear or high risks of bias in some domains.<br/> <sup>e</sup>Downgraded one level due to imprecision: few events. The number of adverse events was zero in the control group, but one case was imputed in this group in order to obtain the relative estimates. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Botulinum toxin A compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012552-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Allopurinol compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Allopurinol compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre studies in Sweden and Iran<br/> <b>Intervention:</b> allopurinol<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with allopurinol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: 3 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms was 17.21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.21 lower<br/> (4.48 lower to 4.06 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p>Follow‐up: 3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No adverse events were observed in the included studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to imprecision: confidence interval includes appreciable benefits and harms.˜<br/> <sup>b</sup>Downgraded one level due to high risk of bias: unclear or high risks of bias in the main study of this comparison.<br/> <sup>c</sup>Downgraded one level due to imprecision: few events (zero events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Allopurinol compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012552-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Traditional Chinese Medicine compared to placebo or usual care for chronic prostatitis/chronic pelvic pain syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Traditional Chinese Medicine compared to placebo for chronic prostatitis/chronic pelvic pain syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with chronic prostatitis/chronic pelvic pain syndrome<br/> <b>Setting:</b> outpatient, single‐centre studies in China<br/> <b>Intervention:</b> Traditional Chinese Medicine (herbs decoctions, capsules and suppositories)<br/> <b>Comparison:</b> placebo </p> <p>Some comparisons included antibiotics, alpha blockers and other Western medications as co‐interventions </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or usual care</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with Traditional Chinese medicine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostatitis symptoms<br/> Assessed with: NIH‐CPSI score. Benefit is indicated by lower scores<br/> Scale from: 0 to 43<br/> Follow‐up: range 2 weeks to 2 months </p> <p><i>A decrease of 25% or 6 points is considered an important improvement</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>835<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean prostatitis symptoms ranged from 11.17 to 15.02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.13 lower<br/> (4.99 lower to 1.28 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: range 4 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>584<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.34<br/> (0.22 to 8.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 more per 1000<br/> (23 fewer to 203 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual dysfunction<br/> Assessed with: International Index of Erectile Function Scale. Benefit is indicated by higher scores<br/> Scale from: 5 to 25<br/> Follow‐up: 2 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual dysfunction was 14.93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.27 higher<br/> (1.17 lower to 1.71 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression: anxiety<br/> Assessed with: Hamilton Anxiety Rating Scale (HAM‐A)<br/> Scale from: 0 to 56<br/> Follow‐up: 2 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety and depression: anxiety was 23.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.5 lower<br/> (11.7 lower to 7.3 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety and depression: depression<br/> Assessed with: Hamilton Depression Rating Scale (HAM‐D)<br/> Scale from: 0 to 54<br/> Follow‐up: 2 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety and depression: depression was 24.07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 7.84 lower<br/> (10.71 lower to 4.97 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>NIH‐CPSI:</b> National Institutes of Health ‐ Chronic Prostatitis Symptom Index; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to inconsistency: high statistical heterogeneity (&gt; 80%). Some of this inconsistency might be explained by the differences between the interventions under this comparison.<br/> <sup>b</sup>Downgraded one level due to high risk of bias: unclear or high risks of bias in most domains in most studies.<br/> <sup>c</sup>Downgraded one level due to imprecision: few events, resulting in a confidence interval that includes appreciable benefits and harms.<br/> <sup>d</sup>Downgraded one level due to imprecision: small sample size resulting in wide confidence interval that crosses the threshold for the minimal clinically important difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Traditional Chinese Medicine compared to placebo or usual care for chronic prostatitis/chronic pelvic pain syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012552-tbl-0009"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of the interventions by study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose for comparison</b> </p> <p><b>Co‐interventions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. "><b>Abdalla 2018</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tadalafil study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both arms received levofloxacin 500 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] "><b>Alexander 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciprofloxacin + tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciprofloxacin 500 mg twice daily, tamsulosin 0.4 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Ciprofloxacin</p> <p>C2: Tamsulosin</p> <p>C3: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>They used double placebo (factorial design)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. "><b>Apolikhin 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cernilton® (pollen extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 pills, 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cernilton® (pollen extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pill, 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. "><b>Bates 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg once daily and then tapered to 5 mg in 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. "><b>Breusov 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prolit super (plant extracts)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 capsules a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0006" title="CaiT , WagenlehnerFM , LucianiLG , TiscioneD , MalossiniG , VerzeP , et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine2014;8(4):1032‐8. "><b>Cai 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deprox ® (pollen extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 capsules a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg three times daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. "><b>Cai 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deprox ® (pollen extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 capsules a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromelain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 tablets a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0008" title="CavalliniG . Mepartricin in the treatment of male pelvic pain syndrome secondary to chronic nonbacterial prostatitis/prostatodynia. Minerva Urologica e Nefrologica [Italian Journal of Urology and Nephrology]2001;53(1):13‐7. "><b>Cavallini 2001</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepatricin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin C (as placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. "><b>Cha 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfusozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Terpene mixture 1 capsule three times a day</p> <p>C2: Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received levofloxacin 300 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. "><b>Cheah 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Titrated from 1 to 5 mg daily in two weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. "><b>Chen 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qiantongding decoction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mix of herbal medications (oral infusion), twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XiaoYanTong</p> <p>(Indometacin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg tablet three times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. "><b>Chen 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0013" title="ChengC‐H , LaiY‐W , HsuehT‐Y , ChiuY‐C , ChenS‐S , LuS‐H , et al. The efficacy of levofloxacin or ciprofloxacin in the management of chronic non‐bacterial prostatitis. International Journal of Urology2010;17:A335. LaiY , ChengC , HsuehT , ChiuY , ChenS , ChiuA . The efficacy of levofloxacin or ciprofloxacin in management of chronic non‐bacterial prostatitis. Urology2012;80(3):S154. "><b>Cheng 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Ciprofloxacin 500 mg daily</p> <p>C2: Levofloxacin 1 g daily</p> <p>C3: No antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. "><b>Choe 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Ciprofloxacin 1g daily</p> <p>C2: Aceclofenac 200 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0015" title="ChurakovAA , KolesnikovAI , BliumbergBI , PopkovVM . Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction. Urologiia2012;5:64‐6, 68. "><b>Churakov 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cytoflavin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 ml intravenously for 10 days, then 4 pills a day for 20 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cytoflavin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both arms received:</p> <p>α‐blockers ‐ 1 month</p> <p>anti‐inflammatory drugs – 2 weeks</p> <p>prostate massage and vibrovacuum fallostimulation – 10 times</p> <p>antibiotics – 10 day<i>s</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0016" title="DeRoseAF , GalloF , GiglioM , CarmignaniG . Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo‐controlled trial. Urology2004;63(1):13‐6. DeRoseAF , TraversoP , MontanaroT , CarmignaniG . The role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS): A randomized prospective placebo‐controlled trial. Journal of Urology2010;183(4):e311. "><b>De Rose 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepartricin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg daily for 60 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. "><b>Dunzendorfer 1983</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenoxybenzamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. "><b>Elist 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pollen extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 mg in Prolit® capsules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0019" title="ElshawafH . Chemodenervation of the rhabdosphincter (EUS) alone versus combined injection of both EUS &amp; prostate in patients with prostatitis and chronic pelvic pain syndrome type III. Prospective randomized controlled trial. (Abstract number 394). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. "><b>Elshawaf 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 units applied in the external urethral sphincter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 units applied to the prostate and sphincter</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. "><b>Erdemir 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quinolone + ibuprofen + terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg, 400 mg and 5 mg respectively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Terazosin 5 mg</p> <p>C2: Quinolone 500 mg + ibuprofen 400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. "><b>Falahatkar 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 units applied to the prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0022" title="GiammussoB , DiMauroR , BernardiniR . The efficacy of an association of palmitoylethanolamide and alpha‐lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Archivio Italiano di Urologia e Andrologia2017;89(1):17‐21. "><b>Giammusso 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palmitoylethanolamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg in Penease® capsules twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serenoa repens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 mg 1 capsule daily</p> <p>[All] "patients received a full course of pharmacological therapy" before allocation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. "><b>Giannantoni 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duloxetin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 mg, escalated during the first 15 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐interventions included Serenoa repens and tamsulosin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. "><b>Goldmeier 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zafirlukast</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> <p>Both arms received doxycycline 100 mg twice daily for 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. "><b>Gottsch 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 units applied to pelvic floor muscles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0026" title="GülO , ErogluM , OzokU . Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. International Urology and Nephrology2001;32(3):433‐6. "><b>Gül 2001</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terasozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. "><b>Hu 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bazheng decoction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320 mL daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Co‐intervention: tamsulosin 0.2 mg a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. "><b>Iwamura 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pollen extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 mg 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eviprostat® (herbal extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 capsule 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. "><b>Jeong 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Doxazosin</p> <p>C2: Levofloxacin + Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. "><b>Jiang 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Desketoprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5 mg 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Indomethacin 25 mg 3 times a day</p> <p>C2: Only co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received terazosin 2 mg daily for 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. "><b>Jung 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 ‐ 4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants received levofloxacin 300 mg/day, tamiflunate 3 tablets/day for 12 weeks </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0032" title="KaplanSA , VolpeMA , TeAE . A prospective, 1‐year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(1):284‐8. "><b>Kaplan 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serenoa repens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finasteride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. "><b>Kim 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Ibuprofen + Misoprostol</p> <p>C2: Tamsulosin + ibuprofen + misoprostol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg ibuprofen three 3 times a day, 300 mcg misoprostol 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. "><b>Kim 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received gatifloxacin 200 mg twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. "><b>Kim 2011a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Diclofenac</p> <p>C2: Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg twice daily</p> <p>Both groups received tamsulosin 0.2 mg daily for 12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. "><b>Kim 2011b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received ciprofloxacin 1000 mg daily for 8 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. "><b>Kong 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mirodenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 500 mg daily for 6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. "><b>Kulovac 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Ciprofloxacin</p> <p>C2: Doxazosin + ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg twice a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. "><b>Lacquaniti 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Tamsulosin</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. "><b>Lee 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0041" title="LeeCB , HaUS , LeeSJ , KimSW , ChoYH . Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World Journal of Urology2006;24(1):55‐60. "><b>Lee 2006a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terpene mixture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rowatinex® 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. "><b>Leskinen 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finasteride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> <p>Ketoprofene was provided to both group for pain relief</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. "><b>Li 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QianLieAnShuan (Prostat, 前列安栓)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal suppository each night</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo suppository</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. "><b>Li 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiaoshen Tonglin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mix of herbal medications (oral 150 ml infusion) daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. "><b>Li 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qianlieping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 g herbal capsule 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Tamsulosin</p> <p>C2: Qianlieping + Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. "><b>Lin 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg daily before sexual intercourse (from week 5 onwards)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received traditional Chinese medicine</p> <p>(Huafenqinutang oral dose for 8 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. "><b>Lu 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenoxybenzamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Flavoxate</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. "><b>Macchione 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deprox ® (pollen extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 tablets a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serenoa repens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0049" title="MauriziA , DeLucaF , ZanghiA , ManziE , LeonardoC , GuidottiM , et al. The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica2019;90(4):260‐4. [PUBMED: 30655636] "><b>Maurizi 2019</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deprox ® (pollen extract)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 tablets a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quercetin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mg twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. "><b>Mehik 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfusozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> <p>Both groups "were allowed to take analgesics (ibuprofen, ketoprofen, diclofenac)"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0051" title="MoKI , LeeKS , KimDG . Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2006;47(5):536‐40. "><b>Mo 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfusozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 100mg 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. "><b>Morgia 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Profluss ® (Serenoa repens + lycopene + seleniated sodium)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serenoa repens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. "><b>Morgia 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Curcumin‐calendula</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>350 mg curcumin and 80 mg calendula in rectal suppositories daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. "><b>Nickel 2003a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. "><b>Nickel 2003b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rofecoxib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg and 25 mg doses daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Rofecoxib</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants had the same regimen</p> <p>All participants were permitted to take up to 2.6 g of paracetamol for rescue analgesia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0056" title="NickelJC , DowneyJ , PontariMA , ShoskesD A , ZeitlinSI . A randomized placebo‐controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU International2004;93(7):991‐5. "><b>Nickel 2004a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finasteride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. "><b>Nickel 2004b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0058" title="NickelJC , ForrestJB , TomeraK , Hernandez‐GraulauJ , MoonTD , SchaefferAJ , et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. Journal of Urology2005;173(4):1252‐5. "><b>Nickel 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pentosan polysulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. "><b>Nickel 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfusozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. "><b>Nickel 2011a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Silodosin (4 mg)</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. "><b>Nickel 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanezumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg intravenous single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. "><b>Okada 1985</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PPC (aminoacid preparation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 capsules a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pollen extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. "><b>Park 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cranberry juice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 ml twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants underwent an 8 week‐run‐in period with levofloxacin 100mg 3 times a day, NSAID, alpha blocker, behaviour therapy, and hot sitz bath; for non‐responder, 4 additional weeks of same treatments were added </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. "><b>Park 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 500 mg daily for 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0065" title="ParkHJ , ParkNC , MoonDG , KimTN , NamJK , ParkSW . Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction. European Urology Supplements2017;16(3):e453. "><b>Park 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 500 mg daily for six weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. "><b>Peng 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antiphlogistic agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixture of herbal remedies 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Antiphlogistic + enema</p> <p>C2: Antiphlogistic + suppository</p> <p>C3: Antiphlogistic + "rectal fumigation"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. "><b>Persson 1996</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allopurinol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Allopurinol 300 mg + placebo</p> <p>C2: Placebo twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received the same number of pills</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. "><b>Pontari 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pregabalin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Titrated from 150 to 600 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0069" title="ReissiglA , DjavanB , PointnerJ . Prospective placebo‐controlled multicenter trial on safety and efficacy of phytotherapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(61):Abstract 233. [MEDLINE: 14665844] "><b>Reissigl 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serenoa repens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No description on dose or regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No description on dose or regimen</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. "><b>Ryu 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfusozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received tosufloxacin 150mg 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. "><b>Shi 1994</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QianLieAnWan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal ball‐shaped formulation, 9g 2 ‐ 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: QianLieKang</p> <p>C2: Pollen extract capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. "><b>Shoskes 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quercetin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. "><b>Singh 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 500 mg for 6 weeks and alfuzosin 10 mg for 6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. "><b>Sivkov 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Titrated to 5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. "><b>Sun 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QianLieAnTong</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal capsule 0.38 g four tables 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No QianLieAnTong</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received terazosin 2 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. "><b>Tan 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QianLieAnShuan (Prostat, 前列安栓)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal suppository each night</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No QuanLieAnShuan (Prostant)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received alpha blockers (tamsulosin or terazosin)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0077" title="TucuV , TasciAI , FazlioluA , OdunctemurA , OzbekE , CekM . Comparison of the efficiency of mono and triple theraphy in chronic pelvic pain syndrome. Turk Urol. Derg.2006;32(3):393‐7. "><b>Tugcu 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiocolchicoside + ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 (sic) and 1200 mg respectively, daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received terazosin 5 mg a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. "><b>Tuğcu 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiocolchicoside + ibuprofen + doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 mg + 400 mg + 4 mg respectively, daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Doxazosin</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Doxazosin 4 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. "><b>Turkington 2002</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluvoxamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. "><b>Wagenlehner 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pollen extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 mg carnitine twice a day, daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> <p>Both groups were pretreated with azithromycin (250 mg every 6 hours for 1 day)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. "><b>Wagenlehner 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐89 (E. coli lysate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg from 18 strains</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> <p>Other medications were allowed in both groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. "><b>Wang 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chuanshentong</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sage and carrot‐family herbal extracts, injected in the prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo injection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen as active treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. "><b>Wang 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Levofloxacin</p> <p>C2: Terazosin + Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levofloxacin dose: 200 mg twice daily</p> <p>Both groups received dietary advice and prostatic massage once a week and were advised to take warm baths </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0084" title="WedrenH . Effects of sodium pentosanpolysulphate on symptoms related to chronic non‐bacterial prostatitis. A double‐blind randomized study. Scandinavian Jpurnal of Urology and Nephrology1987;21(2):81‐8. "><b>Wedren 1987</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pentosan polysulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. "><b>Wu 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Diclofenac</p> <p>C2: Doxazosin + diclofenac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. "><b>Xia 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YuLeShu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal mixture 20 ml 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 0.2g twice a day, doxazosin 2 mg daily, QianLieTongYu 3 times a day, 4 capsules each time and weekly prostate massage </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. "><b>Xu 2000</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pollen extract (普适泰 = 舍尼通)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.375 g 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfamethoxazole 2 tablets, twice daily 10 days, ofloxacin 0.2 g, twice daily 10 days, minocycline 0.1 g twice daily, 10 days, sequentially, repeated monthly for 3 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. "><b>Yang 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 100 mg twice a day for 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0089" title="MinggenY , ZhoudaZ , ZhimingZ , HailiL , ZhenqiangX , ChaoxianZ , et al. Tamsulosin therapy for chronic nonbacterial prostatitis: A randomized double‐blind placebo controlled clinical trial. Chinese Journal of Andrology2010;24(12):32‐5. "><b>Yang 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Tamsulosin</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. "><b>Ye 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pollen extract (普适泰 = 舍尼通)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.375 g twice a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received levofloxacin 100 mg twice a day for 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. "><b>Ye 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Levofloxacin</p> <p>C2: Tamsulosin + levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levofloxacin 0.2 g daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0092" title="YounCW , SonK‐C , ChoiH‐S , KwonDD , ParkK , RyuSB . Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha‐blocker combination therapy for patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome. Korean Journal of Urology2008;49(1):72‐6. "><b>Youn 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose was not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received gatifloxacin 200mg twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0093" title="ZengX , YeZ , YangW , LiuJ , ZhangX , ZhouX , et al. Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis. Zhonghua Nan Ke Xue2004;10(4):278‐81. "><b>Zeng 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Celecoxib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Celecoxib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg 3 times a day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. "><b>Zhang 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aike decoction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: Bazhengsan decoction</p> <p>C2: Prostatitis decoction</p> <p>C3: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All decoctions were administered twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. "><b>Zhang 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Titrated from 50 to 100 mg individually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1:Duloxetine</p> <p>C2: Only co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duloxeine titrated from 30 to 120 mg individually</p> <p>All participants received doxazosin 4 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. "><b>Zhao 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Celecoxib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. "><b>Zhou 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo was "Vitamin B"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012552-bbs2-0099" title="ZiaeeAM , AkhavizadeganH , KarbakhshM . Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. International Brazilian Journal of Urology2006;32(2):181‐6. "><b>Ziaee 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allopurinol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Same regimen</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>C1, C2, C3</b> were used to refer to multiple treatment arms. <b>NSAID</b>: Nonsteroidal anti‐inflammatory drugs. Blank cells indicate that dosing is described in the adjacent cell and co‐interventions were not described. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of the interventions by study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012552-tbl-0010"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Description of studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration ‐ Follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age (years)</b> </p> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Previous treatments</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean NIH‐CPSI score</b> </p> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Funding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0001" title="AbdallaAE , HamdyD , ArefM , MohamrdN , GamalR , MohamrdH . PD62‐01 Daily low dose tadalafil in treatment of chronic prostatitis/chronic pelvic pain syndrome: randomized controlled study of efficacy and safety. Journal of Urology2018;199(4):e1157. "><b>Abdalla 2018</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saudi Arabia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0002" title="AlexanderRB , PropertKJ , SchaefferAJ , LandisJR , NickelJC , O'LearyMP , et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind trial. Annals of Internal Medicine2004;141(8):581‐9. [PUBMED: 15492337] PropertKJ , AlexanderRB , NickelJC , KusekJW , LitwinMS , LandisJR , et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002;59(6):870‐6. [PUBMED: 12031372] "><b>Alexander 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001 ‐ 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA and Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government + Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0003" title="ApolikhinOI , AliaevIG , SivkovAV , VinarovAZ , OshchepkovVN , KeshishevNG , et al. A comparative clinical randomized trial of cernilton efficacy and safety in patients with chronic abacterial prostatitis. Urologiia2010;1:29‐34. ApolikhinOI , SivkovAV , OshepkovVN , KeshishevNG , BedretdinovaDA . Efficacy and safety of pollen extract of several different plants (cernilton) in patients with chronic abacterial prostatitis. European Urology2009;8(4 (Suppl)):260. "><b>Apolikhin 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0004" title="BatesSM , HillVA , AndersonJB , ChappleCR , SpenceR , RyanC , et al. A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. British Journal of Urology2007;99(2):355‐9. "><b>Bates 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000 ‐ 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0005" title="BreusovAA , Kul'chaveniaEV . Influence of combined phytotherapy on sexual function in patients with chronic abacterial prostatitis. Urologiia2014;6:24‐6. "><b>Breusov 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0006" title="CaiT , WagenlehnerFM , LucianiLG , TiscioneD , MalossiniG , VerzeP , et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine2014;8(4):1032‐8. "><b>Cai 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0007" title="CaiT , VerzeP , LaRoccaR , PalmieriA , TiscioneD , LucianiLG , et al. The clinical efficacy of pollen extract and vitamins on chronic prostatitis/chronic pelvic pain syndrome is linked to a decrease in the pro‐inflammatory cytokine interleukin‐8. World Journal of Men's Health2017;35(2):120‐8. "><b>Cai 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0008" title="CavalliniG . Mepartricin in the treatment of male pelvic pain syndrome secondary to chronic nonbacterial prostatitis/prostatodynia. Minerva Urologica e Nefrologica [Italian Journal of Urology and Nephrology]2001;53(1):13‐7. "><b>Cavallini 2001</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0009" title="ChaWH , KimKH , SeoYJ . Comparison of the efficacy of a terpene mixture and alpha‐blocker for treatment of category III chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2009;50(2):148‐53. "><b>Cha 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0010" title="CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Initial, long‐term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology2004;64(5):881‐6. CheahPY , LiongML , YuenKH , TehCL , KhorT , YangJR , et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Journal of Urology2003;169(2):592‐6. "><b>Cheah 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> <p>14 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000 ‐ 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malaysia and US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0011" title="ChenDN , ChenWT , MaQH , QinZ , HuangZW . Qiantongding Decoction: An efficacious therapeutic for type III B prostatitis. Zhonghua Nan Ke Xue2009;15(1):89‐91. "><b>Chen 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0012" title="ChenY , WuX , LiuJ , TangW , ZhaoT , ZhangJ . Effects of a 6‐month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol2011;29(3):381‐5. "><b>Chen 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> <p>120 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003 ‐ 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0013" title="ChengC‐H , LaiY‐W , HsuehT‐Y , ChiuY‐C , ChenS‐S , LuS‐H , et al. The efficacy of levofloxacin or ciprofloxacin in the management of chronic non‐bacterial prostatitis. International Journal of Urology2010;17:A335. LaiY , ChengC , HsuehT , ChiuY , ChenS , ChiuA . The efficacy of levofloxacin or ciprofloxacin in management of chronic non‐bacterial prostatitis. Urology2012;80(3):S154. "><b>Cheng 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taiwan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0014" title="ChoeHS , LeeSJ , HanCH , ShimBS , ChoYH . Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. Journal of Infection and Chemotherapy2014;20(1):20‐5. "><b>Choe 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0015" title="ChurakovAA , KolesnikovAI , BliumbergBI , PopkovVM . Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction. Urologiia2012;5:64‐6, 68. "><b>Churakov 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not ANLZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0016" title="DeRoseAF , GalloF , GiglioM , CarmignaniG . Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo‐controlled trial. Urology2004;63(1):13‐6. DeRoseAF , TraversoP , MontanaroT , CarmignaniG . The role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS): A randomized prospective placebo‐controlled trial. Journal of Urology2010;183(4):e311. "><b>De Rose 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001 ‐ 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0017" title="DunzendorferU , KruschwitzK , LetzelH . Effects of phenoxybenzamine on clinical picture, laboratory test results and spermatogram in chronic abacterial prostatitis [Die wirkung von phenoxybenzamin auf klinik, labor und spermiogramm bei chronisch abakterieller prostatits]. Therapiewoche1983;33(36):4694‐705. "><b>Dunzendorfer 1983</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0018" title="ElistJ . Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double‐blind, placebo‐controlled study. Urology2006;67(1):60‐3. "><b>Elist 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0019" title="ElshawafH . Chemodenervation of the rhabdosphincter (EUS) alone versus combined injection of both EUS &amp; prostate in patients with prostatitis and chronic pelvic pain syndrome type III. Prospective randomized controlled trial. (Abstract number 394). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. "><b>Elshawaf 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0020" title="ErdemirF , FiratF , AtilganD , UluocakN , ParlaktaşBS , YaşarA . The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome). Journal of Clinical and Analytical Medicine2010;1(2):26‐30. "><b>Erdemir 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> <p>20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0021" title="FalahatkarS , ShahabE , Gholamjani MoghaddamK , KazemnezhadE . Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double‐blind and randomized placebo‐controlled study. BJU International2015;116(4):641‐9. "><b>Falahatkar 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011 ‐ 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0022" title="GiammussoB , DiMauroR , BernardiniR . The efficacy of an association of palmitoylethanolamide and alpha‐lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Archivio Italiano di Urologia e Andrologia2017;89(1):17‐21. "><b>Giammusso 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014 ‐ 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0023" title="GiannantoniA , PorenaM , GubbiottiM , MaddonniS , DiStasiSM . The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology2014;83(2):400‐5. GiannantoniA , ProiettiS , GubbiottiM , Rossi de VermandoisJA , PorenaM . The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: A prospective randomized study. European Urology Supplements2013;12(1):e670‐1. "><b>Giannantoni 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009 ‐ 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0024" title="GoldmeierD , MaddenP , McKennaM , TammN . Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD &amp; AIDS2005;16(3):196‐200. "><b>Goldmeier 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0025" title="GottschH , BergerR , MillerJ , YangC . Pelvic floor injection of Botulinum toxin a for pelvic pain: A randomized, controlled pilot study. Journal of Urology2010;183(4):e405. GottschHP , YangCC , BergerRE . A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scandinavian Journal of Urology and Nephrology2011;45(1):72‐6. "><b>Gottsch 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0026" title="GülO , ErogluM , OzokU . Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. International Urology and Nephrology2001;32(3):433‐6. "><b>Gül 2001</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSSI</p> <p>9.61/9.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1997 ‐ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0027" title="HuAD , HuMZ , WangB , WangYZ . Chinese and Western medicine in treatment of chronic nonbacterial prostatitis. Liaoning J. Tradit. Chin. Med.2015;42:353–354. "><b>Hu 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012 ‐ 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0028" title="IwamuraH , KoieT , SomaO , MatsumotoT , ImaiA , HatakeyamaS , et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urology2015;15:120. "><b>Iwamura 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009 ‐ 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0029" title="JeongCW , LimDJ , SonH , LeeSE , JeongH . Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urology International2008;80(2):157‐61. "><b>Jeong 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0030" title="JiangMH , WuGC , LiuHL . Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2009;15(9):825‐8. "><b>Jiang 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0031" title="JungYH , KimJG , ChoIR . The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): Comparison between category IIIa and IIIb. Korean Journal of Urology2006;47(11):1191‐6. "><b>Jung 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004 ‐ 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0032" title="KaplanSA , VolpeMA , TeAE . A prospective, 1‐year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(1):284‐8. "><b>Kaplan 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0033" title="KimSW , HaJS , LeeSJ , ChoYH , YoonMS . Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean Journal of Urology2003;44(2):120‐3. "><b>Kim 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001 ‐ 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0034" title="KimH , ChoiJB , BaeJH , LeeJG . Efficacy of propiverine for chronic prostatitis/chronic pelvic pain syndrome (Abstract number 670). 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 ‐ Oct 3, San Francisco, CA. 2009. KimHJ , HongJH . Efficacy of propiverine for chronic prostatitis / chronic pelvic pain syndrome. Journal of the Korean Continence Society2008;12(2):158‐62. "><b>Kim 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0035" title="KimTH , LeeKS , KimJH , JeeJY , SeoYE , ChoiDW , et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti‐Inflammatory agents in the treatment of chronic pelvic pain syndrome. International Neurourology Journal2011;15(2):92‐6. "><b>Kim 2011a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 ‐ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0036" title="KimDS , KyungYS , WooSH , ChangYS , KimHJ . Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle‐aged patients: a single‐blinded, prospective, multi‐center study. International Neurourology Journal2011;15(3):172‐5. KimH‐J , KyungY‐S , WooSH , KimDS , JangYS . The efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients‐single‐blinded, prospective, multi‐center study. Journal of Urology2010;183(4):e311. "><b>Kim 2011b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0037" title="Kong doH , YunCJ , ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle‐aged males. World Journal of Men's Health2014;32(3):145‐50. ParkHJ , ParkNC . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. European Urology Supplements2014;13(1):e564. ParkHJ , ParkNC , KimTN , NamJK . The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle aged patients. Journal of Urology2013;189(4):e479. "><b>Kong 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0038" title="KulovacB , AganovićD , PrcićA , HadziosmanovićO . Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosnian Journal of Basic Medical Sciences2007;7(3):245‐9. "><b>Kulovac 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bosnia and Herzegovina</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0039" title="LacquanitiS , DestitoA , ServelloC , CandidiMO , WeirJM , BrisindaG , et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo‐controlled study. Archivio Italiano di Urologia, Andrologia1999;71(5):283‐5. "><b>Lacquaniti 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1997 ‐ 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0040" title="LeeRA , WestRM , WilsonJD . The response to sertraline in men with chronic pelvic pain syndrome. Sexually Transmitted Infections2005;81(2):147‐9. "><b>Lee 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSS</p> <p>23.4/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NGO</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0041" title="LeeCB , HaUS , LeeSJ , KimSW , ChoYH . Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World Journal of Urology2006;24(1):55‐60. "><b>Lee 2006a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003 ‐ 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0042" title="LeskinenM , LukkarinenO , MarttilaT . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double‐blind, placebo‐controlled, pilot study. Urology1999;53(3):502‐5. "><b>Leskinen 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0043" title="LiNC , ZhangK , XiaoH , et al. The efficacy and safety of Prostant in the treatment of chronic prostatitis: a multi center, randomized, double‐blind, placebo‐controlled clinical trial. Chinese Journal of UrologyNovember 2003;24(11):780‐2. "><b>Li 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0044" title="LiB , JiangLJ , ChaiJ . Clinical observation on treatment of chronic prostatitis syndrome type III B by Tiaoshen Tonglin Decoction. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(3):251‐4. "><b>Li 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004 ‐ 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0045" title="LiJP , ChongT , ChenHW , LiHC , CaoJ , ZhangP , et al. Qianlieping capsule plus alpha‐blocker for chronic non‐bacterial prostatitis: analysis of 220 cases. Zhonghua Nan Ke Xue2012;18(9):856‐8. "><b>Li 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010 ‐ 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0046" title="LinZF , ChenBT , ZengK , LanHM , WunJ . Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction. Nan Fang Yi Ke Da Xue Xue Bao2007;27(4):532‐4. "><b>Lin 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0047" title="LuM , ZhaoST , WangSM , ShiBK , FanYD , WangJZ . Alpha‐blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH‐IIIa): a prospective, placebo‐controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi2004;25(2):169‐72. "><b>Lu 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000 ‐ 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government + Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0048" title="MacchioneN , CatalaniM . Pollen extract in association with vitamins (deprox 500 ) versus serenoa repens in chronic prostatitis/chronic pelvic pain syndrome; a single center experience. Journal of Urology. 112th Annual Meeting of the American Urological Association, AUA 2017. United States2017; Vol. 197, issue 4 Supplement 1:e120. "><b>Macchione 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0049" title="MauriziA , DeLucaF , ZanghiA , ManziE , LeonardoC , GuidottiM , et al. The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica2019;90(4):260‐4. [PUBMED: 30655636] "><b>Maurizi 2019</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0050" title="MehikA , AlasP , NickelJC , SarpolaA , HelstromPJ . Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double‐blind, placebo‐controlled, pilot study. Urology2003;62(3):425‐9. "><b>Mehik 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0051" title="MoKI , LeeKS , KimDG . Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: A prospective study. Korean Journal of Urology2006;47(5):536‐40. "><b>Mo 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004 ‐ 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0052" title="MorgiaG , MucciardiG , GaliA , MadoniaM , MarcheseF , DiBenedettoA , et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter‐controlled study. Urology International2010;84(4):400‐6. "><b>Morgia 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 ‐ 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0053" title="MorgiaG , RussoGI , UrziD , PriviteraS , CastelliT , FavillaV , et al. A phase II, randomized, single‐blinded, placebo‐controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano di Urologia, Andrologia2017;89(2):110‐3. "><b>Morgia 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2015 ‐ 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0054" title="NickelJC , DowneyJ , ClarkJ , CaseyRW , PommervillePJ , BarkinJ , et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo‐controlled multicenter trial. Urology2003;62(4):614‐7. "><b>Nickel 2003a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government + Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0055" title="NickelJC , PontariM , MoonT , GittelmanM , MalekG , FarringtonJ , et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Journal of Urology2003;169(4):1401‐5. "><b>Nickel 2003b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA and Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0056" title="NickelJC , DowneyJ , PontariMA , ShoskesD A , ZeitlinSI . A randomized placebo‐controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU International2004;93(7):991‐5. "><b>Nickel 2004a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government + Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0057" title="NickelJC , NarayanP , McKayJ , DoyleC . Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. Journal of Urology2004;171(4):1594‐7. "><b>Nickel 2004b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000 ‐ 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0058" title="NickelJC , ForrestJB , TomeraK , Hernandez‐GraulauJ , MoonTD , SchaefferAJ , et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. Journal of Urology2005;173(4):1252‐5. "><b>Nickel 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA and Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0059" title="NickelJC , KriegerJN , McNaughton‐CollinsM , AndersonRU , PontariM , ShoskesDA , et al. Alfuzosin and symptoms of chronic prostatitis‐chronic pelvic pain syndrome. New England Journal of Medicine2008;359(25):2663‐73. "><b>Nickel 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, Canada and Malaysia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government + Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0060" title="NickelJC , O'LearyM , LeporH , CaramelliK , ThomasH , HillLA , et al. Effects of silodosin in men with moderate or severe chronic prostatitis/chronic pelvic pain syndrome: A double‐blind, placebo‐controlled phase 2 study. Journal of Urology2011;185(4):e574. NickelJC , O'LearyMP , LeporH , CaramelliKE , ThomasH , HillLA , et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double‐blind, placebo controlled study. Journal of Urology2011;186(1):125‐31. "><b>Nickel 2011a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 ‐ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0061" title="EUCTR2008‐004861‐25‐SE . A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE‐BLIND PLACEBO‐CONTROLLED, PARALLEL GROUP PROOF‐OF‐CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004861‐25/SE (Date on which this record was first entered in the EudraCT database: 2008‐12‐18). NickelJC , AtkinsonG , KriegerJ , MillsIW , PontariM , ShoskesDA , et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Preliminary assessment of efficacy and safety in a randomized controlled trial. Journal of Urology2011;185(4):e573‐4. NickelJC , AtkinsonG , KriegerJN , MillsIW , PontariM , ShoskesDA , et al. Preliminary assessment of safety and efficacy in proof‐of‐concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology2012;80(5):1105‐10. NickelJC , MillsIW , CrookTJ , JorgaA , SmithMD , AtkinsonG , et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. Journal of Urology2016;195(4P1):942‐8. "><b>Nickel 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009 ‐ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, Canada, France, Sweden and Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0062" title="OkadaS , HamadaK , TakasakiN , DemuraA , OkanoH , KirimeS , et al. Clinical application of PPC for nonspecific chronic prostatitis. Hinyokika Kiyo1985;31:179–85. "><b>Okada 1985</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not ANLZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0063" title="ParkSJ , YoonHN , ShimBS . Prevention of relapse with the cranberry juice in chronic pelvic pain syndrome. Korean Journal of Urology2005;46(1):63‐7. "><b>Park 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002 ‐ 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0064" title="ParkPH , ParkPN . The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. European Urology Supplements2012;11(1):e280. "><b>Park 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0065" title="ParkHJ , ParkNC , MoonDG , KimTN , NamJK , ParkSW . Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction. European Urology Supplements2017;16(3):e453. "><b>Park 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0066" title="PengSF , YangZZ , LinXF , LiSF , XieZ , CaiJ , et al. Clinical trials of antiphlogistic agent series in treating chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2003;9(9):716‐9. "><b>Peng 2003</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not ANLZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999 ‐ 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0067" title="PerssonBE , RonquistG . Abacterial prostatitis and uric acid in prostatic expressate, and objective and subjective effect of allopurinol treatment: A double‐blind, placebo‐controlled study. Scandinavian Journal of Urology Nephrology Supplement1994;164:21‐2. PerssonBE , RonquistG . Allopurinol treatment results in elevated prostate‐specific antigen levels in prostatic fluid and serum of patients with non‐bacterial prostatitis. European Urology1996;29(1):111‐4. PerssonBE , RonquistG , EkblomM . Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double‐blind controlled study. Journal of Urology1996;155(3):961‐4. "><b>Persson 1996</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0068" title="PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. A randomized placebo‐controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2009;181(4):123. PontariMA , KriegerJN , LitwinMS , WhitePC , AndersonRU , McNaughton‐CollinsM , et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Archives of Internal Medicine2010;170(17):1586‐93. "><b>Pontari 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 ‐ 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government + Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0069" title="ReissiglA , DjavanB , PointnerJ . Prospective placebo‐controlled multicenter trial on safety and efficacy of phytotherapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Journal of Urology2004;171(61):Abstract 233. [MEDLINE: 14665844] "><b>Reissigl 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0070" title="RyuY‐G , KimH‐J , ParkH‐J . The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean Journal of Urology2007;48(8):858‐62. "><b>Ryu 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0071" title="ShiZC , TanCY , LiBH . Treating 60 patients with nonbacterial prostatitis by Qian Lie An Wan. Journal of Beijing University of Traditional Chinese Medicine[bei Jing Zhong Yi Yao da Xue Xue Bao]1994;17(1):44. "><b>Shi 1994</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not ANLZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0072" title="ShoskesDA , ZeitlinSI , ShahedA , RajferJ . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double‐blind, placebo‐controlled trial. Urology1999;54(6):960‐3. "><b>Shoskes 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0073" title="SinghP , ShuklaA , DograPN . Role of PDE‐5 inhibitor in the treatment of chronic pelvic pain syndrome: A randomized control trial. Journal of Urology2017;197(4):e119. "><b>Singh 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61‐65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0074" title="SivkovAV , OshchepkovVN , EgorovAA . Double‐blind placebo‐controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis. Urologiia2005;1:47‐53. "><b>Sivkov 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0075" title="SunYY , ChenZG . Clinical observation of Qianlieantong tablet combined with terazosin hydrochlorid in treating chronic nonbacterial prostatitis. Chinese Journal of Information on Traditional Chinese Medicine2008;15(6):65‐6. "><b>Sun 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0076" title="TanY , ZhuX , LiuY . Clinical efficiency of tamsulosin combining with Prostant in the treatment of patients with chronic abacterial prostatitis. Chinese Journal of Andrology2009;23(7):44‐7. "><b>Tan 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0077" title="TucuV , TasciAI , FazlioluA , OdunctemurA , OzbekE , CekM . Comparison of the efficiency of mono and triple theraphy in chronic pelvic pain syndrome. Turk Urol. Derg.2006;32(3):393‐7. "><b>Tugcu 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003 ‐ 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0078" title="TuğcuV , TaşçiAI , FazlioğluA , GürbüzG , OzbekE , SahinS , et al. A placebo‐controlled comparison of the efficiency of triple‐ and monotherapy in category III B chronic pelvic pain syndrome (CPPS). European Urology2007;51(4):1113‐7; Discussion 1118. "><b>Tuğcu 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004 ‐ 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0079" title="TurkingtonD , GrantJB , FerrierIN , RaoNS , LinsleyKR , YoungAH . A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry2002;63(9):778‐81. "><b>Turkington 2002</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0080" title="WagenlehnerFM , SchneiderH , LudwigM , HorstmannA , SchnitkerJ , WeidnerW . Long term efficacy of cernilton in patients with chronic prostatitis/chronic pelvic pain syndrome type NIH IIIA. European Urology Supplements2009;8(4):260. WagenlehnerFM , SchneiderH , LudwigM , SchnitkerJ , BrahlerE , WeidnerW . A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis‐chronic pelvic pain syndrome: a multicentre, randomised, prospective, double‐blind, placebo‐controlled phase 3 study. European Urology2009;56(3):544‐51. WeidnerW . The role of &quot;Pollenextrakt&quot; for the symptomatic therapy of CP/CPPS. Journal of Men's Health2009;6(4):400. "><b>Wagenlehner 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999 ‐ 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0081" title="WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A one year prospective, double‐blind, placebo‐controlled study. European Urology Supplements2014;13(1):e569. WagenlehnerFM , BallariniS , NaberKG . Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one‐year prospective, double‐blind, placebo‐controlled study. World Journal of Urology2014;32(6):1595‐603. "><b>Wagenlehner 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 ‐ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austria, Germany, Poland and Portugal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0082" title="WangW , HeH , HuW , ZhangX , WangY . Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue2004;10(3):182‐4, 187. "><b>Wang 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002 ‐ 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0083" title="WangJ , YanD , LiangK , XuZ . A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. International Urology and Nephrology2016;48(1):13‐8. "><b>Wang 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011 ‐ 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0084" title="WedrenH . Effects of sodium pentosanpolysulphate on symptoms related to chronic non‐bacterial prostatitis. A double‐blind randomized study. Scandinavian Jpurnal of Urology and Nephrology1987;21(2):81‐8. "><b>Wedren 1987</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1984 ‐ 1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0085" title="WuZ , XiaS , GengH , ZhuH , TangJ , ZhangT , et al. Combined therapy for chronic prostatitis /chronic pelvic pain syndrome with doxazosin and diclofenac. Chinese Journal of Andrology2008;22(7):20‐22, 25. "><b>Wu 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 ‐ 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0086" title="XiaYG , ZengWT , MeiXF , LiuX , LiGS , CaiJ , et al. Yuleshu oral mixture combined with conventional therapy for chronic prostatitis. Zhonghua Nan Ke Xue2014;20(2):177‐80. "><b>Xia 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011 ‐ 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0087" title="XuM , ZhangY‐K . Effect of antibacterial agents in treatment of chronic nonbacterial prostatitis. Journal of the Shanghai Medical University2000;27(6):497‐8. "><b>Xu 2000</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not ANLZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1998 ‐ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0088" title="YangMG , ZhaoXK , WuZP , XiaoN , LuC , HouY . Corticoid combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2009;15(3):237‐40. "><b>Yang 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0089" title="MinggenY , ZhoudaZ , ZhimingZ , HailiL , ZhenqiangX , ChaoxianZ , et al. Tamsulosin therapy for chronic nonbacterial prostatitis: A randomized double‐blind placebo controlled clinical trial. Chinese Journal of Andrology2010;24(12):32‐5. "><b>Yang 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0090" title="YeZQ , LanRZ , WangSG , CaiSL , ChenM , LiNC , et al. A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis. Zhonghua Nan Ke Xue2006;12(9):807‐10. "><b>Ye 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005 ‐ 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0091" title="YeZQ , LanRZ , YangWM , YaoLF , YuX . Tamsulosin treatment of chronic non‐bacterial prostatitis. Journal of International Medical Research2008;36(2):244‐52. "><b>Ye 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002 ‐ 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0092" title="YounCW , SonK‐C , ChoiH‐S , KwonDD , ParkK , RyuSB . Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha‐blocker combination therapy for patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome. Korean Journal of Urology2008;49(1):72‐6. "><b>Youn 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005 ‐ 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0093" title="ZengX , YeZ , YangW , LiuJ , ZhangX , ZhouX , et al. Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis. Zhonghua Nan Ke Xue2004;10(4):278‐81. "><b>Zeng 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0094" title="ZhangMJ , ChuKD , ShiYL . Clinical study on treatment of chronic prostatitis/chronic pelvic pain syndrome by three different TCM principles. Zhongguo Zhong Xi Yi Jie He Za Zhi2007;27(11):989‐92. "><b>Zhang 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005 ‐ 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0095" title="ZhangM , LiH , JiZ , DongD , YanS . Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome. Medicine (United States)2017;96(10):e6243. "><b>Zhang 2017</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011 ‐ 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0096" title="ZhaoWP , ZhangZG , LiXD , YuD , RuiXF , LiGH , et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Brazilian Journal of Medical and Biological Research2009;42(10):963‐7. "><b>Zhao 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 ‐ 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0097" title="ChiCTR1800019441 . A clinical observation of dapoxetine combined with tamsulosin in treatment of type III prostatitis with premature ejaculation. http://www.chictr.org.cn/showproj.aspx?proj=28436 (Date of Registration: 2018‐11‐11). ZhaoL , TianR , LiangC , ZhangL , SongW , ZhaoJ , et al. Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation. Andrologia2019;51(8):e13319. [PUBMED: 31131928] "><b>Zhao 2019</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Government</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0098" title="ZhouZ , HongL , ShenX , RaoX , JinX , LuG , et al. Detection of nanobacteria infection in type III prostatitis. Urology2008;71(6):1091‐5. "><b>Zhou 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005 ‐ 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012552-bbs2-0099" title="ZiaeeAM , AkhavizadeganH , KarbakhshM . Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. International Brazilian Journal of Urology2006;32(2):181‐6. "><b>Ziaee 2006</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002 ‐ 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><b>N/A</b> : not applicable; <b>NGO</b> : non‐governmental organization; <b>NIH‐CPSI</b> : National Institutes of Health Chronic Prostatitis Symptom Index; <b>PSS</b> : Prostatitis Severity Score; <b>PSSI</b> : Prostatitis Symptoms Severity Index; <b>USA</b>: United States of America. Duration and follow‐up are differentiated when data were available. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Description of studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/full#CD012552-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012552-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alpha‐blockers versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prostatitis symptoms: short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.01 [‐7.41, ‐2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.73 [‐10.96, ‐0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.17 [‐11.50, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Phenoxybenzamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.80 [‐7.91, ‐3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.89 [‐13.16, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.63 [‐4.55, ‐0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐6.81, ‐0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Prostatitis symptoms: pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.39 [‐3.57, ‐1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.86 [‐6.00, ‐1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.19 [‐4.56, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Phenoxybenzamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.25 [‐3.78, ‐0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.17 [‐6.31, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐1.67, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐2.97, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Prostatitis symptoms: urinary <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.48 [‐2.29, ‐0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.07 [‐3.79, ‐0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.71 [‐4.34, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Phenoxybenzamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐2.28, ‐0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.63 [‐3.85, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐1.05, ‐0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐2.00, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Prostatitis symptoms: quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.61 [‐2.49, ‐0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.51 [‐4.62, ‐0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐3.24, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Phenoxybenzamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.2 [‐3.14, ‐1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.78 [‐4.96, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐1.34, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐2.49, ‐0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Prostatitis symptoms: responders rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.94, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.67, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.07, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [0.48, 6.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.78, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Prostatitis symptoms: long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.60 [‐10.89, ‐0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.76 [‐10.90, ‐4.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐2.73, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.4 [‐7.30, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.7 [‐10.25, ‐9.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Prostatitis symptoms: long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.06, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.06, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.09, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.14, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.75, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Phenoxybenzamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>35.00 [2.25, 544.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.60, 3.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.37, 3.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [1.15, 5.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Sexual dysfunction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [‐1.13, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐0.84, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐4.84, 4.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐2.89, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Quality of life: mental <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐2.63, 2.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐7.16, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.1 [‐0.64, 4.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐3.09, 3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Quality of life: physical <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [‐0.97, 3.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.4 [‐0.52, 5.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐2.51, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [‐0.81, 5.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Anxiety and depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.1 [‐2.54, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.1 [‐2.54, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Urinary symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.68 [‐5.90, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.5 [‐6.64, ‐2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐1.76, ‐0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Prostatitis symptoms: responders rate (sensitivity analysis according to risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.61, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.61, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse events (sensitivity analysis according to risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.63, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.63, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Prostatitis symptoms: short term (subgroup analysis by co‐interventions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.01 [‐7.41, ‐2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Without co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.56 [‐5.26, ‐1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 With co‐interventions (analgesics, antibiotics)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.69 [‐8.90, ‐2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse events (subgroup analysis by co‐interventions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.09, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Without co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.10, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 With co‐interventions (analgesics, antibiotics)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.46, 3.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alpha‐blockers versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012552-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">5 alpha reductase inhibitors versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prostatitis symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Prostatitis symptoms: responder rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.33, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">5 alpha reductase inhibitors versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012552-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antibiotic therapy versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prostatitis symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.43 [‐4.72, ‐0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.69 [‐3.15, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.98 [‐9.41, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Prostatitis symptoms: pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.92 [‐1.78, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.78 [‐1.86, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐2.74, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Prostatitis symptoms: urinary <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.65, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐1.17, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.85, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Prostatitis symptoms: quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.91, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐1.04, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.52, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Prostatitis symptoms: responder rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.73, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.48, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.70, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.66, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.60, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.46, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Sexual dysfunction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Levofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Quality of life: mental <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Quality of life: physical <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Urinary symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Prostatitis symptoms: subgroup analysis (age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.43 [‐4.72, ‐0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Mean age &gt; 50 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐3.79, 4.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Mean age &lt; 50 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.92 [‐5.37, ‐0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events: subgroup analysis (age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.66, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Mean age &gt; 50 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.46, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Mean age &lt; 50 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.60, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Prostatitis symptoms: subgroup analysis (co‐interventions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.43 [‐4.72, ‐0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Without co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.57 [‐4.77, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 With co‐interventions (alpha blockers)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.96 [‐6.28, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse events: subgroup analysis (co‐interventions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.66, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Without co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.66, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 With co‐interventions (alpha blockers)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antibiotic therapy versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012552-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antiinflammatories versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prostatitis symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐3.74, ‐1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.82 [‐4.10, ‐1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Nonsteroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.56 [‐4.50, ‐0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Thiocolchicoside and ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.5 [‐2.10, ‐0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Prostatitis symptoms: pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.28 [‐4.08, ‐0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.67 [‐1.96, ‐1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Nonsteroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐3.80, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Antileukotriene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [‐5.79, 8.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Thiocolchicoside and ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.2 [‐5.59, ‐4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Prostatitis symptoms: urinary <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.75 [‐1.53, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐0.88, ‐0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Nonsteroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.64, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Antileukotriene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐0.84, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Thiocolchicoside and ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐3.47, ‐2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Prostatitis symptoms: quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.25 [‐2.58, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐0.75, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Nonsteroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.90, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Antileukotriene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐4.86, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Thiocolchicoside and ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.5 [‐5.02, ‐3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Prostatitis symptoms: responder rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.68, 3.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.25, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Nonsteroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.69, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Prostatitis symptoms: long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Thiocolchicoside and ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.81, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.24, 102.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Nonsteroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.79, 4.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Antileukotriene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.23, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Thiocolchicoside and ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.83, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Urinary symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Nonsteroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Prostatitis symptoms: subgroup analysis (co‐interventions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐3.74, ‐1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Without co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.62 [‐4.85, ‐2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 With co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.29 [‐3.67, ‐0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.81, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Without co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 20.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 With co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.73, 2.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antiinflammatories versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012552-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Phytotherapy versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prostatitis symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.02 [‐6.81, ‐3.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Pollen extract vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.5 [‐4.44, ‐0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Prolit Super Septo versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.0 [‐16.81, ‐1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Calendula‐Curcuma versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.0 [‐7.28, ‐4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Quercetin (flavonoid) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.80 [‐10.80, ‐0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Add‐on cranberry compared to standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.40 [‐7.51, ‐3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Prostatitis symptoms: pain subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.42 [‐1.99, ‐0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Pollen extract vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐2.05, ‐0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Prolit Super Septo versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐13.31, 5.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Quercetin (flavonoid) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.8 [‐5.41, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Add‐on cranberry compared to standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐2.34, ‐0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Prostatitis symptoms: urinary symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.99 [‐1.75, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Pollen Extract vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐1.15, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Prolit Super Septo versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐6.15, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Quercetin (flavonoid) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.5 [‐3.27, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Add‐on cranberry compared to standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐2.47, ‐1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Prostatitis symptoms: quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐2.30, ‐0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Pollen Extract vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.09 [‐1.66, ‐0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Prolit Super Septo versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.70 [‐9.12, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Quercetin (flavonoid) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐3.97, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Add‐on cranberry compared to standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.2 [‐2.75, ‐1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Prostatitis symptoms: responder rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.25, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Pollen extract vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.05, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Prolit Super Septo versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.23, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Quercetin (flavonoid) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [1.14, 9.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.54, 2.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Pollen Extract vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.34, 3.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Prolit Super Septo versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Calendula‐Curcuma versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 70.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Quercetin (flavonoid) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.18, 16.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Add‐on cranberry compared to standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Sexual dysfunction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Calendula‐Curcuma versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Urinary symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Pollen Extract vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Prostatitis symptoms: subgroup analysis (co‐interventions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.02 [‐6.81, ‐3.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Without co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.06 [‐7.28, ‐4.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 With co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.92 [‐6.76, ‐1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events: subgroup analysis (co‐interventions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.54, 2.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Without co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.33, 13.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 With co‐interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.34, 3.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Phytotherapy versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012552-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Botulinum toxin A versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prostatitis symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Intraprostatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.80 [‐30.15, ‐21.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pelvic floor muscles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.6 [‐5.59, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Prostatitis symptoms: pain subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Intraprostatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.63 [‐16.76, ‐12.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Pelvic floor muscles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐3.23, ‐0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Prostatitis symptoms: urinary subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.82 [‐7.40, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Intraprostatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.17 [‐6.72, ‐3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Pelvic floor muscles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐1.85, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Prostatitis symptoms: quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Intraprostatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Pelvic floor muscles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 99.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Intraprostatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 99.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Pelvic floor muscle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Urinary symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.67 [‐13.97, ‐5.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Intraprostatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.67 [‐13.97, ‐5.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Botulinum toxin A versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012552-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Allopurinol versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prostatitis symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Prostatitis symptoms: pain subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Prostatitis symptoms: urinary subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Allopurinol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012552-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Traditional chinese medicine versus placebo or usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prostatitis symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.13 [‐4.99, ‐1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Prostant versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.93 [‐7.76, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Qianlieping (add‐on) versus medical treatment alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.40 [‐5.03, ‐1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Qianlieantong (add‐on) versus medical treatment alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.67 [‐8.14, ‐5.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Yuleshu (add‐on) versus medical care alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.41 [‐2.57, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Aike Mixture versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.59 [‐8.24, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Bazhengsan versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.53 [‐9.28, 6.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Prostatitis Decoction versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [‐3.78, 5.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Prostatitis symptoms: pain subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.49 [‐2.44, ‐0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Prostant versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.42 [‐2.51, ‐0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Qianlieantong versus medical treatment alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.54 [‐3.24, ‐1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Yuleshu versus medical care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.52 [‐3.64, ‐1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Aike Mixture versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.21 [‐4.60, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Bazhengsan versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [‐1.22, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Prostatitis Decoction versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [‐1.52, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Prostatitis symptoms: urinary subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.78 [‐1.50, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Prostant versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.62 [‐3.37, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Qianlieantong versus medical treatment alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐1.02, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Aike Mixture versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.84 [‐2.31, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Bazhengsan versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐1.35, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Prostatitis Decoction versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐1.73, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Prostatitis symptoms: quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐2.14, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Prostant versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.91 [‐1.00, ‐0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Aike Mixture versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐3.36, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Bazhengsan versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [‐1.65, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Prostatitis Decoction versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐2.59, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.22, 8.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Prostant versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.03, 19.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Qianlieping versus medical treatment alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Aike Mixture versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Bazhengsan versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.33 [0.26, 72.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Prostatitis Decoction versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [0.14, 42.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Sexual dysfunction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Yuleshu versus medical care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Anxiety and depression: anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Yuleshu versus medical care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Anxiety and depression: depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Yuleshu versus medical care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Traditional chinese medicine versus placebo or usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012552.pub2/references#CD012552-tbl-0018">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012552.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012552-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012552-note-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012552-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012552-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012552-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012552-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012552-note-0018">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012552\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012552\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012552\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012552\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012552\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012552.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012552.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012552.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012552.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012552.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724313901"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012552.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724313904"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012552.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e5fc14d72f409',t:'MTc0MDcyNDMxNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 